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Telomerase, discovered in 1985, is considered a near-universal marker of malignancy 
and therefore has a potential use in cancer therapeutics and diagnostics.  In this study, 
I used several approaches to gain a better understanding of telomerase and its 
potential applications in the canine context, for both cancer therapeutics and 
diagnosis. Having already developed an effective siRNA viral vector in vitro, the 
challenge still remained to deliver it efficiently in vivo. Thus, I initially investigated 
two possible approaches for in vivo delivery. First, I investigated a cell-based system 
for direct delivery to the tumours. Specifically I optimised a system for efficient 
gene-transfer to endothelial cells using a green fluorescent protein plasmid vector, 
and monitored systemic delivery by ex vivo imaging of dye-labelled cells in a canine 
xenograft tumour mouse model. In parallel, in vitro I investigated the gene transfer 
mediated by a novel dendrimer vector that can form nanoparticles with DNA and 
accumulate in tumour sites in vivo after i.v. administration. In order to utilize these 
delivery systems, I developed a DNA plasmid-based siRNA vector and tested its 
efficacy on canine tumour cells. 
 
To investigate telomerase as a cancer biomarker, I conducted a study that aimed to 
detect circulating telomerase reverse transcriptase (TERT) mRNA in serum taken 
from canine cancer patients. For this I developed several systems for effective RNA 
isolation from serum and used both conventional and quantitative PCR assays to 
detect TERT expression. Although for the first time I can confirm the existence of 
mRNA in serum of canine cancer patients, in this clinical study, I could only detect 
telomerase transcripts in a very small proportion of canine cancer patients. 
 
In a final pilot study to investigate anti-ageing technologies, I looked at the potential 
for drug-dependant telomerase induction rather than inhibition. For this I investigated 
the ability of three candidate drugs to induce TERT mRNA activation in canine 
embryonic fibroblasts. In this study, telomerase induction was measured using the 
quantitative PCR method that I had developed for serum detection.  
 iv 
 
In summary, I have demonstrated that a cell-based delivery vehicle has a potential 
application in cancer therapy, but that more development is required before it can be 
applied clinically. I have also reported here that PPIG3 dendrimer-based gene 
transfer in vitro is low in canine cancer cells and thus require more optimisation and 
development before it can be utilised as an efficient systemic delivery vehicle. For 
the siRNA experiment, unfortunately, I did not observe any telomerase gene-
silencing in canine cancer cells using the plasmid-based siRNA expression vector, 
and therefore the gene sequence of cTR that we were targeting as well as the siRNA 
plasmid-vector that we used needs further validation in canine cells. I also suggest 
that TERT mRNA may not be a good serum biomarker for canine cancer diagnostics 
as I did not find TERT transcript in most of our serum samples from canine cancer 
patients, although circulating mRNA of a housekeeping gene was detected. Finally, 
in a pilot study, I have demonstrated that telomerase can be induced in normal canine 
somatic cells using small molecules. However, the long-term effects of telomerase 
induction on ageing must be determined in future studies. 
 v 
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CHAPTER 1  
 
INTRODUCTION 
Chapter 1 – Introduction 
 2 
1.1 Cancer Burden 
Despite recent advances in cancer diagnosis and treatment (Petrelli et al., 2009), 
generally human cancer patients still face high morbidity and mortality rates. 
According to Cancer Research UK Annual Report 2009, more than 293,000 people 
are diagnosed with cancer each year in Britain, and in 2007 there were more than 
155,000 cancer patient deaths in the United Kingdom alone. Global deaths from 
cancer were 7.4 million in 2004 according to the World Health Organization 
(http://www.who.int/cancer/prevention/en/). Our canine friends are also affected: it is 
estimated that between one in three and one in four dogs will develop some form of 
cancer during their lifetime (Argyle and Khanna, 2006). These statistics show the 
urgent need for ongoing research in order to better understand and treat this deadly 
disease. Currently, cancer is considered as an accumulation of both inherited and 
acquired genetic mutations that cause the uncontrollable and continuous growth of 
abnormal cells in a living body. Visually, a tumour is a complex tissue composed of 
not only tumour cells but also of extracellular matrix components, fibroblasts, 
immune cells and endothelial cells. Generally, all cancers share six common 
hallmarks: cell division independent of growth signals; insensitivity to growth-
inhibitory signals; inability to induce programmed cell death; limitless replicative 
potential; sustained angiogenesis; and tissue invasion and metastasis (Hanahan and 
Weinberg, 2000). Of these distinct features, the inappropriate activation of cell 
signalling pathways alone is not sufficient to enable cancer cells to grow indefinitely 
and the limitless replicative potential does appear to be an independent mechanism 
that enables the indefinite growth of cancer cells, and the key cellular factor 
underlying this mechanism is telomerase (Hanahan and Weinberg, 2000). Telomerase 
was firstly discovered in protozoa, and its biological function is to synthesize and 
add specific repeat sequences of non-coding DNA onto chromosome ends or 
telomeres (Greider and Blackburn, 1985). 
 
1.2 The Biology of Telomeres and Telomerase 
1.2.1 Telomeres 
Telomeres are located at the end of chromosomes and are composed of double-
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stranded TTAGGG DNA repeats with a single-stranded 3’ (TTAGGG)n overhang, all  
bound by specialized proteins. These structures maintain genome stability 
(O'Sullivan and Karlseder, 2010) by preventing chromosome end-to-end fusions 
(Tusell et al., 2008), and also by preventing the ends of chromosomes from being 
recognized as double-stranded DNA (dsDNA) breaks that could induce unscheduled 
DNA repair (Khanna and Jackson, 2001). Chromosome ends are in fact shielded by 
telomeric DNA and six associated proteins (Table 1), which together form the 
telomeric shelterin complex that is crucial for telomere stability (Martinez and 
Blasco, 2011). During the non-mitotic phase of the cell cycle, the shelterin complex 
helps the telomere to fold correctly to form a closed structure containing two internal 
loops, the D-loop and the T-loop (Tail loop), that stabilize and protect the telomere 
(Greider, 1999). The T-loop is thought to be formed by the 3’-telomeric overhang 
folding back and invading the duplexed telomeric repeat sequence (Griffith et al., 
1999), and the D-loop (displacement loop) is thought to result from base-pairing of 
the 3’ telomeric overhang with one internal strand after this invasion process occurs 
(Figure 1). In this way a structure is created that is distinct from a broken DNA end 
(Greider, 1999), and is not recognized as such. The telomeric sequence TTAGGG is 
evolutionarily conserved in all vertebrates (Meyne et al., 1989). The length of 3’ 
overhang in human cells can vary from 24 nucleotides to over 400 nucleotides 
(Cimino-Reale et al., 2001).  
 
TRF1 Telomeric Repeat Binding Factors 1 
TRF2 Telomeric Repeat Binding Factors 2 
POT1 Protein Protection of Telomeres 1 
RAP1 Repressor Activator Protein 1  
TPP1 also known as TINT1, PTOP or PIP1 
TIN2 TRF1-interacting Nuclear Factor 2  
 
Table 1 - The Shelterin Proteins of Human Telomere 
The telomeric shelterin protein complex consists of TRF1, TRF2, POT1, RAP1, TPP1 and 
TIN2. 













Figure 1 – The Structure of Telomere – Schematic  
adapted from (Cooper, 2000) 
A – Telomere which is located at the very end of chromosome, contains dsDNA repetitive 
TTAGGGs and ssDNA repetitive TTAGGGs overhang.  
B – Telomere folds internally and creates a D-loop and a T-loop to avoid being recognized as 
DNA breaks and thus maintains chromosome stability. 
 
1.2.2 Cell Senescence 
The telomere not only maintains the basic structure and integrity of the chromosome, 
but is also responsible for regulating cell division and cellular replicative senescence, 
by functioning as a mitotic clock (Collado et al., 2007). The DNA end-replication 
problem, whereby DNA polymerase cannot copy the extreme 5’ end of chromosome 
(Watson, 1972), results in the telomeres shortening (Olovnikov, 1996) by a rate of, 
for example, approximately 50bp per cell division cycle in human fibroblasts (Harley 
et al., 1990). It was initially observed that normal somatic cells would enter into a 
senescence phase after a certain number of cell divisions, and this was termed the 
Hayflick Limit (Hayflick and Moorhead, 1961). Cellular replicative senescence was 
originally characterized by a large, flattened and vacuolated cell morphology; 
senescence-associated β-galactosidase activity (Dimri et al., 1995); a lack of 
response to mitogens; and a permanent growth arrest in the G1 phase of the cell cycle 
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(Stein and Dulic, 1995). It was later found that replicative senescence is also 
associated with telomere shortening (Harley et al., 1990) and shown that cellular 
senescence can be triggered by shortened telomeres (Blackburn, 2001). These 
shortened telomeres are recognized as dsDNA breaks and are recognized by sensor 
proteins that activate the DNA damage response machinery (d'Adda di Fagagna et al., 
2003) (Figure 2). The DNA damage pathway firstly activates phosphatidylinositol 3-
kinase-like kinases (PI3Ks), such as ATM (ataxia telangiectasia mutated) or ATR 
(ataxia telangiectasia and Rad3-related) (Guo et al., 2007, Herbig et al., 2004). Once 
activated, these kinases phosphorylate downstream factors, including Checkpoint 
kinase 1 (CHK1) and Checkpoint kinase 2 (CHK2), which subsequently target p53 
(Latif et al., 2004, Gire, 2004). The phosphorylation of p53 inhibits binding of the 
murine double minute 2 (MDM2) protein and thus releases p53 from ubiquitination-
mediated degradation, resulting in its activation. Activated p53 then induces 
expression of cyclin-dependant kinases (CDKs) inhibitor p21, which inhibits cell 
cycle progression and initiate replicative senescence by inhibiting CDKs thus 
activating protein RB (pRb) by phosphorylaiton (Ben-Porath and Weinberg, 2005). 
When pRb is hypophosphorylated, it binds to and represses the functions of E2F 
family of transcriptional factors, which thus decreases the expression of many E2F 
target genes and results in cell cycle arrest (Maehara et al., 2005). Current knowledge 
indicates that p53 and pRb are required not only for the onset of cellular senescence, 
but also for the maintenance of the senescence program, as inactivation of these 
proteins during cellular senescence results in reversal of the senescent phenotype 
(Beausejour et al., 2003). Apart from P21, P16 is another CDKs inhibitor that can 
induce the onset of cellular senescence (Ruas and Peters, 1998) which becomes 
irreversible if a sustained period of p16 expression occurs (Dai and Enders, 2000). It 
is indicated that p16 may have a p53-independent senescent response towards 
telomere dysfunction and this mechanism may be a secondary effector of the 
telomere DNA damage response, after the primary p53-dependent mechanism 
(Jacobs and de Lange, 2004), but its involvement in telomere dysfunction-induced 
senescence is still being debated (Herbig et al., 2004, Smogorzewska and de Lange, 
2002). In fact, both the p16-pRb and p53-p21 pathways are reported to be frequently 
inactivated in human cancers reflecting the importance of these proteins as tumour 
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suppressors. However, the mechanism for determining whether cells undergo 
senescence or apoptosis in response to telomere-induced DNA damage response is 
still not fully understood (Deng et al., 2008). In addition to causing cell cycle arrest, 
telomeres lacking telomeric protein TRF2 can also induce p53- and ATM-dependent 
apoptosis (Karlseder et al., 1999), and an increased level of apoptosis in proliferative 
cells was observed in a mouse model containing dysfunctional telomeres (Attardi, 
2005). 
 













Figure 2 – Telomere Dysfunction Activates the p53 and pRb Pathways  
adapted from (Deng et al., 2008) 
Telomere dysfunction induces senescence via p53-p21 and p16-pRb pathways. P16-pRb 
pathway is less clear. Telomere dysfunction can also cause p53-dependant apoptosis. 
 
1.2.3 Telomerase 
Since its discovery telomerase has been linked with tumour immortalisation, and this 
enzyme has a critical role in preventing telomere loss in cancer cells (Counter et al., 
1992), thereby helping them to escape from cellular replicative senescence and 
apoptosis (Harley, 2008). Normal somatic cells are telomerase-negative and only 
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limited telomerase activity is found in stem cells (Hiyama and Hiyama, 2007) and 
germline cells (Kim et al., 1994), thus making telomerase a tumour-specific marker. 
In contrast, the vast majority (approximately 85%) of human cancer cells are 
telomerase-positive, which identifies telomerase as a near universal tumour marker 
(Kim et al., 1994, Shay and Bacchetti, 1997). In support of this, one report showed 
that 98 out of 100 immortal cell lines, representing 18 different human tissues, and 
90 out of 101 tumour biopsies, representing 12 human cancer types, were 
telomerase-positive, while all human somatic cells and tissues tested were 
telomerase-negative (Kim et al., 1994). In addition, some cancer cells (approximately 
15%) can maintain telomere length in the absence of active telomerase using the 
DNA recombination-based mechanism, alternative lengthening of telomere (ALT) 
(Cesare and Reddel, 2010). Although ALT can be found in common cancers, there is 
a tendency that ALT was found in more tumour types with mesenchymal origin, 
which is currently still unclear (Lafferty-Whyte et al., 2009). Due to all its unique 
and important features, telomerase has been intensively studied and has become an 
attractive anticancer therapeutic target (Harley, 2008) and a potential tumour 
biomarker for use in oncology. 
 
1.2.3.1 The Telomerase Complex 
The telomerase holoenzyme is a ribonucleoprotein that specializes in RNA-
dependent reverse transcription (Wyatt et al., 2010). Although the composition of 
telomerase varies significantly between species (Collins, 2006), it has been found to 
universally contain a telomerase RNA component (TR or TERC, I use TR for the rest 
of the thesis); a telomerase reverse transcriptase (TERT) enzyme; and species-
specific accessory proteins (Wyatt et al., 2010). 
 
The TR component contains a AAUCCC region complementary to the telomeric 
repeat sequence (TTAGGG)n, which serves as an RNA template for reverse 
transcription to elongate the telomere (Feng et al., 1995). This hexameric RNA 
template sequence is highly conserved in all vertebrates examined so far (Garrido-
Ramos et al., 1998, Meyne et al., 1989). In addition to the template sequence, TR 
also contains secondary structure elements that are essential for the processes of 
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telomerase accumulation, nuclear localization and the addition of telomere repeats in 
vertebrates (Theimer and Feigon, 2006). The human TR gene is located at 3q26 
chromosome (Sugita et al., 2000) and hTR RNA is first synthesized from 3′-extended 
precursors transcribed by RNA Polymerase II then processed to a mature hTR 
mRNA lacking a polyadenosine tail (Collins, 2006). In cancer cells, the expression of 
hTR is much higher than in normal cells (Yi et al., 1999) and is essential for 
telomerase activity (Cohen et al., 2007). 
 
TERT is the catalytic subunit of telomerase and is also required for telomerase 
activity in all species (Nakamura et al., 1997). Experimental evidence has indicated 
that TERT is the main determinant of telomerase activity (Kanaya et al., 1998), as (1) 
hTERT mRNA expression levels correlate with telomerase activity (Wu et al., 1999a), 
and (2) telomerase activity can be restored in telomerase-negative cells by ectopic 
expression of TERT (Bodnar et al., 1998). HTERT gene is located at the 5p15 
chromosome (Bryce et al., 2000). 
 
Various species-specific accessory proteins are also involved in the assembly, 
accumulation, localization and function of telomerase (Wyatt et al., 2010). Protein 
components of human telomerase identified so far include the ATPases pontin and 
reptin (Venteicher et al., 2008), TCAB1 (Telomerase Cajal Body Protein 1) 
(Venteicher and Artandi, 2009), NHP2 ( or NOLA2, Nucleolar Protein Family A, 
Member 2), NOP10 (or NOLA3, Nucleolar Protein Family A, Member 3) and 
dyskerin (DKC1) (Fu and Collins, 2007). However, only dyskerin is needed for the 
catalytic function of active telomerase (Cohen et al., 2007). Dyskerin functions by 
binding and stabilizing hTR, and also co-operates with NHP2 and NOP10 in the in 
vivo accumulation of hTR (Fu and Collins, 2007). 
 
1.2.3.2 Telomerase Function and Regulation 
The active assembled telomerase complex has the ability to copy the same template 
multiple times, which results in the addition of hundreds of nucleotides to a single 
DNA primer (Wyatt et al., 2010). During one cycle of telomere elongation, the RNA 
template is reverse transcribed by TERT which adds nucleotides to the 3’ end of the 
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telomere, while the lagging-strand synthesis machinery generates the opposite strand 
(Figure 3). This process is referred to as repeat addition processivity (Autexier and 
Lue, 2006), and this unique mechanism can rapidly elongate critically short 












Figure 3 – Telomerase Reverse Transcription - Schematic 
Telomerase reverse-transcribes its RNA template into TTAGGG DNA repeats and adds them 
to the end of chromosome. 3’- CAAUCCCAAUC- 5’can bind to the first few nucleotides of 
the last telomere sequence and add a new telomeric repeat sequence. It then realigns to the 
new 3’ end of the telomere and repeats the process. 
 
Only TR and TERT can not form the active telomerase (Weinrich et al., 1997), the 
telomerase ribonucleoprotein complex depends on a series of assembly steps with 
various other accessory proteins to form the active holoenzyme (Collins, 2006). 
Telomerase is highly repressed in normal cells by targeting TERT using various 
transcriptional factors, including Mad (Oh et al., 2000), Menin and SIP1 (Lin and 
Elledge, 2003) but can also be activated by protein, such as oncogene-encoded c-
Myc (Wu et al., 1999b, Cukusic et al., 2008). Estrogen and androgen were also found 
to upregulate hTERT (Kyo et al., 1999, Misiti et al., 2000, Guo et al., 2003). In 
addition, alternative splicing of the TERT mRNA occurs in various species, including 
humans, and is also considered as a mechanism of telomerase regulation (Cong et al., 
2002, Kilian et al., 1997). 
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1.3 Telomerase as a Therapeutic Cancer Target 
Since telomerase is specifically upregulated in the majority of cancers, but not in 
normal somatic cells, it has been widely explored as a promising anticancer target 
and so far many strategies have been developed to target different components of the 











Figure 4 – Major Strategies Targeting Telomerase and its Components  
Strategies including antisense, ribozyme and siRNA technology as well as expression of a 
dominant negative form of either TR or TERT have been used to inhibit telomerase. Some G-
quadruplex ligands have also been used to inhibit telomerase in cancer cells. In addition, 
targeting the upstream signalling pathways of TERT and novel inhibitors have been reported 
to inhibit telomerase in cancer cells.  
 
1.3.1 Telomerase Inhibition by Targeting TERT 
As TERT is the catalytic subunit of telomerase, and as studies have shown TERT to 
be the main determinant of telomerase activity (Kanaya et al., 1998), it has become a 
favourite target for many strategies designed to inhibit telomerase function. 
 
For instance, ectopic expression of a dominant-negative TERT protein was found to 
inhibit telomerase activity in cancerous and non-cancerous telomerase-positive cell 
lines (Zhang et al., 1999); sensitize cells to chemotherapy agents (Cerone et al., 
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2006b, Poynter et al., 2009); and eliminate tumorigenicity in vivo (Hahn et al., 1999). 
Overexpression of a dominant-negative TERT is thought to compete with wild-type 
TERT for binding to other telomerase components, thus blocking the formation of 
active telomerase (Nguyen et al., 2009). In support of this, recent evidence has 
shown that dominant-negative hTERT forms a heterodimer with wild-type hTERT, 
and that the heterodimer is exported to the cytoplasm for ubiquitin-mediated protein 
degradation (Nguyen et al., 2009). It is also thought that this heterodimer degradation 
may be faster than that of the wild-type hTERT homodimer (Nguyen et al., 2009). 
However, it was also observed that expressing dominant-negative TERT in 
melanoma cell lines increased their resistance to certain chemotherapeutic drugs 
(Tentori et al., 2003), and that the long-term expression of dominant-negative hTERT 
in both human and murine cancer cells could not prevent telomerase reactivation 
(Delhommeau et al., 2002, Marie-Egyptienne et al., 2008). 
 
Another popular approach for specific gene repression uses ectopic antisense 
oligonucleotides to bind complementary mRNA targets and to promote target mRNA 
degradation using an endogenous process (Bennett and Swayze, 2010). Antisense 
TERT has been shown to target human telomerase to inhibit cell proliferation in 
various tumour cells in vitro, including colon cancer cells (Jiang et al., 2003), liver 
cancer cells (Du et al., 2003), bladder cancer cells (Kraemer et al., 2003), laryngeal 
cancer cells (Tao et al., 2005) and pancreatic cancer cells (Wang et al., 2006). 
Antisense TERT can also sensitize cancer cells to various chemotherapeutic drugs 
(Yuan and Mi, 2002, Kraemer et al., 2004) and has been effective in inhibiting 
tumour growth in vivo in various human cancer models, such as thyroid cancer (Teng 
et al., 2003), liver cancer (Lin et al., 2005, Liu et al., 2004b) and cervical cancer 
(Han et al., 2008). However, despite the current progress made with in vitro and in 
vivo experiments, antisense oligonucleotide-based therapy still faces many 
challenges and the clinical trials have only had limited success so far (Wacheck and 
Zangemeister-Wittke, 2006). 
 
Ribozyme-based therapy uses special RNA molecules with enzymatic activities to 
selectively bind to and cleave specific target RNA (Kuwabara et al., 2000). Certain 
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ribozymes which were originated from the self-splicing group I intron of 
Tetrahymena thermophila can even trans-splice an exon attached to its 3' end onto a 
separate 5' exon RNA (Jones et al., 1996) and have been used to target cancer cells 
(Shin et al., 2004). These ribozyme-based applications have been shown to target 
TERT and inhibit telomerase in vitro (Yokoyama et al., 2000, Yokoyama et al., 2001, 
Hayashidani et al., 2005) and also to induce apoptosis in various types of human 
cancer, including ovarian cancer (Saretzki et al., 2001), breast cancer (Ludwig et al., 
2001) and gastric cancer (Hao et al., 2005), as well as in in vivo tumour models 
(Song et al., 2007, Hong et al., 2008, Song et al., 2009). 
 
Other strategies already used to target TERT include novel enzymatic inhibitors and 
other indirect inhibitory mechanisms. The novel telomerase inhibitor, BIBR1532, is a 
synthetic non-nucleosidic compound that inhibits telomerase by directly binding to 
TERT (Pascolo et al., 2002). BIBR1532 has been reported to inhibit telomerase in a 
variety of human cancer cell lines (Barma et al., 2003, Piotrowska et al., 2005), and 
this inhibition is associated with telomere shortening and apoptosis (Parsch et al., 
2008). BIBR1532 was also observed to sensitize cancer cells to chemotherapeutic 
drugs (Ward and Autexier, 2005) and appeared to cause a direct cytotoxic effect on  
malignant cells with higher concentrations of this drug (El-Daly et al., 2005, El Daly 
and Martens, 2007). On the other hand, however, cancer cells with longer telomeres 
were resistant to BIBR1532 treatment (Mueller et al., 2007), and further 
development is necessary to reduce its high IC50 value (Barma et al., 2003). In 
addition, some studies have also shown that TERT can be indirectly activated by 
epidermal growth factor through the mitogens-activated protein (MAP) kinase 
signalling pathway (Maida et al., 2002). Inhibitors of the MAP kinase pathway, 
including Ets and activator protein-1 (AP-1), were found to downregulate TERT 
transcription (Xu et al., 2007). 
 
1.3.2 Telomerase Inhibition by Targeting the Telomeric G-
Quadruplex Structure 
The telomeric guanine-rich overhang can be folded into a four-stranded G-
quadruplex structure make the 3’-end of the telomere inaccessible and thus unable to 
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hybridize with the telomerase RNA component, which inhibits telomerase 
functioning and therefore prevents telomere elongation (Zahler et al., 1991). Since 
the discovery of telomerase, many quadruplex-binding small ligands have been 
identified that can stabilize the telomeric G-quadruplex (Neidle, 2010). For example, 
BRACO-19, 3,6-disubstituted and 3,6,9-trisubstituted acridines and its analogues, 
have been shown to inhibit telomerase in vitro (Fu et al., 2009, Incles et al., 2003) 
and to have an antitumour effect in vivo (Burger et al., 2005, Gunaratnam et al., 
2009). A second quadruplex-binding drug, Telomestatin, one of the 2,4,6-triamino-
1,3,5-triazine derivatives, has also been reported to inhibit telomerase activity and 
tumour cell proliferation in vitro (Binz et al., 2005), and to inhibit tumour growth in 
vivo (Tauchi et al., 2006). However, mechanisms resistant to such G-quadruplex 
binders  have been reported to exist in primary cancer cells (Sumi et al., 2004), and 
thus the value of the telomeric G-quadruplex structure as a drug target is still being 
debated (Wu and Brosh, 2010). 
 
1.3.3 Telomerase Inhibition by Targeting TR 
Although many telomerase inhibitors have been discovered using the different 
strategies mentioned above, very few of the drug candidates have been taken forward 
for further study, and most of them are still in preclinical development. However, a 
small telomerase antagonist that targets the RNA component of telomerase is the first 
telomerase inhibitor to be taken into clinical trial. 
 
GRN163L, or imetelstat, is a short-chain-lipidated oligonucleotide-based therapeutic 
molecule that binds to the RNA template of telomerase, thus preventing TERT from 
reverse transcribing the template into telomeric repeats (Roth et al., 2010). This 
molecule has been tested in various tumour cell lines and in some tumour-initiating 
cells (Joseph et al., 2010, Marian et al., 2010, Brennan et al., 2010) and has been 
shown to inhibit telomerase activity, shorten telomeres and reduce cancer cell 
proliferation in vitro (Herbert et al., 2005, Hochreiter et al., 2006, Gellert et al., 2006, 
Goldblatt et al., 2009b), and to sensitize cancer cells to chemotherapeutic drugs 
(Djojosubroto et al., 2005, Goldblatt et al., 2009b, Tamakawa et al., 2010, Goldblatt 
et al., 2009a). GRN163L also has shown anti-tumour activity in several tumour 
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models in vivo (Shammas et al., 2008, Uziel et al., 2010) and is currently in clinical 
phase I/II trials (Roth et al., 2010). 
 
A few reports have also shown that expression of a dominant negative form of TR 
can increase levels of apoptosis in some human cancer cell lines (Kim et al., 2001), 
sensitize tumour cells to anticancer drugs (Cerone et al., 2006a) and exhibit an 
antitumour effect in vivo (Li et al., 2004b). 
 
1.3.4 Telomerase Inhibition Using RNA Interference 
Technology 
Apart from the methods mentioned above, RNA interference technology is another 
common approach to inhibit telomerase activity by targeting either TR, TERT or 
other associated proteins (Harley, 2008) and detailed introduction of this section is 
given in Chapter 3. 
 
1.4 Telomerase as a Biomarker for Cancer 
1.4.1 Detection of Telomerase Activity 
Since telomerase was identified as a specific and near universal marker of 
malignancy, the level of telomerase activity has been naturally prompted to be used 
for cancer diagnosis. The most commonly used method for the detection of 
telomerase activity is the Telomere Repeat Amplification Protocol (TRAP) (Kim et 
al., 1994) and its various modifications (Fajkus, 2006). This technique exploits the 
low substrate specificity of telomerase for targeting a non-telomeric substrate primer 
(TS). The TS primer is first extended by the telomerase-mediated addition of specific 
telomeric repeats, and the product is then amplified by PCR using both the TS primer 
and a reverse primer (Kim et al., 1994). This sensitive TRAP method can detect 
telomerase activity in samples containing as few as ten cancer cells(Wright et al., 
1995), as well as in solid tumour tissue samples and body fluids (Hess and Highsmith, 
2002). However, the presence of telomerase activity in some normal cells, especially 
in proliferative stem cells and activated lymphocytes (Hiyama et al., 1995b), can 
complicate the interpretation of the TRAP results. Additionally, low telomerase 
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activity is detectable in certain benign tumours, such as breast fibroadenoma 
(Hiyama et al., 1996) and thyroid adenoma (Matthews et al., 2001), and this must be 
considered when analysing data from this assay. 
 
In addition, telomerase activity has also been proposed as a prognostic marker 
(Hiyama and Hiyama, 2002). Telomerase activity has been found to correlate with 
poor prognosis for gastric cancer patients, and also with an increased stage of cancer 
progression (Hiyama et al., 1995a, Tahara et al., 1995). Further, telomerase activity 
has been identified as an independent predictive factor in the prognosis of colorectal 
cancer (Tatsumoto et al., 2000). 
 
As telomerase activity requires the expression of both TR template and the TERT 
protein, the possibility of using their expression levels as prognostic markers has also 
been tested  (Hiyama and Hiyama, 2002). However, hTR and hTERT splice 
variants can also be detected in cells and tissues that lack telomerase activity (Yi et 
al., 1999) and (Ulaner et al., 1998). Therefore, caution must be taken when designing 
specific primers for assaying active hTERT and hTR expression. In conclusion, 
despite some reports indicating the prognostic potential of telomerase components 
(Hiyama and Hiyama, 2003), technical problems and the lack of large-scale studies 
in more than a few cancer types have limited its acceptance so far (Pang and Argyle, 
2010). 
 
1.4.2 Circulating TERT mRNA Transcript 
Recently, many reports have indicated the diagnostic value of measuring the 
circulating mRNA transcript levels in human patients with various diseases, 
especially cancer (Swarup and Rajeswari, 2007). Excitingly, the TERT mRNA 
transcript was specifically found in serum or plasma samples from various cancer 
patients, and it may therefore hold promise for cancer diagnosis (Fleischhacker and 
Schmidt, 2007). 
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1.4.2.1 The Discovery of Circulating RNA 
Although the presence of circulating nucleic acids was first observed in human 
plasma from both patients and healthy individuals nearly 60 years ago, at that time 
no hypothesis was proposed to link this observation with any disease (Mandel P, 
1948). In fact, circulating DNA was first discovered in human plasma or serum from 
patients with a variety of disease conditions, such as Systemic Lupus Erythematosus 
(Tan et al., 1966, Koffler et al., 1973), arthritis (Leon et al., 1981), and in elderly 
patients with various acute or chronic diseases (Fournie et al., 1993). Following this, 
elevated levels of circulating DNA were then reported in plasma from various cancer 
patients compared with healthy subjects (Leon et al., 1977). 
 
In 1999, circulating RNA was reported for the first time in serum or plasma from 
melanoma patients (Kopreski et al., 1999) and in nasopharyngeal carcinoma patients 
(Lo et al., 1999). Since then, circulating RNA has been found in the serum or plasma 
of human patients with various cancers, such as breast cancer (Chen et al., 2000, 
Silva et al., 2001), lung cancer (Fleischhacker et al., 2001, Schmidt et al., 2005, 
Sueoka et al., 2005), skin cancer (Hasselmann et al., 2001a, El-Hefnawy et al., 2004), 
colon cancer (Silva et al., 2002), liver cancer (Miura et al., 2003), prostate cancer 
(Papadopoulou et al., 2004), oral cancer (Li et al., 2006), nasopharyngeal cancer 
(Wong et al., 2006) and gastric cancer (Tani et al., 2007). 
 
However, circulating RNA is not only present in cancer patients, but also has been 
found in other disease and non-disease conditions, such as trauma (Rainer et al., 
2004, Bottcher et al., 2006) and pregnancy (Poon et al., 2000, Maron et al., 2007), 
respectively. 
 
1.4.2.2 The Origin of Circulating RNA 
The various different tumour-specific mRNAs found circulating in cancer patients 
not only reveal the tumour origin, but their discovery is also consistent with many in 
vitro findings that RNA is found in cancer cell culture medium (Morozkin et al., 
2004, Bottcher et al., 2006, Valadi et al., 2007). However, normal human blood 
lymphocytes have also been found to spontaneously release RNA-containing 
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nucleoprotein complexes in vitro in the absence of cell death (Stroun et al., 1978). 
RNA-containing blebs have also been observed on the surface of thymocytes 
undergoing spontaneous apoptosis (Biggiogera et al., 1998). Thus, existing evidence 
suggest the possibility of different sources of circulating RNA. 
 
1.4.2.3 Proposed Existing Forms of Circulating RNA 
RNA is much more unstable than DNA and endogenous RNA tends to be degraded 
by ubiquitous RNases in the blood (Kamm and Smith, 1972). The rapid degradation 
of exogenous RNA in human plasma samples has been confirmed (Ng et al., 2002, 
Tsui et al., 2002) plus elevated levels of ribonuclease have also been observed in 
blood from patients with certain types of cancer (Reddi and Holland, 1976), so it was 
really surprising when stable circulating RNA was first detected in human plasma or 
serum (Kopreski et al., 1999, Lo et al., 1999). 
 
Although circulating RNA was discovered relatively recently and its presence has 
been linked with that of the relatively well-documented circulating DNA in some 
reports and reviews, there is evidence that circulating RNA and DNA may exist in 
different forms. For example, a 0.22µm filter captured 95% of plasma RNA, whilst 
almost all plasma DNA passed through into the filtrate (Ng et al., 2002). Furthermore, 
an in vitro study showed that DNA and RNA were packaged separately during 
apoptosis (Biggiogera et al., 1998, Halicka et al., 2000), indicating their different 
biogenesis. 
 
The filtration experiment described above indicates that RNA exists within particles 
larger than 0.22µm in size, and this could explain why RNA can be stable in the 
circulation (Ng et al., 2002). Interestingly, adding detergents to plasma resulted in the 
loss of circulating RNA, which indicates that circulating RNA is likely to be 
protected in a form of lipid vesicle, or within a protein complex, or possibly in 
apoptotic bodies (El-Hefnawy et al., 2004). 
 
One of the most popular proposals suggests that circulating RNA is present in 
tumour-derived, RNA-containing microvesicles that can be found in serum or plasma 
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of cancer patients (Garcia et al., 2008). Tumour cells have been reported to shed 
microvesicles, which are fragments of plasma membrane (Taylor et al., 1980). These 
microvesicles have not only been found in cancer cell cultures (Dolo et al., 1995), 
but also in the serum or plasma of patients with colorectal (Huber et al., 2005) and 
oral cancers (Kim et al., 2005). Furthermore, it was found that microvesicles isolated 
from serum and from cell culture media are very similar (Masella et al., 1989), being 
characterized as approximately 1µm, circular or villi-like membrane fragments shed 
by tumour cells (Baj-Krzyworzeka et al., 2006). RNA (Rosi et al., 1988, Baj-
Krzyworzeka et al., 2006) and, more importantly, functionally active mRNA has 
been isolated from these vesicles (Ceccarini et al., 1989, Garcia et al., 2008). The 
finding of the size of these microvesicles is also consistent with the 0.22µm filter 
experiment mentioned above. 
 
Another proposed form of RNA-containing particle is the RNA-proteolipid complex 
that can be found in serum from both patients with malignant disorders, and also in 
the culture media of malignant cell lines (Wieczorek et al., 1985, Wieczorek et al., 
1987). Interestingly, similar RNA-lipid complexes have also been found to be 
released by human colon carcinoma cells in vitro (Rosi et al., 1988). 
 
Furthermore, the RNA-DNA hybrid hypothesis was also suggested to describe a 
possible form of circulating RNA, and it was demonstrated that adding RNase H to 
serum reduced the amount of circulating RNA that could be detected (Sisco, 2001). A 
similar structure was also observed in the cell culture of human lymphocytes (Stroun 
et al., 1978). However one report indicated that DNA-RNA hybrid is probably not 
the existing form for circulating RNA as addition of RNase H into the blood samples 
had no effect on plasma RNA levels (El-Hefnawy et al., 2004). 
 
Although there is no direct evidence that the circulating RNA originates in tumours 
undergoing necrosis or apoptosis, circulating DNA has been reported to originate 
from such sources (Jahr et al., 2001). During either spontaneous or DNA damage-
induced apoptosis, cellular RNA was observed to be sequestered and packed into 
apoptotic bodies (Halicka et al., 2000). RNA-containing apoptotic bodies were also 
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found in melanoma cell culture, and the RNA isolated from cell culture supernatant 
were protected in human serum in contrast to cell-derived mRNA extracts 
(Hasselmann et al., 2001). The observation of apoptotic bodies in cancer cell cultures 
may be explained by their high metabolic rate relative to normal cells (Shaw, 2006). 
This higher metabolic rate results in a much quicker proliferation rate, characterized 
by hypoxia and nutrient depletion (Lal et al., 2001, Chaudary and Hill, 2006), and 
this leads to cancer cell apoptosis. 
 
If circulating RNA does exist in more than one form, the relative contribution of 
different release mechanisms should be established in order to help researchers to 












Figure 5 – Proposed Existing Forms of Circulating RNA 
The proposed existing forms of circulating RNA include tumour-derived, RNA-containing 
microvesicles, DNA-RNA hybrid, RNA-lipid complex and RNA-containing apoptotic or 
necrotic bodies. 
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1.4.2.4 Active or Passive Release Mechanism of 
Circulating RNA 
Although the proposal that circulating RNA originates from the processes of 
apoptosis and necrosis indicates that a passive release mechanism may be involved, 
other evidence suggests that a more active process may exist. 
 
It was observed that the percentage of mRNA in the total RNA extracted from culture 
media (49.8%) was significantly higher than the percentage of mRNA in RNA 
extracted from the growing cells (1.4%). This argues in favour of an active release 
mechanism, as I would expect a similar proportion of mRNA in total RNA extracts 
from both cells and cell culture media to occur in more passive cell death mechanism 
(Garcia et al., 2008). It has also been found that the total RNA extracted from plasma 
contained a large portion of small RNAs that indicates a more active mechanism of 
circulating RNA may exist (Garcia et al., 2008). Interestingly, tumour cells have been 
shown to actively promote tumour growth by influencing surrounding stromal cells 
in the tumour microenvironment (Bhowmick et al., 2004), and tumour-derived 
mRNA-containing microvesicles have been reported to transfer into monocytes and 
modulate them to foster tumour growth (Baj-Krzyworzeka et al., 2006, Baj-
Krzyworzeka et al., 2007). Tumour-released microvesicles either isolated from cell 
culture media or from peripheral blood were found to induce Fas-dependent 
apoptosis in T lymphocytes (Andreola et al., 2002, Huber et al., 2005, Amarzguioui 
et al., 2005), block the T lymphocyte receptor (Taylor et al., 2003) and promote the 
differentiation of immunosuppressive myeloid cells that suppress T lymphocyte 
activity, thus assist in tumour immune escape and contribute to tumour growth 
(Valenti et al., 2006). It was also found that tumour-released microvesicles can 
transfer metastatic ability from highly metastatic human tumour cells to poorly 
metastatic ones (Poste and Nicolson, 1980, Hao et al., 2006) and can also expel 
cytotoxic drugs through lysosomes and subcellular secretory compartments (Shedden 
et al., 2003, Safaei et al., 2005). 
 
1.4.2.5 Discovery of Circulating hTERT mRNA 
Since the first finding of circulating RNA in serum and plasma from human cancer 
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patients (Lo et al., 1999, Kopreski et al., 1999), many instances of elevated tumour-
specific circulating mRNAs have been linked with different types of cancer, and 
these observations may lead to a possible early, non-invasive method for cancer 
diagnostics and prognostics. For example, tyrosinase and other melanoma-specific 
mRNAs have been detected in the sera of melanoma patients (Kopreski et al., 1999, 
Rappl et al., 2001). Further, in the sera from lung cancer patients, heterogeneous 
nuclear ribonucleoprotein B1 (hnRNP-B1) and human epidermal growth factor 
receptor 2 (Her2/neu) specific mRNAs have been observed (Fleischhacker et al., 
2001). The epithelial malignant marker, trophoblast glycoprotein (TPBG or 5T4) 
mRNA has also been found circulating in breast and lung cancer patients (Kopreski 
et al., 2001). Interestingly, the circulating epithelial marker carcinoembryonic antigen 
(CEA) mRNA and also cytokeratin (CK19) mRNA were not only detectable in 
plasma of colon cancer patients, but were also found to associate with more 
advanced tumour stages and with circulating tumour cells (Silva et al., 2002). 
Prostate-specific membrane antigen (PSMA) mRNA was also found in the serum of 
prostate cancer patients (Chu et al., 2004) and circulating β-catenin mRNA 
concentration has been found to correlate with tumour stage and tumour removal in 
the plasma of human colorectal cancer patients (Wong et al., 2004). 
 
In contrast with other tumour markers, hTERT is near universal across cancers; is 
critical for the oncogenic process of most cancer types; and can also be detected in 
the early stages of tumorigenesis (Kolquist et al., 1998). Thus many researchers have 
tried to utilize the hTERT transcript in serum or plasma as an indicator for neoplastic 
disease. So far many reports have shown that hTERT is not only present in plasma or 
serum from a variety of cancer patients but also has potential in clinical use. 
 
Circulating hTERT mRNA has been detected in serum or plasma taken from human 
patients with breast cancer (Chen et al., 2000, Novakovic et al., 2004), follicular 
lymphoma (Dasi et al., 2001), colon cancer (Lledo et al., 2004), melanoma, thyroid 
cancer (Novakovic et al., 2004), gastric cancer (Tani et al., 2007) and gynaecological 
cancer (Miura et al., 2007). In liver cancer patients, circulating hTERT transcript can 
not only be detected (Waguri et al., 2003), but is also found to independently 
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correlate with tumour size and the degree of differentiation of the tumour, and is a 
more sensitive marker than the conventional marker, α-fetoprotein (AFP) (Miura et 
al., 2003). In lung cancer patients, the circulating hTERT transcript was not only 
detectable (Pelosi et al., 2006), but its levels were also found to correlate with many 
clinical parameters, such as tumour size, tumour number, the presence of metastases, 
recurrence, smoking and surgical treatment, and both the sensitivity and specificity 
increased when the circulating EGFR transcript was also present (Miura et al., 2006). 
In prostate cancer patients, circulating hTERT mRNA is not only detectable, but can 
also be used to distinguish between malignant and non-malignant prostate conditions 
(Dasi et al., 2006). 
 
Although one group did not find elevated hTERT in their gene profiling experiments 
to identify circulating RNAs in the plasma of colon cancer patients (Collado et al., 
2007), most other findings show a huge interest and enthusiasm for utilizing 
circulating hTERT transcript measurements in oncology. 
 
1.5 Telomerase in Ageing 
1.5.1 Telomerase in Cellular Ageing 
Telomerase is not only responsible for tumour immortalization, but has also been 
linked with ageing (Mather et al., 2011). Unlike cancer cells, which have limitless 
replicative potential (Hanahan and Weinberg, 2000), normal cells have a finite 
growth potential, with permanent growth arrest (cellular senescence) being triggered 
by critically short telomeres or other telomere dysfunctions (Wynford-Thomas, 1999). 
Tumour cells bypass this cellular ageing barrier by maintaining their telomere length 
through the activation of telomerase. These findings generated a huge interest in 
increasing the lifespan of normal somatic cells using telomerase, not only for 
experimental purposes but also for its relevance to the bigger picture of ageing. The 
significant ability of cells provided with exogenous telomerase components to bypass 
replicative senescence and allow unlimited cell proliferation has been reported in 
several types of human somatic cells (Kang and Park, 2007, Sahin and DePinho, 
2010). For instance, the enforced ectopic expression of TERT, the catalytic subunit of 
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telomerase, has been found to stabilize telomere length in human embryonic kidney 
cells (Counter et al., 1998), human primary endothelial cells (Baumer et al., 2010), 
retinal pigment epithelial cells and foreskin fibroblasts, thereby preventing cellular 
senescence and immortalizing human cells (Bodnar et al., 1998) without generating 
cell malignant transformation (Jiang et al., 1999). 
 
1.5.2 Telomerase in Stem Cell Functionality 
Telomerase not only has an important function in somatic cells, but it is also crucial 
for stem cell function, as in stem cells telomerase must be constitutively activated to 
ensure that a lower rate of telomere erosion occurs than in normal cells (Flores and 
Blasco, 2010). In telomerase-null mice with critically-short telomeres (Flores et al., 
2005), the function of epidermal stem cells, as measured by their ability to mobilize 
and to regenerate skin and hair, is dramatically impaired and this defect can be 
rescued by the reintroduction of telomerase (Siegl-Cachedenier et al., 2007). At the 
same time, hyperactivation of telomerase due to elevated TERT expression in a 
mouse model showed an increased mobilization of stem cells, which resulted in an 
extended capacity for tissue maintenance associated with an increased lifespan 
(Donate and Blasco, 2011). The accumulation of stem cells was also observed in 
telomerase-null mice with critically-short telomeres, which indicates that the stem 
cells in these mice have an impaired ability to respond to stimuli, and this could 
explain their premature skin aging phenotype (Flores et al., 2005). In bone marrow, 
the proliferation (Wong et al., 2003) and regenerative function of haematopoietic 
stem cells were both found to be impaired in telomerase-null mouse with critically-
short telomeres (Rossi et al., 2007), whereas an increased number of haematopoietic 
stem cells was also observed (Rossi et al., 2008). This effect is not specific to high-
turnover tissues, since similar results were also reported for neural stem cells in 
telomerase-deficient mouse with critically-short telomeres (Ferron et al., 2004, 
Ferron et al., 2009). 
 
As well as being present in adult stem cells, activated telomerase has also been found 
in induced pluripotent stem (IPS) cells that exhibit high levels of TERT expression 
and long telomeres similar to embryonic stem cells (Marion et al., 2009). IPS cells 
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are generated from differentiated cells by the addition of defined factors, which 
reprogramme them to become the functional equivalents of embryonic stem cells 
(Takahashi and Yamanaka, 2006). IPS cells have been generated from both mouse 
(Okita et al., 2007) and human (Takahashi et al., 2007) cells, and have the capacity to 
redifferentiate and contribute to a wide range of tissues (Nakagawa et al., 2008), 
including germlines (Takahashi et al., 2007). Interestingly, the reprogramming 
efficiency of telomerase-null cells with critically-short telomeres was found to be 
dramatically reduced, but could be rescued by telomerase reintroduction (Marion et 
al., 2009). 
 
1.5.3 Telomerase in Ageing 
Ageing is fundamentally defined as an overall decline in the function of various 
organs due to a decreasing ability to maintain tissue homeostasis and thus a 
decreasing ability to respond to physiological needs and stress (Kirkwood, 2005, 
Finkel et al., 2007). Ageing in murine and human haematopoietic systems is 
associated with an age-dependant decline of stem cell function (Rossi et al., 2008), 
and the ageing of skeletal muscle is accompanied by a decline in the regenerative 
potential of this tissue (Cerletti et al., 2008). As telomerase plays an important role in 
stem cell function and prolongs the normal cell lifespan via telomere extension, 
many studies have investigated its possible role in ageing (Sahin and Depinho, 2010, 
Espejel et al., 2002). Transgenic telomerase-null mice showed progressive telomere 
shortening in successive generations, accompanied by a shortening lifespan (Blasco, 
2005) and premature age-associated pathologies (Herrera et al., 1999, Espejel et al., 
2002), including hypertension (Wong et al., 2009), cardiac dysfunction (Leri et al., 
2003) and reduced tissue regeneration. Stem and progenitor cells from various 
tissues in these mice were found to be either depleted or functionally compromised, 
possibly due to increased senescence and apoptosis, and to impaired differentiation 
(Rudolph et al., 1999, Sahin and DePinho, 2010). Further, haematopoietic stem cells 
from these mice showed a pronounced differentiation profile similar to that found in 
aged humans (Rossi et al., 2007). Epidermal stem cells from these mice were also 
found to be impaired in both their proliferative capacity and in their ability to move 
out of the hair follicle (Flores et al., 2005). Even in the brain, an organ with a 
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relatively low proliferative activity, those mice exhibited an impaired capacity for 
neural stem cell renewal and differentiation (Wong et al., 2003). In contrast, 
transgenic mice with increased telomerase activity due to TERT overexpression were 
found to have an extended lifespan due to a lower incidence of certain age-related 
degenerative diseases, mainly those related to kidney function and to germline 
integrity (Gonzalez-Suarez et al., 2005). 
 
1.5.4 Telomere Length and Ageing 
Since the main role of telomerase in cellular ageing, or possibly in organismal ageing, 
is to control telomere length, the possibility exists that telomere length could be used 
as an ageing biomarker (Sahin and Depinho, 2010). Mice with short telomeres have 
been shown to have a reduced lifespan and a reduced stress response (Rudolph et al., 
1999). Furthermore, age-dependant telomere attrition has been observed in cells of 
the lung, pancreas, skin and thyroid of non-human primates (Gardner et al., 2007). In 
a study of 143 people aged 60 or older, it was found that individuals with shorter 
telomeres had a significantly higher mortality rate (Cawthon et al., 2003). Three 
other similar studies also reported the similar results (Bakaysa et al., 2007, Epel et al., 
2009, Ehrlenbach et al., 2009). Telomere length has also been found to positively 
correlate with longevity in Ashkenazi centenarians (Atzmon et al., 2010). 
 
In addition to its effects on lifespan, short telomere length has been associated with 
several physical ageing parameters such as increased pulse pressure (Benetos et al., 
2001) and blood pressure (Mather et al., 2011). In contrast, longer telomere length 
has been associated with better self-rated general health (Njajou et al., 2009). In 
addition, telomere length was reported to inversely correlate with levels of 
psychological stress and the risk of development of psychiatric disease (Epel et al., 
2004, Epel et al., 2006, Simon et al., 2006). Patients with inherited degenerative 
disorders such as dyskeratosis congenita, Werner’s syndrome or ataxia telangiectasia, 
caused by mutations in genes responsible for telomere maintenance (Garcia et al., 
2007), have shortened telomeres and reduced lifespans, along with signs of 
accelerated ageing and bone marrow failure (Kirwan and Dokal, 2009). 
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Although some reports have suggested that telomere length could be a potential 
biomarker for ageing, several other studies have failed to find a correlation between 
telomere length and ageing, lifespan or general health (Martin-Ruiz et al., 2005, 
Harris et al., 2006, Bischoff et al., 2006, Njajou et al., 2009, Mather et al., 2010). 
Currently the telomere measurements used in most studies were those from 
peripheral blood cells, which can be repeatedly sampled with minimum harm to the 
participant; however, the length of telomeres in these cells may not reflect the length 
of telomeres in all other tissue types (Thomas et al., 2008). In addition, the current 
methods for measuring telomere length have their limitations and may not be 
sensitive enough for detecting very short telomeres (Mather et al., 2011). Taken 
together, current data regarding the use of telomere length as an ageing biomarker are 
inconclusive, and it is likely that telomere length may not be a universal biomarker. 
Instead multiple biomarkers may be required for use at different stages of life to 
comprehensively evaluate the biological ageing process (Mather et al., 2011). 
 
1.6 Telomerase and Telomere in Other Diseases 
In addition to cancer, variations in telomerase activity and telomere length are also 
associated with a number of other diseases. For example, Cri du chat syndrome 
(CdCS), also known as chromosome 5p deletion syndrome, is a complex genetic 
disorder (Cerruti Mainardi, 2006) in which one allele of hTERT is deleted, and the 
reduced gene dosage is consequently thought to affect telomere maintenance, cell 
growth and development (Zhang et al., 2003). Further, mutations in the telomerase 
complex genes, TERT, TR and DKC1 have been reported in both inherited and 
acquired bone marrow failure syndromes, including dyskeratosis congenita, aplastic 
anaemia (Yamaguchi et al., 2005) and myelodysplastic syndrome (Knight et al., 2001, 
Yamaguchi et al., 2003), and these mutations are thought to influence telomere 
length and thus to attenuate the proliferative potential of haematopoietic stem cells 
(Yamaguchi, 2007). Recently, telomere biology has also been linked with several 
cardiovascular diseases, for example shortened telomere length has been reported in 
patients with atherosclerosis, hypertension and heart failure (Huda et al., 2007, 
Willeit et al., 2010). However, whether telomere dysfunction is a cause or a 
consequence of any of these diseases remains to be elucidated (Wong et al., 2009).  
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Understanding how telomerase functions and how telomere lengths are regulated in 
vivo would not only help us to tackle issues related to cancer, but may also open new 
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Figure 6 – Current Model between Telomere Dysfunction and Diseases 
So far, many evidences have indicated that telomere dysfunction is not only a consequence of 
ageing but also could be caused by genetic mutations or environmental factors. 
Dysfunctional telomeres as a result causes many diseases including cancer. 
 
1.7 Canine Telomerase 
As occurs in humans, telomerase is also activated in the vast majority of canine 
cancer patients (Nasir et al., 2001). Currently most in vivo models used to study 
telomere function and telomerase are mouse models. However, the murine system is 
not ideal, as telomerase is present in all adult mouse tissues and murine telomeres 
(ranging from 40 to 80 kb) are normally much longer relative to those of humans 
(Martin-Rivera et al., 1998). Dogs are more similar to humans, in that telomerase 
activity is upregulated in the majority of tumours, and is absent in normal adult 
tissues (Argyle and Nasir, 2003). Importantly, canine telomere lengths (3–23 kb, 
Yazawa et al., 2001, Nasir et al., 2001) are comparable to those found in humans 
(10–15 kb) (Blasco, 2005). Thus, understanding how canine telomerase functions 
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may not only benefit canine cancer patients, but may also improve our understanding 
of human telomerase function and telomere biology (Nasir, 2008). 
 
1.8 Aims of this Thesis 
Whilst hundreds of scientific articles on human telomerase and its potential 
applications in cancer diagnosis are published each year, reports on canine 
telomerase are very limited so far. In this study, I aimed to answer three fundamental 
questions regarding canine telomerase. First, we explored the potential of two novel 
delivery systems and plasmid-based siRNA vector to downregulate cTR gene. We 
next investigated for the first time if the cTERT mRNA transcript is found in the 
circulation of canine cancer patients and whether it can be utilized as a cancer 
biomarker. Finally, in a pilot study I tested whether endogenous telomerase activity 
can be induced in canine somatic cells by novel telomerase activator compounds. 
Altogether this study has helped us to gain a better understanding of canine 
telomerase and its application in canine oncology, and importantly provides a 
baseline for further investigation. 
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2.1 Cell Culture 
2.1.1 Cell lines 
 
Cell Lines Complete Culture Media (500ml) Origin 
450ml 1X Dulbecco's modified Eagle's 
medium (D-MEM) high glucose  
10% certified foetal bovine serum (FBS; 
Invitrogen, United States) 
0.1mM MEM non-essential amino acids  
6mM L-glutamine  
1mM MEM sodium pyruvate solution  
1% Penicillin-Streptomycin solution  
293FT (500µg/ml Geneticin®)  Embryonic human kidney cells 
500ml 1X D-MEM with L-glutamine  
EOMA 10% certified FBS  
Murine haemangioendothelioma 
cells (ATCC-LGC, United States) 
500ml endothelial cell basal medium-2 
(EBM-2; Lonza, United Kingdom) 
SB-HSA 
EGM-2 SingleQuots (Lonza, United 
Kingdom) 
Canine haemangiosarcoma cells, 
a gift from Dr. Nasim Akhtar 
(Akhtar et al., 2004) 
HUVEC 
The same medium as that used for SB-
HSA (described above) 
Human umbilical vein endothelial 
cells (Lonza, United Kingdom) 
450ml 1X D-MEM GlutaMax-1  
10% certified FBS  
D-17 1% Penicillin-Streptomycin solution  
Canine osteosarcoma cells 
(ATCC-LGC, United States) 
450ml RPMI-1640 (Sigma, United 
Kingdom) 
10% certified FBS  
H1299 1% Penicillin-Streptomycin solution  
Human lung cancer cells, a gift 
from Dr. Matylda Sczaniecka 
450ml 1X D-MEM medium  
10% certified FBS  
6mM L-glutamine  
1mM MEM sodium pyruvate solution 
CEF 1% Penicillin-Streptomycin solution  
Canine embryonic fibroblasts, a 
gift from my colleague, Daniella 
Gattegno 
 
Table 2 - Information of all Cell Lines – Names, Origin and Growth Media 
All cells and growth media supplements were purchased from Invitrogen, United Kingdom, 
unless otherwise stated in the table. Growth medium of 293FT cells without Geneticin® was 
used to recover cells from cryovials and this non-antibiotic medium was replaced with 
complete medium 24h after culture. EGM-2 SingleQuots which contains growth factors, 
cytokines and supplements is specially designed to support the growth of primary cells. 
 
2.1.2 General Conditions and Handlings for Cell Culture 
All cells mentioned above are adherent cells. 0.25% 1X Trypsin-EDTA, phenol red 
(Invitrogen, United Kingdom) was used for detaching cells. After 2ml Trypsin-EDTA 
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was added into the T-75 flask (1ml for T-25 flask; Corning, United Kingdom), cells 
were incubated at 37°C for 5 minutes and the disassociation of cells was checked by 
microscope. 1X Sterile Phosphate-Buffered Saline (PBS) which was diluted from 
10X PBS (Invitrogen, United Kingdom) contains 1.47mM monobasic potassium 
phosphate, 137mM sodium chloride, 2.7mM potassium chloride and 4.3mM dibasic 
sodium phosphate, and was used for washing cells. All cells and related reagents 
were handled in a sterile laminar flow hood, and reagents were warmed up in 37°C 
water bath (if necessary) before use. Cells were grown at 37°C in a humidified 
atmosphere containing 5% CO2. All cells were maintained in T-25 or T-75 flasks in 
either 9ml or 12ml complete growth media respectively. Frozen cell stocks were 
stored at -70°C (for short term storage) or in liquid nitrogen (for long term storage). 
All cells were passaged at least three times after thawing before any experiments 
were done. Cell density, cell viability, β-galactosidase and GFP expression in 
transfected cells were monitored, analysed and photographed using a fluorescence 
microscope (Carl Zeiss, Axiovert 40) equipped with Axiovision 4.7 software. 
 
2.1.3 Initiation of Cell Culture 
For thawing frozen cell stocks, a T-25 culture flask containing 9ml complete medium 
was first warmed to 37°C in an incubator. A cryovial containing frozen cells was then 
thawed quickly in a 37°C water bath, and cells were resuspended in the cryovial and 
dispensed into the 25cm2 flask. The flask was gently rocked to evenly distribute the 
cells, and then it was returned to the incubator. Cells were checked daily until they 
reached 80–90% confluency for subculture. 
 
2.1.4 Subculture of Cells 
When cultured cells reached a confluency of 80-90% they were subcultured. For this, 
the growth medium was removed and cells were washed twice in 5ml PBS followed 
by detaching cells using trypsin-EDTA. After cell-detaching, 8ml growth medium 
was added into the T-75 flask to suspend cells (4ml for T-25 flask). The cell 
suspension was then transferred into a 15ml sterile conical tube and centrifuged at 
150 x g for 5min. After discarding the supernatant, cells were resuspended in 10ml 
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complete growth medium and counted. The cells were calculated and cell viability 
was checked using the nigrosin method (see below 2.1.5) before seeding at the 
required density. For this, cells were diluted into a new T-75 flask with 12ml pre-
warmed complete growth medium and checked daily until they were 80–90% 
confluent. All cells were subcultured in a ratio of 1/3 – 1/8 and growth medium was 
changed every 2 - 3 days. 
 
2.1.5 Cell Counting and Viability Determination 
10μl of cell suspension and 10μl of 0.2% nigrosin (Sigma, United Kingdom) were 
mixed, and then 10μl of this mixture was added to the counting chamber of a 
haemocytometer. Cells in the centre 25 squares of the grid were counted (including 
cells crossing the top and left lines, but not including those touching the bottom and 
right lines). The blue cells were determined to be dead, and cell viability was 
monitored to make sure that they were at least 95% viable (the ideal viability for 
healthy log-phase cultures). The formula below was used for calculating the total 
number of cells in the cell suspension. 
 
Total No. of cells = cell count x volume of cell suspension (10ml) x 2 (dilution factor 
with nigrosin) / 0.0001ml (the volume of the 25 squares in the centre of the 
haemocytometer) 
 
2.1.6 Freezing Cells 
After cell culture was established, cells stocks were frozen in cryovials for future use. 
Each cryovial contained at least 3 x 106 viable cells/ml and the freezing medium was 
90% complete growth medium, 10% DMSO (Sigma, United Kingdom). For freezing, 
cells were tryspinised, counted, then centrifuged and resuspended in a pre-
determined volume of freezing medium. 1ml Aliquots of cells were dispensed into 
cryovials. Cryovials were firstly stored at -70°C inside a Styrofoam box for 24 h to 
slow-freeze cells and then moved to liquid nitrogen for long term storage. 
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2.2 RT-PCR 
All DNA oligonucleotides used in this study (including PCR primers, sequencing 
primers and siRNA inserts) were ordered from Eurofins MWG Operon. All 
sequencing was performed at the GenePool sequencing service at the University of 
Edinburgh using Sanger Sequencing method. 
 
2.2.1 Total RNA Isolation 
Total cellular RNA was extracted using an RNeasy Mini Kit (Qiagen, United 
Kingdom). All components mentioned below were provided by the kit unless 
otherwise stated. Up to 1 x 107 cells can be processed in one reaction. Cells were 
sedimented by centrifugation at 300 x g for 5min and the supernatant was carefully 
removed. 600µl RLT buffer was then added and cells were disrupted by pipetting. 
The cell lysate was loaded into a QIAshredder spin column on top of a collection 
tube and centrifuged at full speed for 2min. After lysing cells, 600µl of 70% ethanol 
was added to the homogenized lysate. Up to 700µl samples were loaded into the 
RNeasy Spin Column assembly and centrifuged at 8,000 x g for 15s. After discarding 
the flow-through, 700µl RW1 buffer was added and the column was centrifuged at 
8,000 x g for 15s to wash the membrane. After discarding the flow-through, 500µl 
RPE buffer was added and the column was centrifuged at 8,000 x g for 15s. This last 
step was then repeated, but with a 2min centrifugation step. After discarding the 
flow-through, RNeasy spin column was placed into a new tube and centrifuged at 
full speed for 1min to spin out any buffer left in the column. Following this, the 
RNeasy spin column was transferred to a new collection tube and 40µl Nuclease-free 
water (NF-water) was added to the membrane. The column was then centrifuged at 
8,000 x g for 1min, and then the eluted RNA was treated with DNase before being 
used for experimental applications. 
 
2.2.2 DNase Treatment 
DNA-free™ kit was used for all DNase treatment of RNA extracts. All components 
mentioned below were provided by the kit unless otherwise stated. 0.1 volume of 
10X DNase I buffer and 1.5µl DNase I was added to 40µl RNA in a 500µl 
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microcentrifuge tube, mixed gently then incubated for 30min at 37ºC. Next, 0.1 
volume of DNase Inactivation Reagent was added and mixed. After incubation for 
2min at room temperature, the tube was centrifuged at 10,000 x g for 1.5min and 
RNA was then transferred to a fresh tube and quantified by spectrophotometry. 
 
2.2.3 Spectrophotometry 
The concentrations of DNA or RNA samples were quantified using a NanoDrop™ 
Spectrophotometer (Thermo, United States). Before measuring samples, 2µl NF-
water was applied to the machine to make a blank measurement. 2µl of DNA or RNA 
was then applied to the machine. The ratio of the absorbance readings at 260nm and 
at 280nm (A260/280) was calculated automatically by the machine and used to estimate 
the purity of DNA and RNA samples. For pure DNA the ratio is close to 1.8 and for 
pure RNA the ratio is close to 2.0. 
 
2.2.4 cDNA Synthesis Using Cellular RNA 
All cDNA synthesis from cellular RNA extracts was done using the Reverse 
Transcription System (Promega, United Kingdom), and synthesized cDNA was used 
in conventional and real-time PCR reactions. The recipe for the reaction mix is given 
below (Table 3). All components mentioned below were provided by the kit unless 
otherwise stated. The reaction mixture was first incubated at room temperature for 
10min, and then the reverse transcription reaction was done at 42ºC for 15min. The 
reaction products were then heated to 95˚C for 5min to inactive the transcriptase and 
prevent it from binding to the cDNA, then cooled at 4˚C for 5min. cDNA can be 
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Component Amount (µl) 
MgCl2, 25mM 4 
Reverse Transcription 10X Buffer 2 
dNTP Mixture, 10mM 2 
Recombinant RNasin® Ribonuclease Inhibitor 0.5 
AMV Reverse Transcriptase, 15U 0.8 
Random Primers, 0.5μg/μl 1 
Total RNA 1μg 
NF-water To a final volume of 20 
 
Table 3 – cDNA Synthesis from Cellular RNA 
This cDNA synthesis kit was used on all cellular RNA extracts only. For serum RNA, cDNA 
synthesis was done using Sensiscript RT kit detailed in Chapter 4 (4.3.3). 
 
2.2.5 RT-PCR 
RT-PCR methods and conditions for different applications are provided in the 
appropriate results chapter. 
 
2.2.6 Agarose Gel Electrophoresis 
2% agarose gels were used to visualize restriction digestion products of 55bp in size. 
It was prepared using 0.7g agarose (Sigma, United Kingdom) and 35ml 1X TAE 
buffer. 1X TAE buffer was prepared by diluted 50X TAE buffer (Qiagen, United 
Kingdom) and contains 40mM Tris acetate and 1mM EDTA. Larger PCR products 
were visualized using 1% agarose gels, which were prepared using 0.35g agarose and 
35ml 1X TAE buffer (for a small gel) or 1.2g agarose gel and 120ml 1X TAE buffer 
(for a large gel). The agarose was weighed and added to the correct volume of TAE 
buffer, then heated in the microwave at full power for 30s at a time until the agarose 
had melted. When the bottle was cool enough to handle, 3.5µl (for a small gel) or 
12µl (for a large gel) of GelRedTM (Biotium, United Kingdom) was added and the 
molten agarose was then poured into a gel tray and allowed to set for at least 1 h. 
DNA samples were mixed with Blue/Orange Loading Dye (Promega, United 
Kingdom) at a ratio of 1:5 v/v. For cell experiments, 10µl PCR product samples were 
analysed, and for serum RNA experiment, 25µl PCR product samples were analysed. 
Electrophoresis was done in 1X TAE buffer, and either 100bp or 1kb DNA ladder 
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(Promega, United Kingdom) were run alongside samples. Gels were run at either 
60V (for a small gel) or 120V (for a big gel) for approximately 40min. After 
electrophoresis, gels were visualised and analysed on Gel Doc XR+ System with 
Quantity One software (Version 4.6.8). 
 
2.2.7 Transformation of E. coli 
LB plates and LB broth were first prepared before transformation of E.coli. LB plates 
were prepared using imMedia™ Amp Blue premixed powder (Invitrogen, United 
Kingdom). A single sachet was mixed with 200ml distilled water then heated in a 
microwave oven on a medium power setting for 2–3min until bubbles started to 
appear, then heating was continued for another 30s reheat until the powder was 
completely dissolved. Every 10ml molten medium was then gently poured into 
standard-sized sterile Petri dishes to reach 1/2 full at most. These plates were allowed 
to cool down, then sealed and put upside down in the refrigerator for up to a month 
until use. LB broth was prepared by mixing 25g Luria Broth Base (Invitrogen, 
United Kingdom) with 1L distilled water and autoclaving. Ampicillin (Sigma, United 
Kingdom) was added to cooled LB broth for a final concentration of 100μg/ml. 
 
One Shot TOP10 competent E. coli cells (Invitrogen, United Kingdom) were 
transformed with plasmid DNA. 2μl DNA was first added to a thawed vial of 50μl 
competent cells, and mixed. After incubating for 5min on ice, cells were heat-
shocked for 30s at 42˚C in a water bath then immediately transferred onto ice. 250μl 
super optimal broth with catabolite repression (S.O.C.) medium (room temperature) 
was added to the cells, then the vial was shaken at 200rpm in a 37˚C incubator for 1h. 
20μl of transformed cells were spread onto a pre-warmed LB plate and incubated 
overnight at 37˚C. The next day, transformed bacterial colonies were picked and 
grown on for plasmid preparation. 
 
2.2.8 Plasmid DNA Preparation 
Two methods were used to prepare plasmid DNA: the QIAprep Miniprep Kit 
(Qiagen, United Kingdom) was used for small-scale DNA isolation to screen 
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colonies, and the Hispeed Plasmid Maxi Kit (Qiagen, United Kingdom) was used for 
large-scale DNA isolation. All the buffers and reagents used below were supplied in 
the kits unless otherwise stated. The manufacturer’s manuals were followed when 
using both kits. 
 
2.2.8.1 Plasmid Preparation Mini Kit 
A single colony was picked from a plate and used to inoculate 3ml LB medium 
containing 100µg/ml ampicillin. After 14h incubation at 300rpm in a 37˚C shaking 
incubator, bacteria were harvested by centrifugation at 6800 x g for 3min at room 
temperature. The bacterial pellet was resuspended in 250µl P1 buffer and transferred 
to a microcentrifuge tube. 250µl P2 buffer was then added and the tube was inverted 
6 times to mix. 350µl P3 buffer was then added and mixed immediately by inverting 
the tube another 6 times. The tube was then centrifuged for 10min at 17,900 x g at 
room temperature. The supernatant was then decanted into a QIAprep spin column, 
which was then centrifuged for 1min. After discarding the flow-through, 0.5ml BP 
buffer was added and the column was centrifuged for 1min and the flow-through 
discarded. The column was then centrifuged for 1min again to remove residual wash 
buffer. Lastly, the column was placed in a 1.5ml microcentrifuge tube and 50µl EB 
buffer was added to the centre of the membrane. After 1min incubation, the column 
was centrifuged for 1min and plasmid DNA was eluted into the microcentrifuge tube. 
 
2.2.8.2 Plasmid Preparation Maxi Kit 
For the Hispeed Plasmid Maxi Kit, a single bacterial colony was picked and 
inoculated into 5ml LB medium containing 100µg/ml ampicillin to form a starter 
culture. This was shaken at 300rpm for 8h at 37˚C. Following this, 0.6ml of the 
starter culture was diluted 1/500 with 300ml LB containing 100µg/ml ampicillin in a 
1L flask and shaken at 300rpm for 14h. Following this, the bacteria were harvested 
by centrifugation at 6,000 x g for 15min at 4˚C. The bacterial pellet was resuspended 
in 10ml chilled P1 buffer for lysis, then 10ml P2 buffer was added and thoroughly 
mixed. After no more than 5min incubation at room temperature, 10ml chilled P3 
buffer was added and mixed by inverting 6 times, then the lysate was immediately 
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poured into the barrel of a QIAfilter cartridge. The plunger was then inserted into the 
cartridge and cell lysate was filtered through a Hispeed Maxi Tip that had been 
previously equilibrated with 10ml QBT buffer. After the cleared lysate had passed 
through the resin by gravity flow, the tip was washed with 60ml QC buffer. Then the 
DNA was eluted from the tip using 15ml QF buffer. 10.5ml (0.7 volumes) room 
temperature isopropanol was then added to the eluted DNA, mixed and incubated for 
5min at room temperature. After this incubation, the eluted DNA/isopropanol 
mixture was transferred to a 30ml syringe attached to a QIAprecipitator Maxi 
Module, and the mixture was pressed through the precipitator using a plunger. The 
precipitator was then removed followed by removal of the plunger. After reattaching 
the precipitator, 2ml 70% ethanol was added into the syringe to wash the DNA and 
the plunger was inserted to press the ethanol through using constant force. Next air 
was pressed through the syringe quickly and forcefully to dry the membrane. This 
step was repeated, and then the nozzle of the precipitator was dried with absorbent 
paper to prevent any ethanol carryover. The precipitator was attached to a new 5ml 
syringe held over a 1.5ml collection tube. 1ml of TE buffer was added to the 
membrane through the syringe and DNA was eluted into the collection tube using 
constant pressure. The eluate was then transferred back in to the syringe assembly 
and a second elution was performed. 
 
The concentration of purified DNA was measured using a NanoDrop machine, and 
DNA was stored at -20˚C. 
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3.1 Chapter Abstract 
Although we have developed a siRNA viral vector to target canine telomerase in 
vitro, an efficient systemic delivery vehicle is still required. Some endothelial lineage 
cells have been reported to specifically home to the tumour formation sites and a 
novel dendrimer, PPIG3 was also found to accumulate in tumour sites following i.v. 
injection. I therefore explored these novel delivery systems in the canine context. In 
addition, I developed a plasmid-based siRNA vector targeting cTR and tested it on 
two canine cancer cell lines. 
 
A series of transient and stable transfections were conducted on 3 endothelial cell 
lines using 3 different reporter genes by 4 different commercial transfection reagents. 
After succeeding the transient and stable transfection on SB-HSA cells, I labelled 
them and analyzed their tissue distribution into a canine xenograft tumour mouse 
model after i.v. injection. In parallel, the transfection ability of PPIG3 dendrimers 
was also tested on two canine cancer cell lines. To this end, I then designed and 
constructed a plasmid-based siRNA vector and tested its ability to downregulate cTR 
in two canine tumour cell lines by RT-PCR.  
 
Initially, I have found SB-HSA cells were more easily transfected than the other two 
cell lines and by using a modified protocol of Lipofectamine™2000, I could even 
achieve better transient and stable transfection results on SB-HSA cells. In vivo 
however, although I did observe some labelled SB-HSA cells homing to tumour sites, 
a wide non-specific tissue distribution was also observed. In parallel, PPIG3 
dendrimers-mediated DNA transfer in vitro was found not as effective as using 
Lipofectamine™2000 method. Using plasmid-based siRNA vector, I did not observe 
any cTR gene-silencing on two canine cancer cell lines. 
 
Although our potential cellular delivery vehicle, SB-HSA cells was optimised in vitro, 
their tumour-homing ability as well as the wide tissue distribution still needs further 
investigation. For PPIG3 dendrimers, their relatively low transfection on canine cells 
may hinder their performance as a systemic delivery vehicle in vivo and so this 
system also needs further development. Since our siRNA vector did not show any 
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cTR gene-silencing, it has raised the question to whether the cTR gene sequence I 
targeted is a valid target for siRNA as well as of whether the siRNA vector itself is 
capable of inducing RNAi in canine cells. 
 
3.2 Introduction 
Despite recent progress in cancer treatment, cancer gene therapy use is limited with 
disappointing results so far. The current inefficiency of cancer gene therapy is caused 
by many factors, including the low efficiency of gene transfer; the immune attack 
and destruction of therapeutic molecules or the delivery vehicle; non-specific 
targeting of cancer cells; insufficient delivery of therapeutic molecules to the target 
site; and delivery approaches that restrict the delivery of therapeutic molecules to the 
local tumour site only. One of the most important factors is the lack of a systemic 
delivery system, which would ideally deliver the therapeutic gene to, and thereby 
mediate transgene expression in, different tumour-cell populations and in all primary 
and metastatic tumour sites. 
 
3.2.1 Systemic Delivery Vehicles for Cancer Gene Therapy 
Naked ssDNA oligonucleotides have a half-life less than an hour in peripheral blood, 
even when modified to resist degradation (Iversen, 1991), and are rapidly cleared 
from the kidney (Sands et al., 1994). Naked dsDNA is also cleared rapidly after 
being administered into the blood circulation and is extensively taken up by the liver 
(Kawabata et al., 1995). In addition, siRNA molecules cannot resist degradation from 
blood and are subject to a similar elimination pathway following intravenous 
injection (Huang et al., 2011). Furthermore, cellular uptake of both DNA and RNA is 
generally inefficient. All of these factors strongly hinder delivery of the therapeutic 
gene to tumour sites. To assist the systemic delivery of therapeutic genes, several 
promising delivery systems are now being proposed and investigated: these are 
generally classified into viral vectors (Sinkovics and Horvath, 2008) and non-viral 
vectors (Roth et al., 2008, Kaneda, 2010) (Table 4). 
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Systemic Delivery Vehicles 
Viral 
Vectors Non-Viral Vectors 
Synthetic Vectors Biological Vectors 























Table 4 – Summary of the Major Current Systemic Delivery Vehicles 
Current systemic delivery vehicles are classed into viral vectors and non-viral vectors.  
Non-viral vectors include synthetic vectors and biological vectors. Synthetic vectors mainly 
include liposomes and polymers among which polyethylenimine (PEI) and other dendrimers 
are popular candidates that are currently being explored. Among biological vectors, 
bacterial vectors and cellular vehicles have been intensively studied. Currently both 
anaerobic and facultative anaerobic bacteria have been investigated as potential systemic 
delivery vehicles. For cellular vehicles, mesenchymal stem cells (MSC) and endothelial 
lineage cells have been proposed as candidates for systemic gene transfer vectors. 
 
3.2.1.1 Viral Vectors 
Viruses appear to be an attractive delivery vehicle because they contain intrinsic 
mechanisms designed to transfer their DNA into host cells (Baranowski et al., 2001). 
Part or all of the viral genome can be modified by replacement with therapeutic 
genes, which enables the virus to be engineered into either a replication-defective or 
a replication-competent recombinant viral vector (Kay et al., 2001). To date, several 
types of viral vector have been developed for cancer gene therapy, including 
retroviral vectors, adenoviral vectors and herpes viral vectors, and these have been 
shown to be efficient gene transfer vectors for both in vitro and in vivo applications 
(Sinkovics and Horvath, 2008). 
 
               Retroviral Vector 
The retrovirus is a single-stranded RNA (ssRNA) virus encoding a reverse 
transcriptase enzyme that can produce DNA from its RNA genome, and then insert 
the DNA into the host genome in order to replicate itself. Thus, the major advantage 
of this vector is its ability to induce long-term gene integration into the host genome, 
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raising the possibility that transferred therapeutic genes could be expressed 
throughout the entire life of the host cell (Dalba et al., 2007). Early clinical trials on 
replication-defective retrovirus-mediated cancer gene therapy indicated a low 
transduction rate for tumour cells in vivo, thus paving the way for using replication-
competent vectors in a clinical setting (Rainov and Ren, 2003). Indeed, intratumoural 
injection of a replication-competent murine leukaemia virus carrying a suicide gene 
into a cancer-bearing mouse resulted in a 100% survival rate (Wang et al., 2003). In 
addition, a promising member of the retroviral family, the lentivirus, has been 
developed as a siRNA expression vector, and has been shown to effectively deliver 
siRNA and induce post-transcriptional gene-silencing in vitro and in vivo in various 
cancer models (Sumimoto and Kawakami, 2007). Additionally, unlike other 
retroviral vectors, the lentivirus has the ability to transduce non-dividing cells 
(Bukrinsky et al., 1993) which has become an attractive candidate to treat brain 
cancer. 
 
               Adenoviral Vectors 
An adenoviral vector has also been developed for cancer gene therapy (Fukazawa et 
al., 2010). The adenovirus has been shown to transfer foreign genes into a broad 
range of cells, including both dividing and non-dividing cells (Shirakawa, 2008). 
First generation adenoviral vectors were also reported to induce an unfavourable host 
cellular immune response (Yang et al., 1995), and therefore more viral genes have 
been deleted in new generation adenoviral vectors and these exhibit less 
immunogenicity and have the ability to mediate long-term gene expression in host 
cells (Sakhuja et al., 2003). This vector requires a helper virus, which has been 
rendered unpackable in the host cells but retains the ability to remain replicate and 
provide helper function, to be fully functional thus should have increased 
transduction ability, increased safety and reduced immunogenicity (Parks et al., 
1996). It is currently one of the most promising viral vectors and more research is 
still required to improve cancer-cell targeting as well as transduction efficiency 
(Fukazawa et al., 2010). 
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               Herpes Simplex Viral Vector 
The herpes simplex virus (HSV) is a neurotropic virus known for its ability to infect 
nerve cells and cause latent infection, and HSV-1 has been the serotype most studied 
in cancer gene therapy applications (Marconi et al., 2008). Similar to lentiviral 
vectors, HSV also has the ability to infect both dividing and non-dividing cells and 
can grow robustly inside a tumour (Todo, 2002, Todo, 2008). The early generation 
replication-defective HSV vectors were developed to deliver transgenes into tumour 
cells such as melanoma (Krisky et al., 1998) and glioblastoma (Niranjan et al., 2000). 
One type of HSV-1 vector, the amplicon vector, is identical to wild type HSV but 
carries a DNA plasmid instead of the viral genome (Sena-Esteves et al., 2000), and 
has been utilised to induce RNAi to silence crucial cancer genes, such as EGFR, in 
human gliomas (Saydam et al., 2005). Various replication-competent HSV vectors 
have also been engineered to not only target cancer cells, but have also been 
developed as oncolytic vectors that retain the ability to lyse and kill the host cell, 
thereby releasing new virus particles capable of infecting neighbouring tumour cells 
(Marconi et al., 2008). However, some clinical trials conducted using the HSV vector 
did not show significant tumour growth retardation (Rampling et al., 2000, Markert 
et al., 2000). Overall, although some progress has been made in the use of HSV viral 
vectors, a combinatorial approach using viral vectors along with chemotherapy might 
achieve a better result for treating cancers (Post et al., 2004). 
 
However, the major concerns involving the use of viral vector include safety 
concerns; immunogenicity; insertional mutagenesis that may cause oncogene 
activation and silencing of tumour suppressor genes. The extent of these concerns 
indicates that further development of viral vectors for use as cancer therapeutics is 
still needed (Tomanin and Scarpa, 2004). 
 
3.2.1.2 Non-viral Vectors 
               Synthetic Non-viral Vectors 
In general, non-viral vectors can be classified into synthetic vectors and biological 
non-viral vectors. Currently synthetic vectors are mainly produced using chemical 
means, and include cationic liposomes and polymers that can self-assemble with the 
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negatively-charged nucleic acid to form DNA–vector complexes (or lipoplex) 
(Kaneda, 2010). It is the most common method employed for the ‘packaging’ of 
nucleic acid which is based on electrostatic interaction between the anionic nucleic 
acid and the positive-charged synthetic to form the nanoparticles where nucleic acid 
is complexed and condensed. Apart from delivery to the desired site, this packaging 
nanoparticle also tends to compact and protect the nucleic acid (Brown et al., 2001). 
Over the past decade, increased interest has been shown in the use of synthetic 
vectors as delivery vehicles for cancer gene therapy, not only because they can 
deliver therapeutic DNA or RNA molecules but also because they can deliver 
chemotherapy drugs to tumour cells, protect these drugs while circulating in the 
blood and also because they have a lower immunogenicity than viral vectors (Morille 
et al., 2008). 
 
                    Liposomes 
Cationic liposomes are amphiphilic molecules that can spontaneously form a lipid 
bilayer in aqueous solution. They were first introduced to facilitate gene transfer in 
vitro (Felgner et al., 1987) and soon became popular as non-viral transfection 
methods (Tarahovsky, 2009). Currently, the internalization of lipoplexes by cells is 
still not well understood, but early reports suggest that fusion with the cellular 
plasma membrane results in DNA delivery direct to the cytosol. However, some 
endocytosis blocking studies have shown that most of the uptake occurs via 
endocytosis (Pichon et al., 2010). Some research has demonstrated that lipoplex of 
size 100–120nm had the best tumour uptake result (Moreira et al., 2001). 
Intratumoural lipoplex-mediated cancer gene therapy has been demonstrated in 
melanoma patients (Nabel et al., 1993), and the systemic delivery of immuno-
siRNA–lipoplex with specific tumour targeting has also been shown to be effective 
in reaching both primary and metastatic tumours in three different tumour models 
(Pirollo et al., 2006) and in several other studies (Wu and McMillan, 2009). Although 
many liposomes have been synthesized for cancer gene therapy (Templeton, 2009), 
very few of them have reached clinical trials so far. The limitations of using 
liposomes as systemic delivery vehicles include aggregation and disintegration of the 
vector in the blood circulation (Li et al., 1999); non-specific liver uptake mainly by 
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Kupffer cells and consequent inflammatory side-effects (Zhang et al., 2005, 
Tousignant et al., 2000); and relatively low transfection efficiency compared with 
viral vectors (Tong et al., 2009). 
 
                    Polymers 
Polymers are large molecules containing repeating structural units and were reported 
as gene transfer vectors in vitro at approximately the same time as liposomes (Wu 
and Wu, 1987).  
 
                         PEI 
The most common non-degradable polymer used for DNA transfer is 
polyethylenimine (PEI) (Boussif et al., 1995), which exists in both linear and 
branched forms and has a high level of gene transfer efficiency (Halama et al., 2009). 
PEI is water soluble and consists of multiple ethylenimine units that contain a high 
density of positive charges contributed by their amino groups (Park et al., 2006). PEI 
was found to mediate gene transfer with a comparable efficiency to those of viral 
vectors in vitro (Kichler et al., 2001), and this transfection efficiency is associated 
with its high affinity for negatively-charged cells that assists the polymer–DNA 
complex (polyplex) uptake (Halama et al., 2009). The exact mechanism of polyplex 
uptake by cells still remains to be elucidated, but the structure of PEI was found to 
assist endosome escape by destabilizing the organelle membrane and cause DNA 
release to the cytosol (Kichler, 2004). Several reports have demonstrated that the 
systemic administration of tumour-specific targeting-ligand-coated polyplexes could 
deliver transgenes to tumour sites (Kircheis et al., 2001, Hildebrandt et al., 2003, 
Kursa et al., 2003), and effective therapeutic effects of PEI-mediated delivery of 
therapeutic plasmid DNAs (Xu et al., 1999), antisense oligonucleotides (Rait et al., 
2002) or siRNA molecules (Hu-Lieskovan et al., 2005) were also observed in several 
mouse tumour models. However PEI-based cancer gene therapy also face challenges, 
such as non-specific lung, liver and spleen uptake and their induction of 
inflammatory side-effects, and these problems indicate the importance of considering 
such factors as structure and molecular weight when designing polymer vectors 
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(Jeong et al., 2007, Bonnet et al., 2008). 
 
 
                         Dendrimers 
Polypropylenimine (PPI) dendrimers are synthetic polymers with a core structure, 
and symmetric branches (Tomalia et al., 1985), and their efficient gene transfer 
ability was first shown in 1997 (Delong et al., 1997). Since then the gene transfer 
ability of numerous dendrimers has been studied, and their unique structure has been 
shown to provide a positively charged surface that can form complexes with 
negatively charged nucleic acids (Guillot-Nieckowski et al., 2007). When complexed 
with DNA, dendrimers were found to spontaneously form nanoparticles that are 
colloidal stable without any flocculation or aggregation and are well-organized 
nanostructures that DNA could condense into (Chisholm et al., 2009).  
 
Generally, the higher the charge density (the generation) of the dendrimer, the higher 
the transfection efficiency (Dufes et al., 2005). However, higher generation 
dendrimers are associated with higher toxicity (Zinselmeyer et al., 2002), although 
the general cytotoxicity of dendrimers is still considered to be lower than some other 
polymers, such as PEI (Fischer et al., 2003). It was also reported that the transfection 
capability of dendrimers was at least comparable with that of other cationic polymers 
(Gebhart and Kabanov, 2001). Dendrimer-mediated gene transfer in cells is thought 
to utilise their pH buffering capacity, which could facilitate release of the bound 
nucleic acid from the DNA–dendrimer complex in cells (Sonawane et al., 2003). 
 
PPI dendrimers consist of a butylenediamine (DAB) core with branched units that 
expand by Michael addition of acrylonitrile to a primary amino group followed by 
hydrogenation of nitrile groups (Dufes et al., 2005), and which can now be 
synthesized easily (de Brabander-van den Berg and Meijer, 1993). PPI dendrimers 
have been developed commercially as transfection agents, and their different 
generations have been reported to efficiently transfer genes and to have a positive 
toxicity profile in vitro (Agashe et al., 2006) and in vivo (Tack et al., 2006). Indeed, 
some dendrimers have been shown to be more efficient gene transfer reagents than 
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PEI (Kim et al., 2007). Several recent studies using PPI dendrimers, especially PPI 
generation 3 (PPIG3), have demonstrated their potential in cancer gene therapy 
(Tekade et al., 2009). 
 
It has been reported that of all the generations of PPI, PPIG3 has the highest 
transfection efficiency combined with adequate cytotoxicity on an epithelial 
carcinoma cancer cell line (Zinselmeyer et al., 2002). Similar findings were also 
reported for several other cancer cells (Hollins et al., 2004, Santhakumaran et al., 
2004). For example, injection of PPIG3 complexed with a TNF-α-expression plasmid 
into the tail vein results in the efficient accumulation of TNF-α in tumour sites in 
murine subcutaneous tumour models, and induces tumour necrosis and interestingly 
injection of PPIG3 alone also showed some anti-tumour activity (Dufes et al., 2005a). 
Further, intravenous administration of oligoethylenimine-grafted PPIG2 and PPIG3 
resulted in an accumulation of both molecules in subcutaneous tumours, with PPIG3 
being accumulated more efficiently (Russ et al., 2008). In addition, the intravenous 
administration of transferrin-conjugated PPIG3, whose receptors are often 
overexpressed in numerous cancers, resulted in its selective accumulation in tumour 
sites, the induction of tumour regression and led to 100% long-term survival with no 
signs of toxicity (Koppu et al., 2010). In a recent in vivo imaging study, PPIG3 
showed highly specific tumour targeting of tumour-bearing mice, with no detection 
of gene transfer occurring in any of the other tissues, and this was thought to be 
achieved by the enhanced permeability and retention (EPR) effect of nanoparticles 
that formed with PPIG3 and DNA (Chisholm et al., 2009). The EPR effect 
constitutes an important mechanism by which certain objects especially with high 
molecular weight drugs can extravasate through the endothelial gaps of tumour blood 
vessels, which are usually larger and more disorganised than normal blood vessels 
(Matsumura and Maeda, 1986, Iyer et al., 2006). 
 
               Biological Non-viral Vectors 
Besides viral and synthetic vectors, certain bacteria (Gardlik and Fruehauf, 2010) and 
mammalian cells (Roth et al., 2008) have also been discovered to be potential 
delivery vehicles for cancer gene therapy. 
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                    Bacteria-based vectors 
The recent advances in cancer gene therapy and the findings that hypoxic and 
necrotic regions are consistently present within solid tumours (Thomlinson and Gray, 
1955) have prompted the notion of using genetically altered anaerobic bacteria as 
delivery vehicles. Hypoxia has been found having a pivotal role in tumour 
angiogenesis, development and metastasis (Zhou et al., 2006). Although lower 
transfection efficiencies have been observed in hypoxic cells (Dachs et al., 2000), the 
hypoxic regions in tumours provide an ideal place for anaerobic bacteria to grow, 
thus providing an excellent opportunity for the development of bacteria-based 
delivery vehicles. In phagocytic cell gene transfer, bacteria can be transported into 
cells in phagosomes, then escape from the phagosome and replicate in the cytosol 
(Grillot-Courvalin et al., 2002). In non-phagocytic cells, bacteria-mediated gene 
transfer can occur through the normal routes of pathogen entry to cells (Marra and 
Isberg, 1996), and recombinant bacteria have been reported to transfer synthesized 
protein (instead of DNA) to target cells as a consequence of the substantial level of 
activity of eukaryotic promoters driving expression of the transferred genes 
(Goussard et al., 2003). Due to these advantages, combined with their preference for 
tumour regions remote from vasculature where synthetic vectors can only travel 
passively, anaerobic bacteria have become regarded as a better delivery vehicle for 
cancer gene therapy (Vassaux et al., 2006). Since the first study of bacteria-based 
gene transfer (Sizemore et al., 1995), there have been many reports regarding 
bacteria-based cancer gene therapy (Jia and Hua, 2009). Predominantly, four types of 
attenuated anaerobic bacteria have been studied for cancer gene therapy so far: 
Bifidobacteria and Clostridia (anaerobes) and Salmonella and Escherichia 
(facultative anaerobes) (Forbes, 2010). 
 
                     Obligate Anaerobic Bacteria-based Vectors 
Obligate anaerobes such as Clostridia and Bifidobacteria cannot survive in oxygen, 
and bacterial spores injected into tumour should only germinate in anoxic regions. 
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                         Clostridia-based Vector 
The specific tumour colonization of Clostridia after intravenous administration of the 
spores was reported nearly 60 years ago (Malmgren and Flanigan, 1955). After 
screening of 26 common anaerobic bacteria, an attenuated strain, Clostridium novyi, 
had the best tumour colonization ability (Dang et al., 2001). Compared with viral 
vectors, Clostridia have several advantages for cancer gene therapy, including fewer 
safety concerns; low immunogenicity; specific tumour-targeting; and no risk of 
insertional mutagenesis. Several studies have shown the tumour-specific colonization 
of this bacterium, and also its anti-tumour activity, either the wild-type bacterium 
itself or when expressing therapeutic genes (Forbes, 2010) such as the pro-drug 
activating gene (Liu et al., 2002). Although all of the studies demonstrated tumour 
inhibition, tumours were not completely eliminated. Therefore, combined therapy, 
for example with chemotherapeutic drugs, may achieve better results (Dang et al., 
2001, Dang et al., 2004). Furthermore, the significant toxicity that was generated 
must be evaluated further (Dang et al., 2001). 
 
                         Bifidobacteria-based Vector 
Bifidobacteria is another obligate anaerobic bacterium that showed specific tumour 
colonization and mediated cancer gene therapy in a tumour mouse model. It was 
found to specifically colonize tumour sites following intravenous administration 
(Kimura et al., 1980). Bifidobacteria have several advantages over other bacteria for 
cancer gene therapy, as it is a common bacteria in the human intestine and may thus 
impose a lower safety risk, and it can be administered both orally and intravenously 
(Cronin et al., 2010). Several studies have reported that Bifidobacteria-mediated 
cancer gene therapy was effective (Li et al., 2003). The limitations of using 
Bifidobacteria include lower tumour colonization, non-oncolysis and no spore-
formation (Wei et al., 2007). Spores are not only easy to produce, stable and 
economical, but also only germinate when they encounter requisite anaerobic 
conditions of tumours and thus mediate more specific tumour colonization (Wei et al., 
2007). 
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                    Facultative Anaerobes 
Facultative anaerobes, such as Salmonella and Escherichia, are also potential 
delivery vehicles for cancer gene therapy (Wei et al., 2007) and were thought to flood 
into tumours following inflammation (Leschner et al., 2009), to migrate towards 
tumours by chemotaxis (Kasinskas and Forbes, 2006, Kasinskas and Forbes, 2007) 
and to exhibit preferential growth in tumour microenvironments (Zhao et al., 2005). 
 
                         Salmonella-based Vector 
Initial studies using attenuated Salmonella typhimurium for cancer gene therapy 
showed excellent tumour colonisation with limited pathogenicity (Saltzman et al., 
1997). The first systemic delivery study also showed suppression of tumour growth 
and prolonged animal survival rate (Pawelek et al., 1997), and most Salmonella 
typhimurium was found to only survive in tissues that became necrotic (Forbes et al., 
2003). So far, Salmonella-based cancer gene therapy has been studied using different 
strategies in a variety of tumour models (Moreno et al., 2010), and its efficacy has 
been demonstrated both orally (Jia et al., 2007, Chen et al., 2009) and by intravenous 
administration (Ryan et al., 2009). One of the major drawbacks of Salmonella-
mediated cancer gene therapy observed in one clinical trial is that the ratio of 
colonisation of tumour to normal tissue is comparatively low, due to it being a 
facultative anaerobe. (Nemunaitis et al., 2003). 
 
                         E.Coli-based Vector 
Probiotic Escherichia coli Nissle 1917 strain was first seen to efficiently colonize 
and to replicate at the necrotic border of tumour tissue in a mouse model (Stritzker et 
al., 2007), and has since been demonstrated to effectively colonize tumours and to 
mediate anticancer gene therapy alone (Forbes, 2010), and when combined with 
radiotherapy (Jiang et al., 2010). 
 
Although many studies have shown the potential of anaerobic bacteria for cancer 
gene therapy, no reports have yet demonstrated complete tumour shrinkage (Wei et 
al., 2008) and challenges still remain to be addressed before bacteria can be used in 
clinical cancer treatment, such as the intrinsic bacterial toxicity, its tumour-targeting 
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efficiency and its efficiency in combination with other therapies (Forbes, 2010). 
 
 
                    Cellular Vehicles 
Despite the fact that many strategies have been developed for cancer gene therapy, 
physiological barriers and toxicity often limit their efficacies in vivo. Cellular 
vehicles have gained increasing interest following the observation that certain cells 
have the intrinsic ability to migrate to tumour sites (Roth et al., 2008). 
 
                         Mesenchymal Stem Cell-based Vehicle 
Mesenchymal stem cells (MSC), which can be isolated from bone marrow 
(Friedenstein et al., 1987), adipose tissue (Zuk et al., 2001) and placenta (In 't Anker 
et al., 2004), are multipotent adult stem cells that can differentiate into several 
mesenchymal lineage tissues, such as bone and cartilage-forming cells, under certain 
conditions (Friedenstein et al., 1987). It was also found that individual MSC can 
retain their multipotent ability when expanded in vitro (Pittenger et al., 1999). Since 
the finding that MSCs migrate to tumour sites, they have emerged as a potential 
cellular vehicle to target tumours, and several properties of MSC have made them 
attractive subjects for the delivery of therapeutic genes for cancer therapy (Hu et al., 
2010). MSC can be easily isolated from a variety of tissue sources and are easy to 
expand in vitro (Compte et al., 2009). It was reported that they can be passaged more 
than 50 times in vitro without losing their multipotency phenotype (In 't Anker et al., 
2004). MSC have also showed a high level of migration towards tumour sites 
(Studeny et al., 2002). They should present low immunogenicity associated with their 
lack of or low level of MHC class I and class II surface molecules, as well as the 
absence of co-stimulatory molecules. No immune response was observed when MSC 
were engrafted into the bone marrow of recipients for 13 weeks after transplantation 
(Saito et al., 2002) and it was shown that the viral transduction of MSC with 
therapeutic genes in vitro did not affect their stem cell properties (Chan et al., 2005). 
The natural tumour-homing ability of MSC should also be more efficient than other 
targeting strategies, such as the ligand–receptor interactions. All of these features 
promote MSC as a useful cellular vehicle. 
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Although the exact mechanism involved in MSC homing to tumour sites has not 
been entirely established, increasing evidence has revealed that the tumour 
microenvironment plays an important role in the migration of MSC, which are 
recruited by the chemokines (Klopp et al., 2007, Dwyer et al., 2007) and cytokines 
(Ries et al., 2007) released by tumour tissues (Xu and Zhu, 2007). Currently, C-X-C 
chemokine receptor type 4 (CXCR4) and its receptor, stromal cell-derived factor-1 
(SDF-1), are considered to be the most important cytokine pair for recruiting MSC to 
tumours (Hu et al., 2010). 
 
So far, MSC have been found not only to migrate towards tumour cells in vitro 
(Nakamizo et al., 2005, Schichor et al., 2006), but have also migrated specifically to 
tumour sites in a variety of xenograft tumour mouse models (Hu et al., 2010) 
including ovarian (Kidd et al., 2009), glioma (Nakamizo et al., 2005), melanoma 
(Studeny et al., 2002) and breast carcinoma (Studeny et al., 2004) and in an 
established lung metastases mouse model (Xin et al., 2007).  
 
 MSC loaded with therapeutic genes were found to be effective in mediating 
therapeutic transgene expression in tumour sites. After the intravenous administration 
of MSC transduced with therapeutic genes in human breast cancer xenograft and 
melanoma xenograft tumour models, tumour growth was suppressed and prolonged 
animal survival was achieved (Studeny et al., 2004). This has been observed in 
various tumour models using different therapeutic genes (Xin et al., 2007, Kucerova 
et al., 2007, Ren et al., 2008, Loebinger et al., 2009). MSC-based gene therapy also 
faces several challenges. It was reported that in vitro expanded MSC showed less 
tumour-homing ability (Potapova et al., 2008). And there is growing evidence that 
human MSC are involved in cancer initiation as a consequence of their ability to 
spontaneous transform in vitro (Rubio et al., 2008) with higher frequency than other 
cell types and to contribute to tumour growth in vivo (Li et al., 2007a). Thus, a 
greater understanding of the true fate of MSC in vivo is needed before they can be 
used as cellular vehicles for cancer gene therapy (Hu et al., 2010).  
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In addition, neural stem cells have also emerged as potential cellular vehicles for 
brain tumour gene therapy, as they were found to engraft in brain tumour sites after 
systemic delivery (Ahmed et al., 2010). 
 
                         Endothelial Lineage Cell-based Vehicle 
In 1997, the discovery of CD34-enriched endothelial progenitor cells (EPC) (Asahara 
et al., 1997) changed our belief that the formation of new blood vessels occurred 
exclusively via the mechanism of sprouting and intussusceptive angiogenesis 
(Folkman and Shing, 1992). EPC are defined as precursor cells that can differentiate 
into mature endothelial cells when attracted to angiogenic sites and are believed to be 
differentiated from haemangioblasts, the haematopoietic stem cells (Rafii and Lyden, 
2003). EPC can be isolated from both bone marrow and peripheral blood (Ferrari et 
al., 2003) and were recently also observed in vascular walls (Ingram et al., 2005, 
Zengin et al., 2006). Over the past few years, a substantial number of reports from 
animal and human studies have contributed to our understanding of EPC, and we 
now know that they are involved in tumour vasculogenesis and are critical to tumour 
neovascularisation; can migrate towards angiogenic signals; and that they can 
proliferate to form tubular structures required for the formation of all blood vessels 
and capillaries (Dome et al., 2007). Inflammatory cytokines were also reported to 
contribute to engraft EPC to tumours (Spring et al., 2005). 
 
Increased numbers of circulating EPC have been found in many human cancer 
patients and levels of circulating EPC correlate with progression of tumours such as 
multiple myeloma (Zhang et al., 2005a; Rigolin et al., 2006), acute myeloid 
leukaemia (Wierzbowska et al., 2005, 2008; Rigolin et al., 2007), chronic 
lymphocytic leukaemia (Rigolin et al., 2010), hepatocellular carcinoma (Ho et al., 
2006), non-small cell lung cancer (Dome et al., 2006), lung cancer (Nowak et al., 
2010), lymphoma (Igreja et al., 2007), glioma (Zheng et al., 2007), classic Kaposi’s 
sarcoma (Taddeo et al., 2008), head and neck cancers (Brunner et al., 2008), ovarian 
cancer (Su et al., 2010) and pancreatic carcinoma (Vizio et al., 2010). Increased 
circulating EPCs have also been observed after chemotherapy (Bertolini et al., 2003, 
Furstenberger et al., 2006, Shaked et al., 2006). 
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The incorporation of EPC in tumours was discovered for the first time when β-
galactosidase labelled-EPCs were found both in tumour stroma and tumour 
endothelium (Asahara et al., 1999). Since then, many groups have reported the 
homing ability of EPC in different tumour model systems. Using a mathematical 
model, EPCs were predicted as having a significant role in the early stages of tumour 
growth (Stoll et al., 2003, Suriano et al., 2008). Bone-marrow-derived EPC were 
found to incorporate into tumour sites in spontaneous mammary tumour (Nolan et al., 
2007) and malignant xenograft glioma models (Zhang et al., 2009). Blocking the 
recruitment of EPC (Murakami et al., 2009) or inhibiting the expression of DNA 
binding fator-1 in EPC inhibited tumour growth (Gao et al., 2008, Mellick et al., 
2010), and these data indicated the contribution of EPC to tumour neovascularisation. 
EPC are not only found migrating to tumour sites, but are also observed to contribute 
to neovascularization under other conditions, such as during wound healing (Asahara 
et al., 1999), induced hindlimb ischaemia (Takahashi et al., 1999, Kalka et al., 2000), 
experimental myocardial infarction (Jackson et al., 2001), venous thrombosis 
(Modarai et al., 2005), endothelial denudation (Ii et al., 2006, Urao et al., 2006) and 
diseased kidney containing microvascular injury (Hohenstein et al., 2010). The 
specific tumour-homing ability of EPC has made them attractive cellular vehicles for 
cancer gene therapy. After intravenous administration, bone marrow-derived EPC 
modified to express thymidine kinase genes have been reported to migrate to tumour 
sites, resulting in extensive tumour necrosis occurring in a xenograft glioblastoma 
mouse model (Ferrari et al., 2003) and in a glioma xenograft tumour model (Zhang et 
al., 2010). 
 
Blood late outgrowth endothelial cells (BOEC) are derived from a subset of CD34-
enriched peripheral blood cells that can differentiate into endothelial cells (Shi et al., 
1998). BOEC have been observed to migrate to Lewis lung carcinomas and lung 
metastases after being injected intravenously (Wei et al., 2007a), and BOEC 
genetically modified to express the angiogenic inhibitor, endostatin, decreased 
tumour vascularisation and tumour volume (Dudek et al., 2007). 
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The intravenous injection of other endothelial lineage cells, such as embryonic EPC, 
can target hypoxic lung metastasis and prolong animal survival when harbouring an 
exogenous suicide gene, yeast cytosine deaminase (CD) gene fused to a uracil 
phosphoribosyl transferase (UPRT) (Wei et al., 2004). Mature murine lung 
endothelial cells expressing interleukin-2, when injected systemically, can migrate to 
lung metastases, decrease tumour burden and prolong animal survival (Ojeifo et al., 
2001). 
 
3.2.2 RNAi-based Technology 
3.2.2.1 The Discovery of RNAi 
Although ssRNA was initially shown to silence specific genes as a result of binding 
to the target mRNA (Fire et al., 1991), the exact mechanism was not understood until 
RNA interference (RNAi) was discovered. RNAi is a natural phenomenon that was 
first found in the nematode worm Caenorhabditis elegans, in which the presence or 
introduction of long double-stranded RNA (dsRNA) molecules can degrade 
sequence-specific mRNA molecules, and the dsRNA-mediated mRNA degradation is 
more effective than either strand alone (Fire et al., 1998). The two scientists Andrew 
Z. Fire and Craig C. Mello, who discovered this natural phenomenon, were awarded 
The Nobel Prize in Physiology or Medicine in 2006. RNAi is now recognized as a 
highly conserved biological process that occurs in cells of almost every multicellular 
organisms, and may have evolved as an essential posttranscriptional gene regulation 
system and/or as a defence mechanism against viral dsRNA (Hannon, 2002). It was 
later reported that RNAi was mediated by dsRNA molecules 21–22 nucleotides in 
length in the Drosophila system (Elbashir et al., 2001b) and in cultured mammalian 
cells (Wianny and Zernicka-Goetz, 2000, Elbashir et al., 2001a). 
 
3.2.2.2 Mechanism of RNAi 
The mechanism of RNAi begins with the processing of long dsRNA molecules 
(Tuschl et al., 1999). These dsRNAs which may either be expressed intracellularly or 
introduced into the cells from an exogenous source are processed into 21–23bp 
siRNA fragments (Zamore et al., 2000) by the action of an RNAse III called Dicer 
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(Bernstein et al., 2001). This Dicer enzyme specifically recognizes and binds to the 
5’ phosphate of dsRNA precursor and makes two staggered cuts in both strands of 
the dsRNA to causes 2-nucleotide 3’ overhangs (Elbashir et al., 2001b). This siRNA 
is produced by Dicer complexed with the dsRNA-binding protein (TRBP/TARBP2P) 
and the protein kinase R (PKR)-activating protein (PACT) (Kok et al., 2007). The 
complex of siRNA, Dicer and TRBP–PACT is then loaded onto the RNA-induced 
silencing complex (RISC) (Hammond et al., 2000). This requires the action of the 
RISC loading complex (RLC) that consists of the double-stranded siRNA, Dicer and 
the dsRNA-binding-domain protein, R2D2 (Liu et al., 2003). R2D2 also helps to 
determine the asymmetry of the siRNA by binding to the more thermodynamically 
stable end of the siRNA (Tomari et al., 2004). The RLC initiates siRNA unwinding 
and determines which strand is to be assembled into the RISC by preferentially 
binding the strand with the highest thermodynamic stability at the 5′ end (Schwarz et 
al., 2003), and this becomes the guide strand (Martinez et al., 2002) and usually the 
antisense strand (Zamore et al., 2000). The other strand, named the passenger strand 
is cleaved by Ago2, an endonuclease and a core component of RISC (Matranga et al., 
2005), and leaves the complex, thereby facilitating activation of RISC (Rand et al., 
2005). The phosphorylated 5′-terminal nucleotide of the guide strand inserts into a 
positively charged pocket on Ago2 and consequently does not participate in the 
recognition of and binding to the target mRNA (Ma et al., 2005). Nucleotides 2–8 of 
the guide strand are exposed and directly recognize the target mRNA (Ma et al., 2005, 
Lewis et al., 2005). The mRNA is then cleaved by Ago2 (Liu et al., 2004a) at the 
centre of the oligonucleotide duplexed with the guide strand (Martinez and Tuschl, 
2004). The RISC remains bound to the siRNA and can execute subsequent rounds of 
cleavage of target mRNA molecules (Hutvagner and Zamore, 2002) (Figure 7). 
Unlike plants and worms, which can replicate siRNA, there is no evidence of siRNA 
replication in mammals (Zamore, 2002). Thus, siRNA-mediated gene silencing in 
mammalian cells is limited by its transient nature. 
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Figure 7 – The Mechanism of RNAi - Schematic 
In mammalian cells, RNAi can be triggered either by DNA-based shRNA expression vector 
(as used in this project) or by direct small siRNA molecules. In each case, gene silencing is 
caused by the destruction of mRNA that is complementary to the input siRNA. 
 
3.2.2.3 Vector-based RNAi Induction 
It has been demonstrated that siRNA can be expressed intracellularly from a DNA 
plasmid vector encoding a short hairpin RNA (shRNA) (Brummelkamp et al., 2002b) 
(Paddison et al., 2002). The shRNA transcript has a hairpin-like stem-loop structure 
which is processed in the nucleus by the microprocessor complex (Lee et al., 2003). 
After being exported to the cytoplasm by exportin-5 (Yi et al., 2003), the hairpin loop 
is removed by the Dicer–TRBP–PACT to form the siRNA (Zeng et al., 2003). 
Plasmid-based shRNA must be chemically transfected like siRNA, and may thus 
exhibit low transfection efficiency on primary cells and difficulty in integrating into 
the host genome for stable expression (Masiero et al., 2007). 
 
To overcome these problems, siRNA viral vectors have been designed via the 
expression of shRNA to achieve more efficient and extended gene silencing effects, 
including in some primary cells (Brummelkamp et al., 2002a, Stewart et al., 2003, 
Rubinson et al., 2003). 
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3.2.2.4 siRNA-based Telomerase Inhibition 
There have been many reports regarding siRNA-based approaches targeting both of 
the core components of human telomerase, hTERT and hTR. The first report of 
utilising siRNA to inhibit TERT and TR showed reduced telomerase activity in a 
variety of human cancer cell lines, including both carcinomas and sarcomas, and the 
results showed that targeting TR was more effective than targeting TERT (Kosciolek 
et al., 2003). 
 
Many groups have utilised different forms of siRNA to inhibit TERT in a variety of 
human cancer cell lines for shorter or longer periods, and they have reported 
significant inhibition of telomerase activity along with either decreased cell 
proliferation or increased apoptosis (Kurvinen et al., 2006, Miri-Moghaddam et al., 
2009, Wang et al., 2007, Zhang et al., 2010b). Targeting TERT by siRNA in vivo in 
different tumour models also caused inhibition of tumorigenicity, tumour growth and 
the invasive capacity of tumours (Pallini et al., 2006, Gandellini et al., 2007). 
 
A recent report comparing siRNA-mediated inhibition of either hTR or hTERT in 
human oral cancer cells showed that targeting hTR caused the greatest telomerase 
inhibition result in vitro and the largest reduction in tumour growth in vivo (Li et al., 
2011). It has been further demonstrated that targeting TR using naked siRNA (Zheng 
et al., 2006), plasmid shRNA vectors or viral shRNA vectors caused significant 
telomerase inhibition and either reduced cell proliferation or increased apoptosis in 
various human cancer cells, including lung cancer cells (Li et al., 2004b) and renal 
cancer cells (Zheng et al., 2006). Furthermore, additive effects on inhibition of cell 
proliferation were observed with siRNA combined with other anticancer treatments 
in various human cancer cell lines (Goldkorn and Blackburn, 2006) and mouse 
tumour models (Xu et al., 2010). Other in vivo reports also showed that siRNA 
targeting telomerase components inhibited tumour growth in tumour mouse models 
(Li et al., 2007b). 
 
3.2.3 Aims of this Chapter 
Having already developed an effective siRNA viral system for telomerase inhibition 
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in vitro, I aimed to explore novel delivery strategies, including cellular vehicles and 
synthetic dendrimers, for the efficient delivery of the siRNA vector in vitro and in 
vivo. In addition, I aimed to develop a DNA plasmid system for siRNA targeting 
canine telomerase. Specifically I aimed to answer the following questions in this 
chapter: 
 
1. What is the transfection efficiency of endothelial cells in vitro? 
 A protocol for the transient transfection of a β-galactosidase vector 
using Lipofectamine™ 2000 was first established in 293FT cells. 
 A series of transfection experiments was conducted in three 
endothelial cell lines, EOMA, HUVEC and SB-HSA cells, with a β-
galactosidase reporter vector using four different commercial 
transfection reagents: Effectene, Fugene 6, Tfx-50 and 
Lipofectamine™ 2000. 
 The transient transfection of SB-HSA cells with a GFP reporter vector 
were further optimised using a modified Lipofectamine™ 2000 
protocol. 
 SB-HSA cells were stably transfected with a luciferase vector using 
Lipofectamine™ 2000. 
 
2. Can endothelial cells migrate to the tumour formation site in vivo? 
 Endothelial SB-HSA cells were investigated as a potential cellular 
vehicle: they were labelled then intravenously administered and tissue 
distribution was analysed in a canine xenograft tumour mouse model. 
 
3. What is the transfection efficiency of PPIG3 dendrimers in cells? 
 The transfection efficiency of SB-HSA cells and D-17 cells were 
explored using novel PPIG3 dendrimers complexed with a GFP vector. 
  
4. Can siRNA plasmid expression vector silence the canine telomerase RNA 
component in vitro? 
 Following optimization of the transfection efficiency of SB-HSA cells, 
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the transfection efficiency of another canine cell line, D-17, was also 
tested. 
 A plasmid siRNA expression vector targeting cTR was designed, 
constructed and tested on canine SB-HSA cells and D-17 cells. 
 
3.3 Materials and Methods 
3.3.1 Transient Transfection of 293FT Cells and All 
Endothelial Cells 
293FT, EOMA, HUVEC and SB-HSA cells were transiently transfected with pSV-β-
galactosidase control vector (Promega, United Kingdom) using four different 
commercial chemical reagents: Lipofectamine™ 2000 (Invitrogen, United Kingdom), 
Tfx™-50 Reagent (Promega, United Kingdom), Fugene 6 (Roche, United Kingdom) 
and Effectene (Qiagen, United Kingdom). All transfections were performed in 24-
well plates (Corning, United Kingdom) in triplicates except for 293FT cells (Corning, 
United Kingdom) where 6-well plates were used; each well was used for a single 
transfection reaction, and mock transfection and untreated cell controls were 
included. When analyzing transfected cells, after examining the whole plate, three 
microscopic fields of transfected cells which represented the best of the whole plate 
were photographed and one photo was chosen and presented in the result section.  
 
3.3.1.1 Lipofectamine 2000 Standard Protocol 
24h before transfection, sufficient cells were plated so that cells would be 
approximately 90% confluent at the time of transfection. For each transfection, 2µl 
of Lipofectamine™ 2000 was first diluted with 50µl Opti-MEM® I Reduced Serum 
Medium (Invitrogen, United Kingdom) and incubated at room temperature for 5–25 
min. 0.8µg DNA was then diluted with 50µl Opti-MEM® I Reduced Serum Medium. 
The solutions were then combined, gently mixed then incubated for 20 min at room 
temperature. The mixture was then was added to the cell medium. After transfection, 
cells were grown in a 37˚C incubator, monitored regularly and analysed after 48h. 
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3.3.1.2 Tfx™-50 
24h before transfection, sufficient cells were plated so that cells would be 
approximately 80% confluent at the time of transfection. Prior to transfection, a stock 
solution of Tfx™-50 reagent was prepared by resuspending one vial of reagent in 
400µl NF-water and vortexed, followed by incubation in a 65ºC water bath for 1min. 
Before use, the Tfx reagent stock solution was thawed at room temperature and 
thoroughly mixed. 1µg of DNA was first mixed with 3µl Tfx reagent, then diluted 
with growth medium to a final volume of 200µl and incubated at room temperature 
for 15 min. After incubation, the medium was removed from the cells and the reagent 
mixture was added. After 1h incubation at 37ºC, another 1ml growth medium was 
gently overlaid onto the cells and the plate was return to the incubator for 48h until 
analysis. 
 
3.3.1.3 Fugene 6 
24h before transfection, sufficient cells were plated so that cells would be 
approximately 80% confluent at the time of transfection. 1.5µl reagent was first 
diluted with serum-free medium then 0.25µg DNA in 23.5µl of serum-free medium 
was added to the diluted reagent to make a final volume of 25µl. The mixture was 
vortexed for 1s then added to the cells in a drop-wise manner. Cells were then put 
back to the incubator until 48h later for analysis 
 
3.3.1.4 Effectene 
24h before transfection, sufficient cells were plated so that cells would be 
approximately 80% confluent at the time of transfection. For transfection, 0.2µg 
DNA was diluted in 60µl EC buffer followed by the addition of 1.6µl enhancer and 
vortexing for 1s. This mixture was incubated at room temperature for 5min, then 5µl 
Effectene reagent was added to the enhancer mix and mixed by vortexing for 10s. 
The mixture was then incubated at room temperature for 10min to allow complex 
formation to occur. The cell medium was aspirated from the cells, which were then 
washed with PBS, followed by addition of 350µl fresh medium to each well. The 
transfection mix was then diluted with 350µl medium and then added to the cells in a 
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drop-wise manner. Cells were incubated at 37ºC for 48h before analysis. 
 
3.3.2 In Situ Staining of Cells for β-galactosidase Activity 
Directly before staining, glutaraldehyde solution and x-gal solution were freshly 
prepared. 0.25% glutaraldehyde solution was prepared by mixing 25µl 100% 
glutaraldehyde solution (Sigma, United Kingdom) with 9975µl PBS. 0.2% x-gal 
solution was prepared by 2% x-gal (Sigma, United Kingdom), 2mM MgCl2 (Sigma, 
United Kingdom), 5mM K4Fe(CN)6.3H2O (Sigma, United kingdom) and K3Fe(CN)6 
(Sigma, United Kingdom) in 10ml PBS. 
 
48h after transfection, cell medium was aspirated and cells were washed 3 times in 
PBS. 0.2ml glutaraldehyde solution was added to each well and incubated for 15min. 
The glutaraldehyde solution was then removed and cells were then washed 3 times 
with PBS to remove residual glutaraldehyde that could inhibit β-galactosidase 
activity. 0.1ml x-gal solution was then added to each well and cells were incubated at 
37˚C until they were visibly stained. X-gal was then removed and replaced with PBS 
for microscopic analysis. 
 
3.3.3 Lipofectamine 2000 Modified Protocol 
After replacing β-galactosidase vector with a GFP plasmid vector, pmaxGFP (Lonza, 
United Kingdom), instead of plating cells 24 hours before transfection, cells were 
plated on the day of transfection to reach approximately 90% confluency followed by 
adding DNA-transfection reagent complex. This protocol was used on SB-HSA cells 
and D-17 cells to compare with the standard protocol and used in all experiments 
from then. 
 
3.3.4 Stable Transfection 
SB-HSA cells were stably transfected with a pGL4.18 luciferase expression vector 
containing a neomycin resistant gene (Promega, United Kingdom) using 
Lipofectamine 2000 modified protocol. Before transfection, G418 was titrated into 
SB-HSA cells to determine their drug sensitivity and the optimal plating density was 
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3.3.4.1 G418 Titration 
2 x 104 SB-HSA cells were plated into each well of a 24-well plate containing 1ml of 
culture medium. After 24h, 500µl culture medium containing either 0, 25, 100, 300, 
500, 1000 or 4000µg/ml G418 (Invitrogen, United Kingdom) was added to triplicate 
wells. Cells were cultured for 10–14 days and the correct concentration of G418-
containing medium was replaced every three days. Cells were examined for viability 
and photographed every 2 days. This experiment was designed to identify the lowest 
G418 concentration that induced cell death in approximately 7–9 days and that killed 
all cells within 2 weeks. This concentration was then used to select cells transfected 
with the pGL4.18 luciferase expression neo vector. 
 
3.3.4.2 Optimization of Plating Density 
Different amounts SB-HSA cells (0.25 x 105, 0.5 x 105, 1 x 105 and 2 x 105) were 
plated in triplicate wells of a 24-well plate containing 1ml of culture medium in 
triplicates. After 24h, 500µl culture medium containing G418 was added using 
250µg/ml, the concentration determined earlier in the G418 titration experiment. 
Cells were then cultured for 5–14 days and G418-containing medium was renewed 
every 3 days. In this way, a cell plating density was identified that allowed the cells 
to reach 80% confluency before cell death occured, and this density was used to plate 
SB-HSA cells transfected with the pGL4.18 luciferase expression neo vector. 
 
3.3.4.3 Stable Transfection of SB-HSA Cells 
SB-HSA cells were transfected with pGL4.18 luciferase expression vector (Promega, 
United Kingdom) containing a neomycin resistance gene using Lipofectamine 2000. 
The modified transfection protocol mentioned earlier was followed (3.3.3). 
 
After transfection, cells were incubated for 48h, then G418-containing medium was 
added and transformed cells were selected for one week using the G418 
concentration and cell seeding density determined previously. During this time cells 
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were monitored regularly. After a week cells were harvested for the luciferase assay 
to examine if stable-transfection was successful. In order to measure the long-term 
gene expression of luciferase, stably-transfected cells were continuingly grown in 
two separate flasks: one flask of cells was grown in normal growth medium and the 
other flask was grown in medium containing 125µg/ml G418. After 6 months, cells 
in both flasks were assayed for luciferase activity. 
 
3.3.4.4 Luciferase Assay 
The luciferase assay was performed on stably transfancted cells using the Bright-
GloTM Luciferase Assay System (Promega, United Kingdom) to measure the 
luciferase expression. All reagents and cells were equilibrated to room temperature 
starting the assay. First, 1 x 103 luciferase-transfected or untransfected SB-HSA cells 
were plated one day before starting the assay in 100µl culture medium in a 96-well 
plate (Corning, United Kingdom). After 24h, the culture medium was removed 
completely and cells were carefully washed 3 times with PBS. 100µl Glo Lysis 
Buffer (Promega, United Kingdom) was then added and plates were gently rocked to 
ensure an even coverage. Cells were then incubated at room temperature for 5min for 
cell lysis. After the incubation, the cell lysate was transferred to a 96-well 
luminometer plate, followed by the addition of 100µl Bright-GloTM Luciferase Assay 
Reagent. The luminescence from each cell lysate was then measured immediately 3 
times within the first two min using a Wallac 1420 Multilabel Counter, and corrected 
against empty well controls. The values of luminescence from each group of stably-
transfected cells, untransfected cells and empty wells were used to generate the 
column. 
 
3.3.4.5 Irradiation of SB-HSA-Luc Cells 
For γ irradiation, triplicate samples of 5 x 105 SB-HSA-Luc cells were subjected to 
doses of 5Gy, 10Gy or 20Gy. The original dose from the γ-irradiator was 
16.02Gy/min, and the conversion factor 0.8606 was used to determine the radiation 
emitted in June 2009. The irradiation time for the required doses was then calculated 
as follows: 
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Exposure time = required dose x conversion factor / original dose 
After irradiation, cells were then cultured for a week before the luciferase assay was 
done. 
 
3.3.5 Ex Vivo Imaging 
3.3.5.1 Mouse strain 
10 NOD-SCID female mice (Charles River, United Kingdom) were housed in three 
groups in the animal unit at 19–23˚C with a 12h light–dark cycle, and fed with a 
conventional diet with mains water ad libitum at Little France Small Animal Unit, 
University of Edinburgh. All mice experiments were conducted with appropriate 
ethical approval and in accordance with the U.K. Home Office regulations. 
 
3.3.5.2 Tumour Initiation 
10 mice were each injected subcutaneously with 3 x 107 SB-HSA cells in their right 




5µl DiR dye (50mg/ml stock solution in dimethylsulfoxide (DMSO), from Dr Kev 
Dhaliwal) was added to 5 ml 1 x 108 SB-HSA cells in suspension. After 5min room 
temperature incubation, cells were pelleted and supernatant was removed. Cells were 
then resuspended by PBS and centrifuged again. This PBS washing process was then 
repeated twice to discard any free dye left in the solution. At the last time of washing, 
cells were resuspended in growth medium. Labelled SB-HSA cells were then kept on 
ice in the dark and used immediately for mouse injections. 
 
3.3.5.4 Ex Vivo Cell Trafficking 
Before injection, all injected solutions were warmed in a 37˚C water bath then 1 x 
107 labelled SB-HSA cells in 200µl medium were administered intravenously into 
the tail vein of 4 mice. As a control, 1µl DiR stock was diluted 1:1000 1ml growth 
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medium, corresponding to the same dilution of the cell-staining process. 200µl 
diluted dye was then administered intravenously into 3 mice. All mice, including 3 
untreated control mice, were euthanized 24h after injection by a standard procedure 
and all major organs were collected, including the liver, spleen, kidney, heart and 
hind limbs. Ex vivo fluorescent imaging was then performed using a Xenogen IVIS 
200 imaging system combined with Living Image (Version 3.2.0.8156) software. 
 
3.3.6 Optimization of Transfection Efficiency Using PPIG3 
Dendrimers 
3.3.6.1 Extra Desalting of Plasmid DNA 
The GFP plasmids used in this experiment were purified with an extra desalting 
procedure using Illustra NAP-10 Columns (GE Healthcare, UK) to assist effective 
nanoparticle formation. Excess NF-water was firstly passed through the column for 
rehydration, then another 15 ml NF-water was passed through for equilibration. A 
1ml sample of plasmid DNA was then added to column, and desalted plasmid DNA 
was eluted using 1.5ml NF-water. 
 
3.3.6.2 Preparation of Nanoparticles 
After desalting, GFP plasmids were sent to Dr Andreas Schatzlein’s laboratory 
(University of London) by special courier for nanoparticle assembly. The ratio of 
DNA to PPIG3 dendrimers was kept at a constant 1:5 in 5% dextrose solution and 
nanoparticle formation was checked before being posted back to our laboratory.  
 
3.3.6.3 Transfection Protocol Using PPIG3 Dendrimers 
on Canine Cells 
A transfection efficiency tests was performed on both SB-HSA cells and D-17 cells 
using these dendrimers and is independent from those transfection test performed 
earlier using commercial transfection reagents (3.3.1). This was done in 24-well 
plates with the GFP plasmid complexed to PPIG3 dendrimers, and 1.5µg, 3µg, 4.5µg 
and 6µg DNA in triplicate were compared for optimizing transfection conditions. For 
transfection, Opti-MEM® I Reduced Serum Medium was used to dilute the 
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nanoparticles to a final volume of 250 µl. Cells were seeded to reach an approximate 
60% confluency and diluted nanoparticles were added to each well. Experimental 
controls were PPIG3 dendrimers only in 5% dextrose as mock transfections and 
untreated cell controls. After transfection, cells were grown in a 37ºC CO2 incubator 
for 96h. Cells were checked regularly and photographed at 48h and 96h after 
transfection using a fluorescent microscope fitted with a black and white camera. 
 
3.3.7 Preparation of siRNA 
3.3.7.1 Construction of siRNA Plasmids 
The plasmid-based siRNA vector was constructed using the psilencer 4.1-CMV neo 
siRNA expression vectors kit, which also contains a siRNA insert targeting human 
GAPDH gene and ready-to-use scrambled siRNA to be used as negative controls. 
Construction of all siRNA expression vectors was done following the manufacture’s 
protocol. All components mentioned below were provided by the kit unless otherwise 
stated. Oligonucleotides of cTR or hGAPDH inserts were first dissolved in 100µl 
NF-water each, then diluted in TE buffer to obtain an approximate concentration of 
1µg/µl. 50µl of annealing mixture was assembled from: 46µl 1X DNA annealing 
solution; 2µl diluted sense oligonucleotides; and 2µl diluted antisense 
oligonucleotides. The annealing mixture was heated in a heating block to 90˚C for 3 
min, and then cooled in a 37˚C incubator for 1h. 5µl of the annealed product was 
then diluted with 45µl NF-water to obtain a concentration of 8ng/µl. Two sets of 
10µl ligation reactions were then set up: a plus-insert ligation and the minus-insert 
negative control. For ligation reactions (plus-insert), 1µl diluted annealed siRNA 
insert, 1µl 10X T4 DNA ligase buffer, 1µl psilencer 4.1-CMV neo vector, 1µl T4 
DNA ligase and 6µl NF-water were combined. In control reactions (minus-insert), 
1µl diluted annealed siRNA insert was replaced by 1µl 1X DNA annealing solution. 
All ligation reactions were incubated at room temperature for 3h. Ligation products 
from both sets of reactions were transformed into competent cells, which were then 
plated and incubated overnight at 37°C. The number of colonies on all plates (plus-
insert, minus-insert or non-transformed competent cells) were then counted. Ideally, 
the plate containing non-transformed cells should yield no colonies, and the plate 
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containing cells transformed with the plus-insert reaction products should yield 2–
10-fold more colonies than the plate containing cells transformed with the minus-
insert reaction products. Several clones were picked from each plate and plasmids 
were isolated using a mini kit (2.2.8.1) to screen for positive ligation products. 
 
3.3.7.2 Confirmation of shRNA Insert  
Restriction Enzyme Digestion 
Isolated siRNA plasmid DNA was subjected to BamHI and HindIII (Promega, 
United Kingdom) double restriction enzyme digestion to confirm the presence of the 
55bp cTR or hGAPDH shRNA insert. The reaction recipe for restriction enzyme 
digestion was shown below (Table 5). After mixing all components gently, it was 
incubated at 37°C for 4h. 
 
Component Amount (µl) 
Restriction Enzyme 10X Buffer E 2 
Acetylated Bovine Serum Albumin, 10µg/µl 0.2 
Constructed siRNA Vector 1µg 
BamHI, 10U/µl 0.5µl 
HindIII, 10U/µl 0.5µl 
NF-water To a final volume of 20µl 
 
Table 5 – Double Restriction Enzyme Digestion 
All components were provided in the kit, unless otherwise stated. Buffer E and 37°C 
incubation are the optimal reaction buffer and temperature for both restriction enzymes. 
 
DNA Extraction from Agarose Gel  
After double-restriction enzyme digestion, the product was run on a 2% agarose gel. 
Gels were then photographed under UV light and correspondent bands were excised. 
Excised GAPDH and cTR band on agarose gel were recovered using Wizard® SV 
Gel and PCR Clean-up system. While visualizing the DNA, correspondent DNA 
band was excised from the gel quickly to reduce the UV-damage to the DNA and 
transferred into a microcentrifuge tube. The gel slice was then weighed and 10µl 
Membrane Binding Solution per 10mg agarose gel was added into the tube. The 
mixture was vortexed and incubated at 65°C until the gel was completely dissolved. 
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The dissolved gel slice mixture was then transferred to the SV minicolumn assembly 
and incubated at room temperature for 1 min. After incubation, the assembly was 
centrifuged at 16,000 x g for 1 min. After discarding the liquid, 700µl Membrane 
Wash Solution previously diluted with 95% ethanol was added into the assembly and 
centrifuged at 16,000 x g for 1 min. After emptying the assembly, the wash was 
repeated with 500µl Membrane Wash Solution at 16,000 x g for 5 mins. The 
flowthrough was then discarded and the assembly was centrifuged at 16,000 x g for 1 
min with the lid open to allow evaporation of any residual ethanol. After 
centrifugation, the column was transferred to a new tube and 50µl NF-water was 
added in. It was then incubated at room temperature for 1 min followed by 
centrifugation of 16,000 x g for 1 min. The eluted DNA was stored in - 20°C and sent 
for sequencing confirmation later. 
 
Sequencing Confirmation 
After the confirmation by restriction digest, positive plasmids were sent for 
sequencing. Sequencing primers for the siRNA insert in plasmid vector is shown 
below (Table 6). After sequencing confirmation, the positive colonies were expanded 
again and plasmids were isolated using Hispeed Plasmid Maxi kit (2.2.8.2). 
 
Sequencing Primers for siRNA Insert Confirmation 
Forward Primer Reverse Primer 
AGGCGATTAAGTTGGGTA CGGTAGGCGTGTACGGTG 
 
Table 6 – Sequencing Primers for siRNA Insert Confirmation 
This set of sequencing primers was designed by Ambion to fit the siRNA plasmid vector. 
 
3.3.8 Duplex RT-PCR for siRNA Experiment 
The GoTaq® PCR Core system kit was used for all conventional PCR reactions. All 
PCR reactions were done using a 50µl total volume in triplicate with two control 
groups. RNA control groups use RNA instead of cDNA in the reaction to detect any 
genomic contamination and the added RNA amount is equivalent to the amount that 
was used to generate the added cDNA in one reaction. The water control group used 
NF-water to replace the same amount of cDNA in the reaction to detect any other 
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contamination. The PCR mixture was subjected to an initial denaturation step of 
95°C for 5min, followed by 30 cycles of denaturation at 95°C for 1min, annealing at 
a primer-dependant temperature for 1min and extension at 72°C for 1min, followed 
by a final extension step at 72°C for 10min. After completing the reactions, samples 
were incubated at 4°C until ready to analyse. The amounts of dNTP, MgCl2, 5X 
GoTaq® Taxi Buffer and GoTaq® DNA Polymerase were kept constant. 
 
A duplex RT-PCR system (Table 7) was established for analysing the silencing effect 
on cTR and cGAPDH after transfection and was first demonstrated on D-17 cells and 
SB-HSA cells. The silencing ability of the siRNA vector was demonstrated in the 
human H1299 cell line using the siRNA vector against hGAPDH and siRNA 
expression was confirmed by singleplex PCR. Finally, siRNA plasmids were tested 
in the SB-HSA and D-17 cell lines. All primers used in the RT-PCR are shown below 
(Table 8).  
 
Component Amount (µl) 
cDNA / RNA / Water 2 / RNA / Water  
dNTP, 10mM 1 
MgCl2, 25mM 4 
5X Go Taxi Buffer 10 
Human or (Canine) GAPDH 
Forward Primer, 100pmol/µl  0.1 
Human or (Canine) GAPDH 
Reverse Primer, 100pmol/µl 0.1 
(cTR Forward Primer, 100pmol/µl ) 0.1 
(cTR Reverse Primer, 100pmol/µl ) 0.1 
GoTaq® DNA Polymerase, 5u/μl  0.25 
NF-water 
Add to make 50µl total 
volume 
 
Table 7 – Duplex RT-PCR Reaction for siRNA Experiment 
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Table 8 – All Primer Sets Used in the siRNA Experiments 
cTR and cGAPDH primers were used for duplex RT-PCR to analyze the gene-silencing effect 
of siRNA in canine cells. hGAPDH primers were used for singleplex RT-PCR to analyze the 
gene-silencing effect of siRNA in human cells.  
 
3.4 Results 
3.4.1 Transfection of 293FT Cells 
As a standard producer cell line for our previously-established siRNA lentiviral 
vector, the transfection of 293FT cells was demonstrated first in vitro with a β-
galactosidase vector using Lipofectamine™ 2000. Strong positive β-galactosidase 
staining was found in transfected 293FT cells compared with mock-transfected 
negative control (Figure 8). 
 




Figure 8 – Transient Transfection of 293FT Cells 
A, gross appearance of transfected 293FT cells on a 6-well plate- blue colour on the plate. 
B, transfected 293FT cells – blue stained 
C, negative control – mock transfection of 293FT cells 
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3.4.2 Transfection of EOMA, HUVEC and SB-HSA Cells 
As potential cellular delivery vehicles, the transfection efficiency of four different 
commercial transfection reagents, Effectene, Fugene 6, Tfx-50 and Lipofectamine™ 
2000, were tested on three types of endothelial cell, EOMA cells, HUVEC cells and 
SB-HSA cells. As I expected, very low transfection efficiencies were observed 
generally for all three cell lines. In particular, no positive β-galactosidase staining 
was found in HUVEC cells using all four transfection reagents. When using 
Effectene, very limited β-galactosidase staining was detected in EOMA cells only 
(Figure 9A). However in SB-HSA cells, much more β-galactosidase staining were 
observed, but this was present only in when Lipofectamine 2000 was used as a 
transfection reagent (Figure 9B). Qualitative summary of transfection results is 
shown below (Table 9)   
 




Figure 9 – Transient Transfection of EOMA and SB-HSA cells 
A, EOMA cells were transfected using Effectene 
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 SB-HSA Cells EOMA Cells HUVEC 293FT Cells 
Lipofectamine 2000 + + - + 
Effectene - - - NA 
Tfx-50 - - - NA 
Fugene 6 - - - NA 
 
Table 9 – Cells with Successful Transfection by Various Reagents 
Cell type which was transfected successfully was marked as + and - if not 
NA – not applicable.  
  
3.4.3 Transfection of SB-HSA Cells by the Modified 
Protocol of Lipofectamine 2000 
The transfection efficiency of SB-HSA cells with a GFP vector using standard Lipofectamine 
2000 protocol (3.3.1.1) recommended by the manufacturer was compared with using the 
modified protocol. The transfection efficiency was strongly increased as seen below (Figure 
10) 
 




Figure 10 – Transfected SB-HSA cells Using Standard and Modified Protocol 
SB-HSA cells were transfected by Lipofectamine 2000 with a GFP vector using both 
standard protocol and modified protocol. 48h after transfection, cells were photographed 
and compared. 
 
3.4.4 Stable Transfection of SB-HSA cells 
I next explored whether SB-HSA cells can be stably transfected. From preliminary 
antibiotic titration and optimal cell seeding density experiments, the optimal 
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transfection conditions were determined to be 250µg/ml G418 in growth medium 
and 60% confluent cell-seeding-density. These conditions were used to stably 
transfect SB-HSA cells with a luciferase vector containing a neomycin resistant gene, 
pGL4.18. After a week of antibiotic selection, a population of luciferase-expressing 
SB-HSA cells (SB-HSA-Luc) was observed and confirmed by luciferase assay 
(Figure 11). 
 
Long-term culture of SB-HSA-Luc cells in either normal culture medium or G418-
containing medium for 6 months revealed little difference in the levels of luciferase 
expression level (Figure 12), which indicates that the luciferase plasmid vector may 
have integrated into the genome of SB-HSA cells and a population of SB-HSA cells 
that constantly express luciferase has formed. 
 
Since SB-HSA cells are also cancer cells, their use as delivery vehicle will raise 
safety concerns, I therefore tested if the proliferation of SB-HSA cells can be 
deactivated using irradiation without affecting their gene expression. After irradiation 
of SB-HSA-Luc cells, their proliferation was monitored for a week. Although a 5Gy 
dose did induce some cell death (Figure 13F-G) compared to untreated cells (Figure 
13A-D), it did not stop the proliferation of SB-HSA-Luc cells (Figure 13G-H). 
10Gy-dose completely inhibited SB-HSA cell proliferation and after 7 days (Figure 
13L), those cells still expressed strong luciferase activity compared to normal SB-
HSA cells (Figure 14). These data indicate that an adequate dose using 10Gy to 
irradiate SB-HSA-Luc cells could strongly inhibit their proliferation without 
abolishing their metabolic activity such as their luciferase expression and thus these 
cells could be applied as delivery vehicles (Table 10). 
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Figure 11 – Luciferase Assay of Stably-transfected SB-HSA Cells 
After G418 antibiotic selection of stably-transfected SB-HSA cells, luciferase assay was 
performed along untransfected normal SB-HSA cells and empty wells as controls. 
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Figure 12 – Luciferase Assay of SB-HSA-Luc Cells in Medium with and without 
G418 
After confirmation of stably-transfected SB-HSA cells, SB-HSA-Luc cell population was 
grown in two flasks with or without G418 antibiotics for 6 months. Luciferase assay was then 
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Figure 13 – Culture of SB-HSA-Luc Cells after Irradiation 
SB-HSA-Luc cells were subjected to different doses of irradiation then continuously grown 
for 1 week. Photographs of cells were taken at Day 1, 3, 5 and 7. 
 
 Day 1 – Day 7 
0 Gy + 
5 Gy + 
10 Gy - 
20 Gy - 
 
Table 10- Qualitative Summary of Irradiation Results 
Continued proliferation of cells that were subjected to certain dose is marked as + and 
ceased proliferation is marked as - 
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Figure 14 – Luciferase Assay of SB-HSA-Luc Cells after Irradiation 
After 7 days culture of irradiated SB-HSA-Luc cells, luciferase assay was performed on 
10Gy irradiated SB-HSA-Luc cells, on non-irradiated SB-HSA-Luc and untransfected 
normal SB-HSA cells. 
 
3.4.5 Tissue Distribution of Intravenously Injected SB-HSA 
Cells in a Canine Tumour Mouse Model 
To investigate if SB-HSA cells can be used as a potential cellular vehicle, SB-HSA 
cells were labelled with DiR-cell-membrane dye followed by i.v. administration into 
four mice containing canine tumour xenografts. 24 h after injection, a strong 
fluorescent signal was detected in the liver of these mice, indicating a strong liver 
uptake of these cells. A weaker fluorescent signal was found in the spleen, heart, hind 
leg, but not in the kidney. A strong fluorescent signal was also observed in the 
tumour site in any of the 4 mice and the signal level was comparable to the ones seen 
in other organs, indicating some SB-HSA cells did migrate to tumour site (Figure 15). 
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Figure 15 – Ex vivo Imaging of Labelled SB-HSA Cells after i.v. Injection 
A-D, Labelled SB-HSA cells in cancer-bearing mouse 
E, DiR dye alone in cancer-bearing mouse 
F, Untreated cancer-bearing mouse 
  
 
3.4.6 In Vitro Optimization of Transfection Efficiency of 
PPIG3 Dendrimers 
To investigate the in vitro transfection nature of PPIG3 dendrimers, two canine 
tumour cell lines were transiently transfected with a GFP vector complexed to PPIG3 
dendrimers (Table 11). Despite varying the input DNA amount from 1.5μg to 6μg, 
SB-HSA cells remained hard to transfect (Figure 16). Relatively higher transfection 
efficiency was achieved in D-17 cells (Figure 17). However, the overall transfection 
ability of PPIG3 found here is much lower and less efficient than that found using the 
Lipofectamine 2000 method. 
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Figure 16 – Transfection of SB-HSA Cells by PPIG3 Dendrimers 
SB-HSA cells were transfected with different amount of GFP plasmid complexed with PPIG3 
dendrimers and photographed at 48h and 96h after transfection 
 





Figure 17 - Transfection of D-17 Cells by PPIG3 Dendrimers 
D-17 cells were transfected with different amount of GFP plasmid complexed with PPIG3 
dendrimers and photographed at 48h and 96h after transfection 
 
 PPIG3 Dendrimers 
SB-HSA Cells + 
D-17 Cells + 
 
Table 11- Qualitative Summary of Transfection by PPIG3 Dendrimers 
Successful transfection using PPIG3 dendrimers was marked as + 
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3.4.7 Design and Construction of a siRNA Expression 
Vector Targeting cTR 
Having achieved much higher transient and stable transfection in SB-HSA cells using 
a plasmid vector (Figure 10B, 11 and 12); I next decided to continue with the 
plasmid vector approach and to develop a DNA plasmid-based siRNA expression 
vector to target the canine telomerase RNA component. 
 
The sequence of Human telomerase RNA component gene was obtained from the 
National Centre for Biotechnology Information (NCBI) website 
(http://www.ncbi.nlm.nih.gov/nuccore/NR_001566.1). I next used the BLAST 
algorithm to search the canine genome (Canis lupus familiaris) for this sequence to 
identify the predicted canine TR sequence (Figure 18). The sequence 5’-
CGTCTAACCCTAACTGAGCAG-3’ which was based on a previous study (Lund et 
al., 2008) was reported to target the template region of cTR and inhibit telomerase 
activity more consistently than other areas of the sequence. The insert sequence for 
siRNA plasmid was then designed (Figure 19) using the Ambion online design tool 
(http://www.ambion.com/techlib/misc/psilencer_converter.html), and the siRNA 
expression vector was then constructed according to the manufacturer’s protocol. 
 
Chapter 3 – Exploration of Novel Delivery Systems for Plasmid-based siRNA Vector 






Figure 18 – Alignment of hTR Gene and Dog Genome  
A, Human telomerase RNA component gene sequence 
B, dog genome resources 
Red box contains the target sequence of cTR gene and green box contains the template 
region of cTR. 
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Figure 19 – Map of the siRNA Expression Vector and the Sequence of siRNA 
Insert  
A, Map of the siRNA expression vector (adapted from pSilencer 4.1-CMV neo instruction 
manual). siRNA insert part is coloured in red. 
B, The siRNA insert sequence targeting cTR 
Highlighted sequence in the centre represents the loop sequence and highlighted sequence 
on both sides represents the restriction enzyme sites. 
 
3.4.8 Optimizing the Transfection Efficiency of D-17 Cells 
To analyse the gene-silencing effect of the siRNA vectors, I not only used canine 
cancer SB-HSA cells, but also chose another canine cancer cell type, D-17 cell, and 
the optimized transfection of this cell line using Lipofectamine 2000 modified 
protocol was demonstrated (Figure 20).  A similar result (Table 12) was found for D-
17 cells as was found in SB-HSA cells (Figure 10), in that the modified protocol of 
Lipofectamine 2000 strongly increased the transfection ability in these cells 
comparing with using standard protocol. 
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Figure 20 –Transient Transfection of D-17 Cells Using Standard and Modified 
Protocol 
D-17 cells were transfected with a GFP plasmid using two different Lipofectamine 2000 
protocols then photographs were taken 48h after transfection.  
 
 Standard Protocol Modified Protocol 
SB-HSA Cells + ++ 
D-17 Cells + ++ 
 
Table 12- Summary of Improved Transfection 
Successful standard protocol was marked as + 
Any improved transfection result by using modified protocol of Lipofectamine  2000 was 
marked as ++  
 
3.4.9 Design of a Duplex RT-PCR System for Analysing 
siRNA Effect 
A duplex RT-PCR system was established to analyse the expression of cGAPDH and 
cTR in siRNA-transfected cells. Amplified cGAPDH corresponds to a 457bp band 
and cTR corresponds to a 157bp. These two bands appeared in the cDNA-added 
reaction groups only but not in the control reaction groups where cDNA was replaced 
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D-17 cells SB-HSA cells
cGAPDH - 457bp
cTR - 157bp
RNA Water cDNA RNA Water
 
 
Figure 21 – Establishment of Duplex RT-PCR for cGAPDH and cTR 
RT-PCR products were presented on gel in duplicates. DNA ladder was run on both sides of 
the gel.  
cDNA, normal PCR reaction with cDNA in it. 
RNA, PCR reaction with RNA replacing cDNA  
Water, PCR reaction with water replacing cDNA 
 
3.4.10 Demonstrating the Gene-silencing Ability of siRNA 
Expression Vector targeting hGAPDH 
The siRNA expression vector kit came with a prevalidated siRNA insert ready to be 
ligated into the vector targeting human GAPDH. Thus I constructed this siRNA 
vector targeting hGAPDH and tested it on the human tumour cell line, H1299 to 
demonstrate its gene-silencing ability. Human GAPDH was shown to be significantly 
silenced 48h after transfection with the siRNA vector, compared with a scrambled 
siRNA negative control (Figure 22). 
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hGAPDH - 457bp
cDNA RNA Water cDNA RNA Water cDNA RNA Water cDNA RNA Water
hGAPDH Neg Mock Untreated
 
 
Figure 22 – Singleplex RT-PCR of hGAPDH-siRNA Vector-treated H1299 Cells 
hGAPDH, hGAPDH-siRNA vector-treated H1299 cells 
Neg, scrambled negative control siRNA vector-treated H1299 cells 
Mock, mock transfection of H1299 cells 
Untreated, untreated H1299 cells 
DNA ladder was run on both sides of the gel. 
CDNA, RNA and Water lane are the same as defined above (Figure 21) 
 
3.4.11 Test of siRNA Targeting cTR in SB-HSA Cells 
After demonstrating the gene-silencing ability of the vector itself, siRNA targeting c 
TR was transfected into canine cancer SB-HSA cells. 48h after transfection, results 
were analysed on the pre-established duplex RT-PCR system (Figure 21) for 
cGPAHD and cTR. No cTR gene-silencing was observed in SB-HSA cells following 
transfection of cTR siRNA (Figure 23). 
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cDNA RNA Water cDNA RNA Water cDNA RNA Water cDNA RNA Water





Figure 23 – Duplex RT-PCR of cTR-siRNA-treated SB-HSA Cells 
cTR, cTR-siRNA treated-SB-HSA cells 
DNA ladder was run on both sides of the gel. 
Neg, Mock, Untreated, cDNA, RNA and water are the same as defined above (Figure 21 and 
22) 
 
3.4.12 Test of siRNA Targeting cTR in D-17 Cells 
After testing on SB-HAS cells, the siRNA targeting cTR was tested on another 
canine cancer D-17 cells. No cTR gene silencing was observed in D-17 cells 
following transfection of cTR siRNA (Figure 24). 
 
 
Chapter 3 – Exploration of Novel Delivery Systems for Plasmid-based siRNA Vector 
Targeting Canine Telomerase  
 88 
cDNA RNA Water cDNA RNA Water cDNA RNA Water cDNA RNA Water





Figure 24 - Duplex RT-PCR of cTR-siRNA-treated D-17 Cells 
DNA ladder were run on both sides of the gel. 
cTR, Neg, Mock, Untreated, cDNA, RNA and water are the same as defined above (Figure 21, 
22 and 23) 
 
3.5 Discussion 
Although we had already developed a viral siRNA vector capable of inhibiting 
canine telomerase in vitro (Lund et al., 2008), we still lacked an efficient delivery 
system for siRNA-based applications. As endothelial lineage cells have been reported 
to home to the tumour formation site, three endothelial cells, SB-HSA, HUVEC and 
EOMA cells were initially selected to begin our study. 
 
As a high transfection efficiency is crucial for any siRNA-mediated gene silencing 
either in vitro or in vivo, I tried to achieve this by firstly exploring the ability of four 
different commercial transfection reagents to transfect these three different 
endothelial-type cell lines. Our initial experiments using the β-galactosidase reporter 
gene vector confirmed our expectation that endothelial cells are very hard to be 
transfected by most of the commercial reagents that were tried. However, SB-HSA 
cells transfected with Lipofectamine™ 2000 showed a relatively higher transfection 
efficiency compared with the other two cell types. This result prompted us to further 
optimize the transfection efficiency of SB-HSA cells. In order to perform consistent 
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and effective transfection experiment, I replaced the reporter gene β-galactosidase 
vector with a GFP vector, as I did encounter difficulties when handling β-
galactosidase. Firstly, in situ detection of β-galactosidase within cells requires 
staining by x-gal before it can be visualised by microscopy and in order to gain 
consistent and effective staining, a fixation step before staining is also required. 
These two steps need multiple PBS washes to ensure that no inhibitors from either 
the cell medium or cell fixation process hinder the staining process. Moreover, I have 
found certain type of cells, such as 293FT, detached from the bottom of the plate 
very easily, sometimes even without PBS washing, which thus made it very difficult 
for us to do sufficient PBS washes while preventing these adherent cells detaching 
from the bottom of the plate. So the whole process of staining is very time-
consuming. Losing cells during multiple steps of PBS washes could hinder us from 
obtaining a correct staining result. In addition, glutaraldehyde that was used in the 
fixation step is considered carcinogenic (Zeiger et al., 2005). In contrast, GFP emits 
green fluorescence upon exposure to UV or blue light and, unlike luciferase or β-
galactosidase enzymes, does not require additional substrates for the enzymatic 
reaction (Martin and Murray, 2000), which thus saves significant assay time, 
especially in large experiments of transfection of multiple cell types using multiple 
transfection reagents. 
 
Traditionally, most of the liposome-based reagents recommend plating cells 24h 
prior to transfection, which have limitations on transfection efficiency. Sometimes, 
despite varying the ratio of DNA:reagent, the cell-seeding density and/or the amount 
of DNA input, the improved is still very limited. I have shown here that by simply 
adding the DNA–Lipofectamine complex immediately following cell-plating on the 
day of transfection instead of plating cells 24h before transfection, I can significantly 
increase the transfection of both SB-HSA cells and D-17 cells to achieve at least 
double the transfection efficiency obtained using the standard protocol (Figure 10 
and 20). This new transfection protocol, which can save at least 24h of the 
experiment time, is based on the so-called ‘reverse transfection’ and is mainly used 
for high throughput transfection assays (Martin and Murray, 2000, Dalby et al., 
2004). With this enhanced transfection effect, not only an increased population of 
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transfected cells can be analysed for downstream applications, but also it gave us the 
idea of developing a plasmid vector-based siRNA to utilize this enhanced in vitro 
ability. 
 
Cells generally can be transfected in vitro and in vivo using physical, viral or 
chemical approaches (Greco et al., 2002, Azzam and Domb, 2004, Kawakami et al., 
2008). Physical methods, such as electroporation, has achieved some success in 
certain cell types and is cell cycle-independent, but may be toxic to some cell types 
and requires specialized equipment (Villemejane and Mir, 2009). Viral-vector-based 
transduction is reported to be efficient for gene transfer, especially for in vivo use 
(Work et al., 2004), but concerns have been raised over insertional mutagenesis, the 
immune response or viral infection that might be caused by these vectors (Glasgow 
et al., 2004, Kreppel and Kochanek, 2008). Generally higher safety measures are still 
required to use viral vector as transfection tools (Manilla et al., 2005, Raty et al., 
2008). In contrast, transfection of cells using chemical methods is widely used, 
because the reagents are relatively simple to use, cheap and easy to handle (Douglas, 
2008). 
 
One of the most important features of an ideal cellular vehicle is that it should be 
easily modified to express foreign genes, either reporter genes for cell tracking or 
therapeutic genes for cancer therapy. Currently most studies modifying potential 
cellular vehicles have used viral methods for gene therapy-based studies (Chen et al., 
2008). Also it was reported that using viral vectors to transfer therapeutic genes into 
endothelial progenitor cells could achieve as much as 80% transfection efficiency 
(Kealy et al., 2009). However, this method also bears the risk of introducing 
unexpected adverse or side-effects such as toxicity, immunogenicity (Marshall, 1999), 
mutagenesis and oncogenesis (Hacein-Bey-Abina et al., 2003, Kerbel et al., 2008). I 
transfected SB-HSA cells with pGL-4.18, a luciferase plasmid vector bearing an 
antibiotic resistant gene using chemical transfection methods followed by antibiotic 
selection. A luciferase assay demonstrated that transfected SB-HSA cells showed 
significant luciferase expression compared with untreated cells. I then cultured these 
cells in growth medium with or without antibiotics. Interestingly, six months after 
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transfection both cell populations were still strongly expressing luciferase indicating 
the plasmid may have integrated into the genome of cells. This observation suggests 
that non-viral methods can be used to transfer genes into cellular vehicles ex vivo to 
achieve long-term cancer gene therapy. 
 
Even SB-HSA cells can be potential cellular vehicles for cancer gene therapy, 
although injecting malignant endothelial cells systemically increases the risk of 
initiating tumours in vivo. However, an adequate dose of irradiation should abolish 
the proliferation of malignant cells while allowing them to remain metabolically 
active. Thus, I investigated the irradiation response of luciferase-stably-transfected 
SB-HSA and SB-HSA-Luc cells. I can confirm that a high dose of 10Gy irradiation 
completely abolished the proliferation of SB-HSA cells compared with untreated 
cells, while still maintaining adequate expression of the reporter gene seven days 
after irradiation. This finding makes irradiation a possible way to abolish cancer cell 
proliferation without affecting its gene expression, and thus paves the way to utilize 
malignant cells, such as SB-HSA cells as cellular vehicles for cancer gene therapy. 
 
Potential cellular vehicles with specific tumour-homing ability have always attracted 
great attention for cancer gene therapy. Our hypothesis is based on the fact that 
circulating endothelial lineage cells can migrate to solid tumour sites and contribute 
to tumour neovascularization to support tumour growth. However, this homing 
ability was reported to depend on the specific cancer type (Ruzinova et al., 2003, 
Kerbel et al., 2008), stage (Spring et al., 2005), grade (Li et al., 2004a), site and even 
mouse strain used (Duda et al., 2006, Madlambayan et al., 2009). In this study, I 
demonstrated that after intravenous administration of fluorescent DiR-dye labelled 
SB-HSA cells, one out of four cancer-bearing mice showed the localisation of SB-
HSA cells to the subcutaneous tumour site. However the fluorescent signal also 
indicated that labelled SB-HSA cells also migrated to other major organs, such as the 
liver, spleen and bone marrow, but not the kidney. In the group injected with DiR 
only, I injected the same amount of DiR dye without cells into the tumour-bearing 
mice and a strong fluorescent signal was observed in all major organs, which 
indicates the non-specific binding of this dye to cell membranes in vivo. To avoid this 
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problem, after labelling cells, I washed cells with PBS 3 times each combined with 3 
times centrifugation steps to eliminate any remaining dye from the cell medium. 
Although bioluminescence imaging bears certain advantages, it requires an 
additional step of administration of a substrate, luciferin, for the luciferase reaction in 
vivo. DiR membrane dye offers a simple solution and only requires an ex vivo cell-
labelling step before intravenous administration (Kalchenko et al., 2006, Kerbel et al., 
2008). Our finding is largely consistent with other reports regarding potential cellular 
vehicles that systemically delivered Mesenchymal stem cells which homed to major 
organs but not to kidney (Xiang et al., 2009). Although tumour localisation of SB-
HSA cells was observed in one mouse out of four, its migration to other major organs 
would make it less efficient to deliver therapeutic genes to tumour sites. In the future, 
a second strategy is required to specifically direct these cells to any target organ or 
tissue for targeted cancer gene therapy. For systemically targeting all primary and 
metastatic tumours, strategies must be developed to increase specificity by avoiding 
major organ intake to reduce toxicity. 
 
Recent encouraging in vivo reports of PPIG3 dendrimers have made it an attractive 
vector for cancer gene therapy. However, only a few studies report the transfection 
efficiency in a few human cell lines in vitro (Zinselmeyer et al., 2002, Hollins et al., 
2004, Santhakumaran et al., 2004), let alone in any canine cells. In this study, for the 
first time I tested the transfection ability using PPIG3 dendrimers in two canine 
cancer cell lines, SB-HSA haemangiosarcoma cells and D-17 osteosarcoma cells. I 
kept the ratio of DNA to PPIG3 at 1:5 constantly in this study, as this has been 
confirmed to enable PPIG3 to pack DNA firmly and to form stable colloidal 
nanoparticles (Chisholm et al., 2009). However, I encountered a major difficulty to 
transfect SB-HSA cells, despite varying the DNA amount from 1.5 µg to 6 µg. As the 
reported transfection efficiency of endothelial cells is generally low (Hunt et al., 
2010), this result was expected. In D-17 cells, better transfection was achieved with 
more than 50% GFP-positive cells 96 hours after transfection. Although I was able to 
transfect many more D-17 cells than SB-HSA cells using PPIG3 dendrimers, the 
efficiency using PPIG3 in these two cell lines was much lower than I demonstrated 
using Lipofectamine 2000 in the previous chapter. It was also reported that PPI 
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dendrimers including PPIG3 altered the endogenous expression of many genes in 
transfected cells (Omidi et al., 2005, Barar et al., 2009), However, although this 
could be cell dependant (Omidi and Barar, 2009), the intrinsic gene regulation 
mediated by PPI should be seriously considered when designing and developing 
vectors for cancer gene therapy. To utilize PPIG3 for cancer gene therapy in the 
canine subject, more studies are required to explore their in vitro effect on canine 
cells first. 
 
After exploring two potential systemic delivery vehicles, I then designed and 
constructed a DNA plasmid-based siRNA expression vector that expresses shRNA in 
cells. It has been reported that the same vector construct targeting either 
housekeeping gene (Shan et al., 2009) or cancer-specific gene (Li et al., 2010) in 
human cancer cells can effectively knock down target gene expression, and a similar 
vector construct has been shown to downregulate hTERT gene effectively in a human 
cancer cell line (Zhang et al., 2006). 
 
I also established a duplex semi-quantitative RT-PCR system to analyse target gene 
silencing and housekeeping gene expression and used proper controls of reaction 
groups with added RNA or NF-water replacing cDNA to rule out any general or 
genomic DNA contamination. I did try to build a quantitative real-time RT-PCR 
system but, because only a short partial sequence of cTR has been published, no 
probe/primer could be designed from Roche ProbeLibrary using that sequence and 
only one probe/primer pair was available to try from Applied Biosystems. 
Unfortunately, this probe/primer pair also amplified non-specific bands in RT-PCR 
despite trying several annealing temperatures. 
 
In the siRNA experiments, I first used a siRNA expression construct targeting human 
GAPDH housekeeping gene in the human lung cancer H1299 cell line to explore the 
gene-silencing capability of this plasmid vector. I found that 48 hours after 
transfection, expression of the hGAPDH gene was significantly inhibited in the 
siRNA-vector-treated group, but was unaffected in both the mock transfection group 
and untreated group, which indicated the strong silencing ability of this vector. 
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However, I also observed some hGAPDH gene knockdown in cells transfected with 
a scrambled siRNA vector (Neg) that should not target any known human gene. This 
might be explained by the off-target effects of siRNA molecules, for which only a 
short region of sequence complementarity triggers the silencing effect (Jackson and 
Linsley, 2010). Although I tried our siRNA vector on two canine malignant cancer 
cell types, I did not observe any cTR gene knockdown. Currently there is no 
complete sequence of cTR gene published and only one short partial sequence of 
cTR is available online. I obtained the cTR sequence using BLAST algorithm to 
align the human TR sequence with the canine genome. Based on 19nt target 
sequence from previously-established siRNA viral vector (Lund et al., 2008), I then 
designed the new plasmid-based siRNA expression vector targeting the same region 
of cTR (21nt target sequence by extending the 19nt target sequence 1 nucleotide 
from both ends as well as replacing 1 nucleotide) according to the BLAST algorithm 
alignment between hTR and dog genome. 
 
Transfection efficiency directly influences the gene silencing result. The canine SB-
HSA cell line that I used in this study was derived from malignant endothelial cells 
(Akhtar et al., 2004). Although there is no direct report on the transfection efficiency 
of this cell line, there have been several reports regarding the transfection efficiency 
of human endothelial cells, either using chemical reagents (Sipehia and Martucci, 
1995, Fife et al., 1998, Zeng et al., 2000, Kaiser and Toborek, 2001, Colombo et al., 
2001) or electroporation (Teifel et al., 1997). So far, the best transfection efficiency 
achieved on human endothelial cells by chemical reagents is approximately 32%, and 
most of the reports indicated a transfection efficiency below 25% (Hunt et al., 2010). 
Our result demonstrated a strongly improved transfection in the canine endothelial 
type cell, SB-HSA, which should enhance the gene silencing effect in theory. 
 
The transfection method also influences gene silencing efficiency. It was reported 
that Lipofectamine 2000 which I used in this study gave the best transfection 
efficiency for human endothelial cells when compared with other commercial 
chemical reagents (Hunt et al., 2010). Although one report showed greater than 90% 
transfection efficiency using viral vector on endothelial cells, this method is limited 
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by the investment of time, facilities, overall expense, and safety considerations 
(Wrighton et al., 1996, Merrick et al., 1996). 
 
Due to the lack of publications on studies regarding canine telomerase (Colitz, 2008), 
I do not have a complete published sequence of canine telomerase RNA component. 
Thus I used the human TR gene to align the published dog genome as well as using 
the target sequence of a previously established siRNA viral vector. As the plasmid-
based siRNA vector requires a 21nt target sequence, unlike the siRNA viral vector 
from Invitrogen which only requires a minimum of 19nt target sequence, it is 
reasonable to speculate that extending the previously-proven target sequence of cTR 
might have hindered the gene-silencing mediated by the induced RNAi. It is known 
that siRNA molecules targeting different sequences of the gene vary markedly in 
their effectiveness (Holen et al., 2002). There is also a possibility that secondary 
structures of the targeted mRNA region and/or binding of regulatory proteins might 
block the induced RNAi by our vector.  It is also reasonable at this stage to question 
the vector’s capability of mediating gene-silencing in canine cells, as currently the 
gene-silencing ability of this vector has only been demonstrated in human cells. 
Again, as canine telomerase inhibition mediated by siRNA is not as well documented 
as human telomerase, novel regulation of telomerase might also exist in dogs. It was 
reported that, unlike in humans, inhibition of murine TERT led to quick telomerase 
reactivation accompanied by upregulation of TERT and that this might be explained 
by the longer telomere present in murine cancer cells (Marie-Egyptienne et al., 2008, 
Sachsinger et al., 2001). 
 
In this study I could not downregulate the cTR gene in canine malignant tumour cells 
by plasmid-based siRNA vector, but telomerase still remains an attractive anticancer 
target. In the future, more research needs to be done on canine telomerase to explore 
effective ways of inhibiting telomerase, as well as developing the dog as a model for 
studying human telomerase. Further, not only is an effective way to inhibit 
telomerase needed, but a systemic delivery method is also crucial for its successful 
anticancer therapeutic application. 
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3.6 Conclusion 
In this study, I initially explored two novel delivery systems which could be 
potentially utilized to deliver therapeutic genes systemically for treating cancer. As a 
starting point, I explored the transfection efficiency of three endothelial cell lines. 
Then I further optimised the transfection efficiency of SB-HSA cells using a 
chemical transfection reagent. Canine SB-HSA cells, as I found in our in vitro 
experiments, can be manipulated by chemical transfection methods for gene transfer 
short-term or long term. In vivo, although I did observe some cell migration into the 
tumour sites in one of the mice, labelled SB-HSA cells showed a wide tissue 
distribution to all major organs. Thus, SB-HSA cells might be difficult to utilize as a 
systemic delivery vehicle at this stage and this approach therefore requires further 
evaluation. Although the PPIG3 dendrimer was found to passively accumulate 
specifically in tumour sites in vivo, the in vitro transfection ability in canine cells 
were found to be relatively low in this study. Thus, this approach needs further study 
to improve its transfection ability as well as to understand the nature of its specific 
tumour accumulation in vivo. While numerous promising delivery systems have been 
developed for cancer gene therapy, most of the findings have not passed the proof-of-
principle stage in vitro or in vivo. Each vehicle bears both advantages and drawbacks, 
thus harnessing their individual advantages to target different cancers, as well as 
using them in combination, may be the future solution for cancers treatment. After 
exploring two novel delivery systems, I then designed and constructed a plasmid-
based siRNA expression vector targeting canine TR gene to inhibit telomerase. 
However, I did not observe any gene knockdown of cTR gene using the siRNA 
vectors. Although human telomerase is a promising anticancer target that has been 
intensively studied, canine telomerase is still poorly documented. This study 
indicated that using siRNA at least plasmid-based siRNA vector to target canine 
telomerase needs to be validated by more research in the future. 
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4.1 Chapter Abstract 
Despite the current advances in anticancer therapy, cancer still remains a high 
morbidity and mortality disease in both the human and canine fields. Finding a non- 
or minimum-invasive method to detect cancer has become the priority in the cancer 
research field worldwide. Although there have been many reports regarding the 
potential diagnostic use of hTERT mRNA found in the circulation of human cancer 
patients, the exact mechanism behind it is still poorly understood, and there is 
currently no investigation in the canine area. 
 
To utilize the many canine cancer cases in the Hospital for Small Animals, I have 
investigated the existence of circulating TERT mRNA in the serum of canine cancer 
patients and its potential use in canine cancer diagnostics. Three different methods 
have been developed successfully to extract circulating RNA from as little as 100 µl 
canine serum, and both conventional RT-PCR and quantitative real-time RT-PCR 
systems have been established to analyse the levels of circulating RNA. 
 
Among 36 canine serum samples that were randomly collected from the oncology 
department, 18s rRNA was present in all samples that were tested and cGAPDH 
mRNA was detectable in 26 serum samples. However, cTERT mRNA was only 
detected in 1 of these samples. 
 
Although this project is only a pilot study of circulating RNA in the canine cancer 
field, the results have shown that more research needs to be done regarding the 
general mechanism behind circulating RNA before circulating cTERT can be used as 
a canine cancer diagnostic marker. 
 
4.2 Introduction 
According to the definition of ‘biomarker’ in the dictionary of cancer terms 
published online by the National Cancer Institute (www.cancer.gov/dictionary), it is a 
biological molecule found in blood, other body fluids or tissues that is a sign of a 
normal or abnormal process, or of a condition or disease. An effective biomarker for 
cancer should facilitate cancer detection in clinical or, preferably, sub-clinically 
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affected patients, and may also help to improve the clinical outcome of cancer 
patients. Thus, the identification of biomarkers that distinguish cancer patients from 
normal individuals is of great interest in both the human and veterinary fields. 
Although some research has been conducted in veterinary oncology to identify 
cancer biomarkers using advanced techniques such as proteomics (McCaw et al., 
2007), there is still a long way to go before any candidate can be utilised in cancer 
clinics (Henry, 2010). Circulating RNA found in a number of human cancer patients 
provides a new way to discover biomarkers to detect cancer and, together with the 
universal tumour marker telomerase, if found to be valid, can be applied not only in 
cancer diagnosis but possibly also in prognosis, cancer staging or in monitoring the 
response to therapy. Despite there having been many studies linking circulating RNA 
with human cancers as a clinical marker, there has been no research done in the 
canine cancer field. Utilising the resources of our Oncology Department in the 
Veterinary Teaching Hospital, I aimed to answer two questions in this pilot study. 
 
1. Is RNA present in the serum of canine cancer patients? 
 Three methods were investigated for total RNA extraction from serum 
of canine cancer patients. 
2. Is amplifiable mRNA present in the serum of canine patients? 
 I investigated whether 18S rRNA and GAPDH mRNA could be 
detected in serum from canine cancer patients by conventional and/or 
real-time PCR. 
3. Does TERT mRNA exist in the serum of canine cancer patients? 
 I investigated whether TERT mRNA can be detected in serum from 
canine cancer patients 
 
4.3 Materials and Methods 
4.3.1 Blood Sample Processing 
Canine blood samples were randomly collected by veterinarians from canine cancer 
patients in the Oncology Department of Hospital for Small Animals at the University 
of Edinburgh. Samples were kept on ice and immediately processed to separate 
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serum from blood cells. To obtain a cell-free serum, I used 3-spin protocol. Blood 
samples were centrifuged at 1,000 x g for 10min, then at 1,500 x g for 10min, and 
finally at 3,000 x g for 10min at 4˚C. The serum was harvested at each step and taken 
forward to the next step. Purified serum was then stored at - 70˚C. 
 
4.3.2 Total RNA Isolation from Serum 
As total RNA from serum was reported to be extremely low (Fleischhacker and 
Schmidt, 2007), and presumably the amount of mRNA was even lower, three 
different methods were tried to optimize mRNA recovery. 
 
4.3.2.1 The SV Total RNA Isolation System 
The first method I will describe is the SV Total RNA Isolation System (Promega, 
UK). All components mentioned below were provided by the kit unless otherwise 
stated. Serum samples were first thawed on ice. In the meantime, NF-water (provided 
in the kit) was added to a vial of lypholized DNase I, and 200µl β-mercaptoethanol 
(Sigma, UK) was added to 10ml RNA Lysis buffer. 8ml and 20ml 95% ethanol were 
added to the DNase Stop solution and to the RNA Wash solution, respectively. The 
manufacturer’s protocol was followed with only slight modifications (Chen et al., 
2000). 175µl RNA Lysis buffer was directly added to 100µl serum, and then 
thoroughly mixed by inversion. 350µl RNA Dilution buffer was then added to the 
lysate before placing in a heating block at 70ºC for 3 min. The lysate was then 
centrifuged at 14,000 x g for 10min. After centrifugation, the supernatant was 
transferred to a new microcentrifuge tube and 200µl 95% ethanol was added and 
mixed by pipetting 3–4 times. The mixture was transferred to the Spin Column 
Assembly and centrifuged at 14,000 x g for 1min. After discarding the flow-through, 
600µl RNA Wash solution was added into the spin column, which was then 
centrifuged at 14,000 x g for 1min. The column collection tube was emptied, then the 
DNase incubation mix was prepared by combining 40μl Yellow Core buffer, 5μl 
90mM MnCl2 and 5μl of DNase I enzyme. 50μl of the DNase mix was then applied 
to the membrane of the column. After incubating for 15min at room temperature, 
200μl DNase Stop solution was applied to the membrane then centrifuged at 14,000 
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x g for 1min. 600μl RNA Wash solution was applied to the column for a second time 
followed by 14,000 x g centrifugation for 1min. After empting the collection tube, 
another 250μl RNA Wash solution was added to the spin basket and it was then 
centrifuged for 2min at 14,000 x g. Finally, the spin column was transferred to an 
elution tube 30μl NF-Water was added and it was then centrifuged at 14,000 for 
1min. 
 
4.3.2.2 The High Pure Viral RNA Kit 
The second method I will describe is the High Pure Viral RNA Kit (Roche, UK). 
This system was designed for processing 200μl serum samples, but it can be used to 
process up to 600μl serum at a time if all components are increased proportionately 
and loaded into the filter tubes three times. All components mentioned below were 
provided by the kit unless otherwise stated. 600μl serum samples and 1.2ml Carrier 
RNA-supplemented Working solution was added to a clean tube and mixed well. The 
mixture was then loaded onto a High Pure Filter Tube several times and centrifuged 
at 8,000 x g for 15s after each addition. After discarding the flow-through, the filter 
tube was transferred to a new collection tube. 500μl Inhibitor Removal buffer was 
then added to the tube assembly and centrifuged at 8,000 x g for 1min. This process 
was repeated twice. After this, 450μl Wash buffer was added to the tube assembly 
three times and centrifuged at 8,000 x g for 1min after each addition. The filter tube 
was then transferred to a new collection tube and washed three times with 450μl 
Wash Buffer, with centrifugation at 8,000 x g for 1min after each addition. After 
empting the collection tube, the assembly was centrifuged at 12,000 x g for 10s to 
remove any residual Wash buffer and this step was repeated three times. The filter 
tube was then placed into a clean microcentrifuge tube and 30μl (50μl for 
200403,300664 and 172229 for tests in both conventional and real-time PCR) 
Elution buffer was applied to the assembly and centrifuged at 8,000 x g for 1min to 
elute the RNA. 
 
4.3.2.3 The TRI Reagent® BD 
The third method I will describe is the TRI Reagent® BD (Sigma, UK). For using the 
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TRI BD Reagent, 250µl serum was added to 750µl TRI Reagent® BD and mixed 
thoroughly by vortexing. After incubation at room temperature for 5min, 100µl 1-
bromo-3-chloropropane was added to TRI Reagent-serum mix. The tube was then 
covered and shaken vigorously for 15s. After 5min incubation at room temperature, 
the mixture was centrifuged at 12,000 x g for 15min at 4ºC. Centrifugation resulted 
in 3 phases of the mixture. The aqueous phase containing the RNA was carefully 
transferred to a new tube and 0.5ml isopropanol was added to the tube containing 
RNA. After 10 min incubation, the mixture was centrifuged at 12,000 x g for 8min at 
4˚C. The centrifugation step resulted in a RNA pellet forming on the side and bottom 
of the tube. The supernatant was carefully removed and 1ml 75% ethanol was added 
in to precipitate RNA. The sample was vortexed and centrifuged at 7,500 x g for 
5min at 4ºC. The supernatant was removed and the RNA pellet was briefly dried for 
5–10 min, then 30µl NF-water was used to dissolve RNA. This method can be scaled 
up if more than 250µl serum needs to be processed. 
 
RNA samples obtained from each of the above methods were either stored at -70˚C 
or treated with DNase for immediate use in downstream applications. 
 
4.3.3 cDNA Synthesis from Serum RNA  
4.3.3.1 cDNA Synthesis from Serum RNA for RT-PCR 
Due to the very low amount of RNA in serum, all cDNA synthesis for downstream 
RT-PCR was conducted using Sensiscript RT Kit (Qiagen, UK). The recipe for a 
single reaction is given below (Table 13). Mixed components were then incubated at 
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Component Amount (µl) 
10x Buffer RT 2 
dNTP Mix (5mM each dNTP) 2 
Random Primers, 0.5μg/μl 1 
RNase inhibitor (10 units/μl) 1 
Sensiscript Reverse Transcriptase 1 
Total RNA from Serum « 13 
NF-water (If needed) To a final volume of 20 
 
Table 13 – cDNA Synthesis from Serum RNA for Conventional PCR 
All components mentioned above in the table were provided by the kit unless otherwise stated. 
As much as possible serum RNA was added into the reactions to generate the cDNA for 
downstream PCR detection, as long as enough RNA was saved for the control groups of PCR.  
 
4.3.3.2 cDNA Synthesis from Serum RNA for Real-time 
PCR 
For real-time PCR, Transcriptor High Fidelity cDNA Synthesis Kit was used to 
match the LightCycler 480 system. As much as 9.4µl extracted serum RNA was first 
mixed with 2µl of 600pmol/µl Random Hexamer Primer to make a 11.4µl RNA-
primer mix. The mixture was then denatured in a heating block at 65˚C for 10min 
followed by immediate cooling on ice. The full reaction mixture was then assembled 
according to the table below (Table 14). It was then incubated at 29˚C for 10min 
followed by 60min at 48˚C. Finally, the reverse transcriptase was inactivated at 85˚C 
for 5min. Synthesized cDNA can be used in downstream real-time PCR directly or 
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Component Amount (µl) 
Serum RNA and Random Hexamer Mix 11.4 
Transcriptor High Fidelity Reverse Transcriptase Reaction Buffer 
5X 4 
Protector Rnase Inhibitor 40U/µl 0.5 
Deoxynucleotide Mix, 10mM each 2 
Dithiothreitol (DTT) 1 
Transcriptor High Fidelity Reverse Transcriptase  1.1 
 
Table 14 – cDNA Synthesis from Serum RNA for Real-time PCR 
All components mentioned above were provided by the kit unless otherwise stated. As much 
as possible serum RNA was added into the reaction to generate the cDNA for downstream 
PCR detection, as long as enough RNA was saved for the control groups of PCR. 
 
4.3.4 Conventional RT-PCR for Serum RNA 
Conventional RT-PCR was performed using the GoTaq® PCR Core System to detect 
cGAPDH and cTERT cDNAs. The recipe and primer sets are shown below (table 15 
and 16) and cGAPDH primers were the same set that was used in the previous 
chapter (Table 7). The PCR products were run out on a 1% agarose gel, and the 
cTERT PCR product corresponded to a 279bp band. The same programme of PCR 
was run according to the previous chapter (3.3.8), and primer-dependent temperature 
was applied to the annealing temperature.  
 
PCR products were then subjected to DNA electrophoresis and corresponding bands 
for cTERT and cGAPDH were excised using the same method mentioned in the 














Component Amount (µl) 
cDNA / RNA / Water 5 / RNA / Water  
dNTP, 10mM 1 
MgCl2, 25mM 4 
5X Go Taxi Buffer 10 
cTERT (cGAPDH) Forward Primer, 
100pmol/µl 0.25 
cTERT (cGAPDH)  Reverse 
Primer, 100pmol/µl 0.25 
GoTaq® DNA Polymerase, 5units/μl  0.25 
NF-water To a final volume of 50 
 
Table 15 – Conventional PCR of cGAPDH or cTERT in Serum RNA 
All components mentioned above in the table were provided by the kit unless otherwise stated. 
This set of PCR reactions used 5μl cDNA solution and 0.25µl PCR primers in order to detect 
the target gene in serum RNA. 
 





cTERT TACCTGCCCAACACGGTAAC GCGTGTGGGTCTGAGGTC 58 
 
Table 16 – The Primer Set in Conventional PCR for Serum RNA 
cGAPDH primers were the same set that was used in the previous chapter (Table 7) 
 
4.3.5 Real-time PCR for Serum RNA 
Duplex real-time PCR of serum RNA was performed analysing cTERT or cGAPDH 
mRNAs with 18S ribosomal RNA as control. cTERT and cGAPDH primers were 
labelled with the FAM dye and 18S rRNA was labelled with the VIC dye. All real-
time PCR were done using LightCycler® 480 Probes Master (Roche, United 
Kingdom) on a LightCycler® 480 System. Real-time probes and primers were 
designed using the Universal ProbeLibrary System. Real-time PCR was conducted 
using 96-well plate in 10µl reaction volumes. 
 
The efficiency of all Primers (Table 18) was tested first by running duplex real-time 
PCR of cGAPDH or cTERT with 18S rRNA using serially diluted cDNA samples 
(Table 17). Real-time PCR conditions were: an initial pre-incubation step of 95ºC for 
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10min; followed by 50 cycles of the amplification step, consisting of 95˚C for 10s, 
then the primer-dependent annealing temperature (Tm) for 30 s, followed by 72˚C for 
1s; then with a cooling step of 40˚C for 10s. For each primer pair, the Tm is based on 
the mean annealing temperature of each primer pair. Control reactions included RNA 
or water to replace cDNA in the reaction, and all reactions were done in triplicate. 
 
Component Amount (µl) 
LightCycler® 480 Probes Master Mix 10μM  5 
Probes and Primers Mix 50μM  0.15 
Probes and Primers Mix 50μM (2nd set) 0.15 
cDNA / RNA / Water 4.7 
 
Table 17 – Reaction Recipe for Duplex Real-time PCR of cGAPDH/cTERT with 
18S rRNA 
The above recipe is for one reaction. LightCycler® 480 Probes Master Mix was purchased 













Eukaryotic 18s r RNA Endogenous 












Table 18 – Primer Sets for Duplex Real-time PCR Analysing Serum RNA 
Eukaryotic 18S rRNA was purchased from Applied Biosystems and was ready to use in the 
reaction. The primer sequence is proprietary. 
 
4.4 Results 
4.4.1 Collection of Blood Samples 
From June to December 2009, 36 canine blood samples from the oncology 
department of Hospital for Small Animals were randomly collected. All the dogs 
sampled were suspected cases of neoplasia. This study was ethically approved and 
informed consent was obtained from each patient’s owner. 




4.4.2 Processing of Blood Samples 
The sample processing is summarized in the diagram below (Figure 25). 36 serum 
samples ranging in volume from 100µl to 3.5ml were harvested and immediately 
stored at -70 ˚C. Three different methods for isolating total RNA from serum of 
canine cancer patients were tried, depending on the volume of serum in each sample. 
First, total RNA was successfully isolated using the Promega SV total RNA isolation 
system, but this system could only process up to 100µl serum sample at a time (Chen 
et al., 2000). The Roche High Pure Viral RNA kit protocol was also used to isolate 
total RNA successfully and could process up to 600µl serum at a time. Lastly, all 
serum samples larger than 600µl were processed using the Sigma TRI BD Reagent 
method. 
 
One serum sample that was subjected to the Promega SV total RNA isolation method 
produced, after DNase treatment, 8.34ng/µl and the ratio of absorbance at 260nm and 
280nm was 1.33. 16 samples that were subjected to Roche High Pure Viral RNA kit 
gave a yield ranging from 1.42ng/µl to 4.85ng/µl and the 260/280 ratio was from 
0.54 to 1.5. Using TRI BD reagent, I extracted total RNA from nineteen samples 
where the yield ranged from 17.47ng/µl to 600.91ng/µl and the 260/280 ratio was 
from 0.59 to 2.08.  
 














Figure 25 – Workflow of Blood Sample Processing  
Experiment started with blood sample collection from the clinic followed immediately by 
serum separation and then the serum was stored at -70˚C. After extraction of total RNA 
from serum samples and DNase treatment, they were subjected to conventional 
and/or real-time PCR. At the end of the experiment case files relating to each sample 
were accessed and studied. 
 
4.4.3 Establishment of Conventional RT-PCR 
A conventional singleplex RT-PCR method was established to analyse cTERT or 
cGAPDH mRNA levels in both serum and cells (Figure 26). Canine malignant SB-
HSA cells were used as cTERT and cGAPDH positive controls in this system. A 
band of 457bp cGAPDH and 278bp cTERT could be amplified from cDNA reaction 
group with cDNA synthesised from total RNA of SB-HSA cells compared with no 
band amplified from reaction groups with added RNA or water replacing cDNA.  
 
 









cDNA RNA Water DNA 
Ladder  
 
Figure 26 – Establishment of Conventional PCR for cTERT and cGAPDH 
Expression Analyzing Serum RNA 
 
DNA ladders were run on the right side of both gels. 
CDNA, RNA and Water lane are the same as mentioned earlier (Figure 21) 
 
4.4.4 Establishment of Duplex Real-time PCR 
Two duplex quantitative real-time RT-PCR systems were designed to analyse cTERT 
or cGAPDH mRNA expression with 18S rRNA levels as control in both serum 
samples and control SB-HSA cells. Canine malignant SB-HSA cells were used as 
positive controls for cTERT, cGAPDH mRNA and 18S rRNA amplification reactions. 
The efficiency of all 3 sets of primers was determined using serial dilutions of input 
cDNA. For duplex cGAPDH and 18S real-time PCR system, the R2 is 0.9702 and 
0.9751 (Figure 27) and for duplex cTERT and 18S real-time PCR system, the R2 is 
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Figure 27 – Primer Efficiency Test of Duplex Real-time PCR of cGAPDH mRNA 
and 18S rRNA 
A, The primer efficiency of cGAPDH mRNA within the system 
B, The primer efficiency of 18S rRNA within the system 
Av Cp stands for average Cp value 
 
Chapter 5 – The Investigation of Telomerase Induction in Canine Somatic Cells: a Pilot 
Study 
 111 
cTERT expression of SB-HSA cells in duplex real-time 
PCR






0 0.1 0.2 0.3 0.4 0.5 0.6





18s rRNA expression of SB-HSA cells in duplex real-
time PCR














Figure 28 – Primer Efficiency Test of Duplex Real-time PCR of cTERT mRNA 
and 18S rRNA 
A, The primer efficiency of cTERT within the system 
B, The primer efficiency of 18S within the system 
Av Cp stands for average Cp value 
 
4.4.5 Result of Samples subjected to Conventional PCR 
Test 
In the beginning of the test, I randomly analysed 13 samples using conventional RT-
PCR and after this I started using real-time PCR system to analyse the remaining 23 
samples. For the 13 serum samples subject to conventional PCR analysis, 6 samples 
were positive for the expression of the cGAPDH gene, and within these only 1 
sample was positive for canine TERT gene expression (Figure 29). This TERT-
positive sample, 305195 is a mast cell tumour case. 
 



















Figure 29 – Positive Serum Samples of cGAPDH or cTERT in Conventional 
PCR 
A, cGAPDH expression in serum samples 
B, c TERT expression in serum samples 
CDNA, RNA and Water lane are the same as defined above (Figure 21). 
 
4.4.6 Result of Samples subjected to Real-time PCR Test 
In a total of 26 samples subjected to real-time PCR analysis, eukaryotic 18S 
ribosomal RNA expression was found in all samples with Cp values ranging from 
20.69 to 34.99. Canine GAPDH gene expression was found in 23 out of the 26 
samples with Cp values ranging from 31.20 to 37.26. However, canine TERT gene 
expression was not detected in any of the 26 samples (Table 19). 200403, 300664 
and 172229 which were subjected in the previous conventional test, were also tested 









Case Number 18S Av Cp cGAPDH Av Cp c TERT Av Cp 
SB/HSA cells 10.2 19.29 29.87 
304610 32.11 - - 
304327 27.55 35.83 - 
304364 24.3 34.09 - 
303505 20.69 32.58 - 
304779 21.64 - - 
304022 23.43 34.62 - 
303878 22.26 34.23 - 
204205 33.01 - - 
304163 20.74 36 - 
304819 24.12 33.91 - 
301309 31.17 37.26 - 
304395 25.02 34.43 - 
200403 21.69 31.97 - 
300664 21.7 31.96 - 
172229 25.29 33.38 - 
305214 28.03 35.03 - 
303060 20.94 31.2 - 
304299 24.56 33.64 - 
204230 25.74 34.79 - 
304882 24.95 35.03 - 
204578 22.31 32.3 - 
201763 29.92 36.73 - 
305759 24.63 33.98 - 
203399 27.2 34.48 - 
303166 34.99 38.66 - 
302093 24.15 33.24 - 
 
Table 19 - Results of Serum RNA Subjected to Duplex Real-time PCR 
Av Cp stands for average Cp value and it was calculated from the triplicates. Only serum 
samples with three clear Cp values were included in the table. Blank cells mean that no Cp 
value was detected.  
 
4.4.7 Summary of Serum RNA Result 
In total 36 canine serum samples from the oncology department were investigated. 
Apart from case 304395 which was diagnosed as penile bleeding trauma, all other 
cases were diagnosed with a variety of canine cancers including mast cell tumour, 
lymphoma, squamous cell carcinoma, adenocarcinoma, leukaemia, histiocytoma, 
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splenic sarcoma, lipoma, transitional cell carcinoma and round cell tumour. 10 serum 
RNA samples were subjected to conventional RT-PCR test. 23 serum RNA samples 
were subjected to real-time PCR. 3 serum RNA samples were able to be subjected to 
both tests because in the beginning of RNA extraction, 50µl NF-water instead of 
30µl was used for elution of the extracted RNA from these serum samples. 18S 
rRNA were found in all samples that were tested. The cGAPDH mRNA was present 






























Case Number 18S rRNA cGAPDH cTERT Clinical Case 
305195 NA + + Mast Cell Tumour 
200403 + + - Multi-site Mast Cell Tumour 
300664 + + - Mast Cell Tumour 
172229 + + - Squamous Cell Carcinoma 
305457 NA + - Mast Cell Tumour 
304972 NA + - 2-sites Mast Cell Tumour 
304404 NA - - Squamous Cell Carcinoma 
201603 NA - - Multi-site Mast Cell Tumour 
305178 NA - - Histiocytoma 
309300 NA - - Lymphoma 
304439 NA - - Lymphoma 
304925 NA - - Squamous Cell Carcinoma 
204763 NA - - Mast Cell Tumour 
304327 + + - Round Cell Tumour 
304364 + + - Round Cell Tumour 
303505 + + - Multicentric Lymphoma 
304022 + + - Mast Cell Tumour 
303878 + + - Multicentric Lymphoma 
304163 + + - Adenocarcinoma 
304819 + + - Mast Cell Tumour 
301309 + + - Mast Cell Tumour 
304395 + + - Penile Trauma-caused Bleeding 
305214 + + - Lipoma 
303060 + + - Transitional Cell Carcinoma 
304299 + + - Aculte Lymphoblastic Leukemaia 
204230 + + - Adenocarcinoma 
304882 + + - Cranial Tumour 
204578 + + - Mast Cell Tumour 
201763 + + - Cervical Tumour 
305759 + + - Mast Cell Tumour 
203399 + + - Splenic Sarcoma 
303166 + + - Lymphoma 
302093 + + - Lymphoma 
304610 + - - Parathyroid Tumour 
304779 + - - Squamous Cell Carcinoma 
204205 + - - Mast Cell Tumour 
 
Table 20 – Summary of all Serum Sample Results 
Samples that were subjected to conventional RT-PCR do not have 18S rRNA data, an this is 
shown as NA (not applicable).  
 
4.5 Discussion 
In this study, I have shown that 18S rRNA can be detected in all canine serum 
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samples, which is consistent with the findings in humans (Dasi et al., 2001). I have 
also shown that cGAPDH mRNA can be detected and amplified in most of our serum 
samples, which is also consistent with publications in human studies (Miura et al., 
2003, Wong et al., 2004, Li et al., 2006, Rykova et al., 2006). From the Cp value gap 
between TERT mRNA and 18s rRNA of SB-HSA cells (19.67), the expected cTERT 
Cp value of our samples is between 40.36 and 54.66, which is beyond the detection 
limit of our real-time PCR machine. Therefore, even if circulating cTERT mRNA 
does exist in the serum of canine cancer patients, the real-time PCR would not be 
able to detect it mainly because of the poor quality and quantity of RNA. In addition, 
even if circulating cTERT mRNA could be detected in canine cancer patients, it 
would still be a challenge to translate the whole process into clinical practice at this 
stage. An effective cancer biomarker should not only be present at significant levels 
for identification, but the process of detection should also be practical in real clinical 
circumstances. Not only do all steps involved in processing blood samples need to be 
done in a well-equipped lab, but also every step requires the attention of an 
experienced technician in order to protect the samples from RNA degradation and to 
avoid contamination. In addition, the process of biomarker detection should be cost-
effective, and this currently cannot be achieved in reality. Thus the complexity 
involved from the beginning of obtaining blood samples to the end of analysing the 
level of TERT transcripts in serum makes circulating mRNA very unlikely to become 
an effective cancer biomarker in the near future. 
 
As it had previously been shown that in order to obtain stable serum RNA 
concentrations, clotted blood should be stored at 4˚C and processed within six hours 
(Tsui et al., 2002), I aimed to process all blood samples immediately after collection. 
However, on several occasions blood samples was left at room temperature for up to 
1 hour before being processed but no significant difference in subsequent RNA yield 
and quality was observed when compared with the blood samples that were 
processed immediately after collection. 
 
There have been many protocols reported for isolating serum or plasma from blood 
samples in order to gain a pure cell-free solution. Some early studies only used one 
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centrifugation step to isolate serum or plasma from blood samples (Silva et al., 2001, 
Kopreski et al., 2001). However, it has been reported that a single centrifugation step 
cannot efficiently spin down all the platelets (El-Hefnawy et al., 2004), which are 
also known to contain RNA (Martincic et al., 1999, Bugert et al., 2003) and would 
therefore contaminate the cell-free serum mRNA of the samples. Thus, I adopted the 
three centrifuge step protocol (Miura et al., 2003) to ensure that I obtained as pure a 
cell-free serum as possible. This protocol uses 1,000 x g, 1,500 x g and 3,000 x g at 
each 10min centrifugation step. Each step was followed by careful harvesting of 
serum and transfer of serum to new RNase-free tubes. Interestingly, it was reported 
that filtering plasma samples from cancer patients through a 22µm filter before RNA 
extraction resulted in a detectable human GAPDH mRNA signal, and that a small 
signal of GAPDH was still observed even after ultracentrifugation (99, 960 x g) of 
the plasma. This data thus questions the particle-associated nature of circulating 
RNA, as the ultrahigh speed force would be expected to pellet virtually all particulate 
matter (Ng et al., 2002). It has also been reported that after filtration of plasma 
samples through a 0.22µm filter, a clear difference in hGAPDH expression was 
observed between healthy controls and patients with minor, moderate or severe 
trauma injuries and patients who died (Rainer et al., 2004), where the median filtered 
plasma GAPDH concentration was increased more than 7 fold in all injury groups. 
This evidence suggests that circulating RNA may exist in another form distinct from 
the particle-associated form. 
 
To ensure our findings truly reflect the nature of circulating RNA, apart from careful 
handling of RNA in general, we used three experimental strategies. Firstly, the 3-step 
spin protocol ensured a cell-free serum environment as any cellular RNA 
contamination would change the gene profile of the circulating RNA. Secondly, any 
extracted Serum RNA was subjected to a Dnase treatment to avoid any genomic 
DNA contamination carried over to the downstream PCR analysis. Lastly, I used 
intron flanking primers to identify amplification of contaminating genomic DNA. 
With all these three controls, the PCR result on circulating RNA would be more 
realible. 
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It has been observed that repeated freeze–thaw cycles promote degradation of RNA 
in serum (Kopreski et al., 1999) but that a single freeze–thaw cycle does not have a 
significant effect on RNA concentration in serum or plasma (Tsui et al., 2002, 
Cerkovnik et al., 2007). Therefore, all of our serum samples were frozen at -80˚C 
immediately after centrifugation and processed for RNA isolation immediately after 
thawing.  
 
As currently there is no standard method of isolating circulating RNA from human 
serum or plasma, and there have been more than ten methods published using 
existing RNA isolation technique with modifications, I decided to try 3 different total 
RNA isolation methods. The Sigma TRI BD reagent was chosen because it was 
reported to be the most efficient way to isolate circulating RNA from large volumes 
(in ml quantity) of serum or plasma (El-Hefnawy et al., 2004). In fact I was able to 
isolate detectable and amplifiable circulating RNA using all three methods. However, 
the Promega SV Total RNA Isolation system could only process up to 100μl serum 
samples. Although I successfully used the Roche High Pure Viral RNA Kit to process 
serum samples of up to 600μl, the kit was designed only to process 200μl serum at a 
time, and thus required the sample to be loaded three times at each step. I found that 
this procedure was not only time-consuming, but also increasing the risk of 
contamination. Although the Sigma TRI BD method can potentially process large 
volume serum samples, I found it very difficult to isolate the tiny RNA pellets from 
the large aqueous phase. As a result, total RNA isolated from almost all samples 
using all three methods above had very low quantity as well as poor quality. However, 
it was reported that circulating hTERT mRNA could be detected in as little as 50µl of 
serum from human cancer patients (Miura et al., 2003), but I could not detect cTERT 
mRNA in most of our canine serum samples of volumes ranging from 100µl to 3.6ml. 
This may be explained by either the different amounts or mechanisms of circulating 
RNA in humans and dogs. 
 
After quantifying the total RNA purified from serum, the 260/280 absorbance ratio 
that indicates the quality of RNA was extremely low. This could have been the result 
of using suboptimal methods of circulating RNA isolation or due to the existing form 
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or forms of the RNA itself. Interestingly, there have been reports indicating that the 
circulating RNA detected in human plasma is highly fragmented and degraded (El-
Hefnawy et al., 2004, Cerkovnik et al., 2007). 
 
There also have been studies using GAPDH mRNA as control for total RNA in 
quantitative real-time PCR analysis (Wong et al., 2004), but an interesting result 
showed no correlation between GAPDH mRNA and 18S rRNA copy number and 
total RNA concentration in both healthy donor and breast cancer patients. This 
indicates that the process involved in the generation and circulation of circulating 
mRNA may not be universal and maybe different for specific RNA forms (Rykova et 
al., 2006). 
 
Finally, in this study, all the dogs sampled were suspected cases of neoplasia. Among 
all the samples collected, 35 are canine neoplasia cases with one non-neoplasia case. 
Among the 35 neoplasia cases, 4 cases are benign tumour and 31 cases are 
malignancy. 
 
Although the potential use of circulating TERT mRNA for canine cancer diagnostics 
is highly attractive, more questions regarding the mechanism involved in generating 
circulating RNA still need to be answered, and an effective standard protocol for 




Although our study did not detect TERT transcript in the majority of serum samples 
from canine cancer patients, I did confirm that canine mRNA transcript are found in 
the circulation of dogs as in humans. However, whether circulating TERT does or 
does not exist in the serum of canine cancer patients, I found that it is currently not 
practical to utilize circulating mRNA as a cancer biomarker in dogs. As the methods 
and techniques of biomarker research and clinical application are largely transferable 
from humans to animals, and as more advanced methods are developed to detect 
circulating RNA in humans in the future, then we can expect to obtain a more 
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comprehensive understanding of the nature of these molecules and their validity as 
cancer biomarkers in humans and dogs. 
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5.1 Chapter Abstract 
Telomerase is not only crucial for tumour immortalization, but emerging evidence 
has also linked telomerase with ageing. Ectopic expression of TERT in a variety of 
telomerase-negative normal somatic cells has been shown to prolong cellular lifespan 
without any malignant transformation of the cells. Telomerase has been found to play 
an important role in stabilizing stem cell functionality which is crucial for 
maintaining tissue homeostasis and potentially organismal ageing. By using 
telomerase-null mice in many in vivo studies, the late generations of these mice with 
critically-short telomeres have shown many signs of premature ageing at the organ, 
tissue and cellular level. In the meantime, telomere length has also been investigated 
as a potential biomarker for ageing. Very recently, the screening of compounds and 
natural product extracts has identified several novel telomerase activators that can 
induce telomerase in normal cells and may thus provide an alternative strategy to 
study the role of telomerase in ageing. 
 
In this study, three novel compounds provided by Sierra Company were tested for 
their ability to induce telomerase in telomerase-negative canine embryonic 
fibroblasts. A duplex real-time RT-PCR system was established to analyse cTERT 
expression level relative to the expression of 18S rRNA in cells. 
 
A strong increase of cTERT mRNA level was found after 24 hours of compound 
exposure by compounds C00 and C01 but not C03. In addition, varying the dose of 
these compounds had no effect on the elevated cTERT levels. 
 
Taken together I have shown that telomerase can be activated endogenously by novel 
compounds in normal canine somatic cells through elevation of TERT mRNA levels. 
As far as I know this is the first study of telomerase induction being investigated in 
the canine subject, and this study has also demonstrated the capability of novel 
telomerase activators in canine somatic cells, thus providing an alternative way to 
study the role of telomerase in ageing.  
 




In addition to reports indicating that telomerase can be activated by the ectopic 
expression of TERT, recent studies have shown that compounds and natural product 
extracts can activate endogenous telomerase. 
 
Resveratrol (trans-3,5,4′-trihydroxystilbene), a natural polyphenol phytoalexin that 
possesses diverse biochemical and physiological actions, was found to significantly 
increase telomerase activity in endothelial progenitor cells through the PI3K pathway 
and to prevent the senescence of EPC (Xia et al., 2008) 
 
Cycloastragenol (TAT2), a saponin derived from the herb Astragalus  was found to 
slow down telomere shortening of CD8+ T lymphocytes from HIV-infected patients 
through telomerase activation, and this effect was induced via activation of the 
MAPK pathway which subsequently increased hTERT mRNA and/or phosphorylated 
hTERT protein (Fauce et al., 2008). A similar effect was also reported using ectopic 
expression of TERT (Rufer et al., 2001). 
 
Furthermore, TA-65 proprietary capsules, made mainly from extracts of the dried 
root of Astragalus, were found to moderately activate telomerase in human 
keratinocytes, fibroblasts, and immune cells in vitro. In addition, when taken as part 
of a dietary supplement program, patients taking TA-65 were found to have 
proportionally fewer immune cells with critically-short telomeres 3 months later 
compared to the start of the study and this effect continued until the end of study (12 
months after taking TA-65) (Harley et al., 2010). In a mouse study, TA-65 was found 
to activate telomerase and elongate critically-short telomeres in mouse embryonic 
fibroblasts in vitro, to increase TERT levels in some tissues and to improve the 
healthy lifespan of mice when administered orally (de Jesus et al., 2011). 
 
So far most studies regarding telomerase induction in normal cells were based on 
mouse or human studies, using either gene transfer of TERT or by administering a 
telomerase activator. In this small pilot study, I aimed to answer one important 
question: can endogenous telomerase be induced in canine normal somatic cells? 
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Thus for the first time, I tested three novel compounds for their ability to activate 
telomerase in telomerase-negative normal canine somatic cells. These compounds 
were a gift from the Sierra Science Company which identified novel telomerase 
activators by screening hundreds of thousands of compounds and natural product 
extracts. 
 
5.3 Materials and Methods 
5.3.1 Telomerase Induction in CEF Cells 
Canine embryonic fibroblasts were seeded at a density of 2.5 x 104 in a 96-well plate 
containing 50µl medium per well. 24h after cell-seeding, several doses (20µM, 
33µM and 50µM) of compounds C00, C01 and C03 were added to triplicate wells. 
As negative controls, mock treatment with DMSO and untreated cells were also 
included. Cells were allowed to grow for another 24h and then total RNA was 
extracted. 
 
5.3.2 Duplex Real-time PCR to Detect Induced cTERT m 
RNA 
Duplex real-time PCR was conducted to analyse levels of 18S rRNA and cTERT 
mRNA gene expression in these cells. Relative gene expression was calculated using 
18S rRNA to calibrate samples. Results were obtained using the ΔΔCp method. In 
detail, ΔCp was firstly obtained using the TERT Cp value minus the 18S value. 
ΔΔCp was then obtained using the compound ΔCp value minus the DMSO-treatment 
Cp value. Finally, the 2^(-ΔΔCp) was calculated. Primer sets and running program were 
the same as that in the previous chapter (Table 12). 
 
5.4 Results 
5.4.1 CTERT Expression of Compound-treated CEF Cells 
Canine embryonic fibroblasts were treated with three compounds: C00, C01 and C03. 
After 24 hours exposure to each compound, TERT mRNA expression level was seen 
to be significantly increased for both C00- and C01-treated cells, compared to 
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DMSO-treated cells, but not for compound C03-treated cells. The increased level of 
TERT mRNA in cells treated with compounds C00 and C01 did not differ 











































Figure 30 – Relative Expression of cTERT between Compound-treated and 
DMSO-treated CEF cells 
After Real-time PCR, relative cTERT expression level was calculated against the expression 
of 18S r RNA. 
 
5.5 Discussion 
In this pilot study, three novel compounds were tested for their ability to induce 
cTERT mRNA in telomerase-negative primary canine embryonic fibroblasts. 
Although several studies have reported the capability of telomerase activators in 
normal somatic cells, none has clearly demonstrated a corresponding increase in 
TERT mRNA levels and none have used the sensitive quantitative real-time PCR 
method to investigate changes in TERT mRNA levels (Fauce et al., 2008, Xia et al., 
2008, Harley et al., 2011, de Jesus et al., 2011). Here we report a dramatic increase in 
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canine TERT mRNA levels caused by a 24-hour exposure to compounds C00 or C01, 
but not C03, measured using a real-time duplex RT-PCR system. 
 
There are always concerns regarding possible associated toxicity when using 
compounds as telomerase activators, as significantly elevated apoptosis has been 
observed in some reports (Xia et al., 2008). However, although doses up to 50 µM of 
the three compounds were used, no apparent toxicity effects were seen in these 
canine embryonic fibroblast cells. 
 
I used 18S rRNA as a control gene, as 18S rRNA levels are relatively more 
consistent and its expression level is less likely to fluctuate under treatments that may 
affect the expression of mRNAs of some commonly used housekeeping genes. Part 
of the reason for this is that rRNA constitutes approximately 80% of a total RNA 
sample from eukaryotic cells, and therefore the concentration of a total RNA sample 
determined by spectrophotometry is already normalized to the amount of rRNA 
present. Second, rRNA is transcribed by RNA polymerase I (Russell and Zomerdijk, 
2005) which is different from the polymerase used for mRNA transcription, and thus 
its expression may be differentially regulated. Interestingly, several reports have 
shown that the expression level of rRNA remained stable while levels of β-actin 
and/or GAPDH gene varied in individual rat livers (de Leeuw et al., 1989), in some 
breast cell lines (Spanakis, 1993), human skin fibroblasts (Mansur et al., 1993) and in 
some malignant mouse cell lines (Bhatia et al., 1994). 
 
As most studies have used the genetic transfer of TERT to activate telomerase, 
several concerns have been noted. First, gene therapy applications may take longer to 
be translated into clinics due to significant safety concerns, especially when using 
viral vectors and the subsequent inability to control the level and extent of telomerase 
induction in the whole body. On the contrary, compound-based telomerase activator 
application can be conducted in a dose- and duration-controlled manner, and some 
evidence has shown that drug-induced telomerase activation can be short term and 
reversible without any effects on cell viability (Fauce et al., 2008). Second, the 
introduction of telomerase bears the risk of inducing cancer, as has been found in 
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some in vivo studies using ectopic TERT expression (Gonzalez-Suarez et al., 2005, 
Donate and Blasco, 2011). However, so far studies conducted on telomerase 
activators have shown that they did not significantly increase the intrinsic telomerase 
activity in tumour cells nor promote any loss of control or malignant transformation 
(Fauce et al., 2008). 
 
5.6 Conclusion 
Despite being a small pilot study, I have clearly shown for the first time that 
telomerase can be activated in telomerase-negative canine somatic cells through 
upregulating TERT mRNA levels and that telomerase can be induced by two novel 
compounds. This study has brought more knowledge to the current study of 
telomerase induction. In the future, it will be important to further investigate and 
characterize the telomerase induction effect. It would be interesting to explore 
whether telomerase induction is transient and if there is an immediate or long-term 
effect on telomere length and cellular lifespan. Also it would be intriguing to explore 
whether the same effect can be found in other canine cell types including tumour 
cells and eventually also in animal experiments. Taken together, as a novel approach, 
this non-genetic compound-based telomerase activation strategy may provide an 
alternative way to study telomerase and its role in ageing. 
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As cancer still tops the list of deadly diseases in both humans and dogs, developing a 
method for cancer early detection as well as finding a way to cure it have been the 
absolute priorities in scientific research. Telomerase, which represents a key enzyme 
in cancer immortalization, holds great promise as an attractive cancer biomarker and 
anticancer target. In addition, beyond cancer, increasing evidence has highlighted its 
role in ageing. Since its discovery, telomerase has been intensively studied for more 
than two decades. Although its discovery has changed our way of seeing cancer, we 
still have not gained a comprehensive understanding of this enzyme or a clinical 
solution on how it may be targeted in order to cure cancer. Currently, most of cancer-
based research has relied on rodent tumour models. However the question of whether 
data obtained from these models can truly reflect human cancer remains to be 
answered. Canine cancer, one of the most deadly diseases in dogs with a high 
incidence estimated at 1437 per 100,000 dogs per year for skin and soft tissue cancer 
in UK (Dobson et al., 2002), represents a potential new model to study telomerase 
and telomeres. Unlike mice and other rodents, canine cancer contains a wide range of 
naturally-occurring tumours and canine telomere length is also comparable with 
humans. 
 
As an efficient delivery system is essential for any anticancer therapeutic application 
to treat tumours systemically, I explored two novel systemic delivery systems in the 
canine context in order to gain a better understanding of their efficacy in vitro and in 
vivo. Both cellular vehicles and synthetic polymers have their own advantages. 
Cellular delivery vehicles as a novel strategy to target tumours systemically with a 
transgene have been proved feasible. As I have shown in this study, the canine 
malignant endothelial cell type SB-SHA cells can be manipulated easily to express a 
foreign gene in vitro, however their in vivo tumour-homing ability is still not clear. 
Currently there is still debate regarding the concept of endothelial lineage cells, 
especially endothelial progenitor cells, and their tumour homing ability, and thus 
further studies are needed to understand their nature in vivo. If possible, other canine 
endothelial cell types should also be investigated in the future in vitro and in vivo for 
their potential tumour-homing ability. If proven, these cellular delivery vehicles will 
be ideal to treat primary tumour as well as distant metastases. 
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The PPIG3 dendrimer is an emerging polymer vector that has recently been 
developed as both a systemic delivery vehicle as well as for its intrinsic antitumour 
activity. In this study we have tested its gene transfer ability and observed its low 
transfection efficiency with canine cells compared with commonly-used 
Lipofectamine™2000. The low transfection rate with canine cells suggests further 
improvement of this vector as this could hinder its efficacy when used systemically. 
As these polypropylenimine dendrimers are synthetic polymers, further development 
should also be focused on structurally modifying these dendrimers to improve their 
gene transfer ability without affecting their unique property of forming nanoparticles 
with DNA that are adapted to the EPR effect. In addition more research is required to 
further prove their specific tumour accumulation ability in vivo and the EPR effect 
which it is based on. In the future, it would be also very interesting to further explore 
their intrinsic antitumour activity as well as their potential influence on cellular gene 
expression to assist the development of new generations of these dendrimers as 
systemic delivery vehicles.  
 
After having explored two novel delivery systems, I then constructed a plasmid-
based siRNA vector targeting canine telomerase RNA component and tested it on 
two canine cancer cell lines. Since the discovery of RNAi, it has been utilized to 
inhibit specific gene expression by synthetic siRNA molecules in vitro and in vivo 
and this has become a common and standard method in the laboratory. The recent 
first in-human phase I clinical trial of systemically-administered siRNA has further 
proved its ability for specific gene inhibition at both mRNA level and subsequent 
protein level; thus siRNA technology is still a popular and attractive strategy for 
anticancer applications. Although using siRNA to target telomerase is not a new idea, 
scientific publications on canine telomerase itself are very limited, the inhibition of 
canine telomerase by siRNA which has also been rarely documented. In this study, I 
designed and constructed a plasmid-based siRNA expression vector, since not only 
does this vector plasmid-based vector have many advantages over viral or naked 
siRNA, it can also be combined with the two novel delivery vehicles we explored 
earlier. In the siRNA experiment, I did not observe any gene-silencing of cTR, 
Chapter 6 – Future Perspectives 
 131 
however, it did not necessarily suggest that cTR can not be targeted by siRNA. 
Although this plasmid-based siRNA vector has been designed to induce gene-
silencing in mammalian cells, only gene-silencing in human cells has been 
demonstrated so far. Future studies should investigate its ability to induce gene-
silencing in canine cells to validate its efficacy. I also have noticed the difference of 
the minimal length of target mRNA required in different siRNA expression systems 
and this could also play a part in the failed cTR gene-silencing. In the future, more 
target regions on cTR gene using the siRNA vector should be established and the 
potency of these regions for RNAi induction should be compared 
 
Telomerase not only represents a potential anticancer target, but is also considered a 
near-universal tumour marker. As currently there are urgent needs for a specific, 
accurate and informative biomarker in cancer clinics not only for diagnostics, but 
also ideally for tumour staging as well as post-treatment monitoring, cancer-specific 
circulating mRNA has been explored as a promising candidate. If proven it would be 
an ideal biomarker for minimally invasive cancer detection and progression with 
repetitive monitoring from blood. However although circulating TERT mRNA has 
been found in human cancer patients and several reports have highlighted its 
potential diagnostic value and prognostic value, I did not identify TERT mRNA in 
the circulation of the majority of canine cancer patients in this study. However this 
finding does not necessarily preclude the existence of TERT transcripts in the 
circulation of cancer-bearing dogs but alternatively suggests the possibility that failed 
detection using the current methods is due to its extremely low expression level as to 
the complexity of the isolation process of serum RNA which prevented its detection 
in our system. Therefore, circulating canine TERT mRNA cannot be utilized as a 
cancer biomarker currently. As recent studies have also concluded that the amount of 
mRNA found in serum or plasma of cancer patients is highly variable among 
different published papers (Schwarzenbach et al., 2011), future studies should not 
only focus on the extraction method of these RNA transcripts, their nature should 
also be investigated in order to evaluate their suitability as biomarkers. As 
experimental techniques and methods for RNA extraction and molecular detection 
are advancing year by year, it might be even possible to detect them straight from 
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serum or blood without an extraction step in the future. Lastly similar studies should 
be performed again to re-evaluate their existence in canine cancer patients. 
 
Human life expectancy has nearly doubled in the last century because of medical 
advances; however there is still a lack of a complete understanding of the biological 
processes and mechanisms underlying ageing and ageing-related disorders. Much 
evidence has shown that beyond cancer, telomerase and telomeres function not only 
in cellular ageing but also possibly in organismal ageing. Although a pilot study, for 
the first time our finding of the endogenous expression of TERT being induced by 
novel compounds clearly demonstrated that telomerase can be activated in canine 
normal somatic cells.  Future work should follow up this discovery to determine the 
effect of telomerase induction on the lifespan of CEF cells as well as on other canine 
somatic cells. It is also important to investigate the mechanism underlying this drug-
induced telomerase induction. After that, in vivo experiments could also be 
conducted to see if these compounds have influence on health and lifespan of 
animals. Fundamentally, understanding the role of telomerase and telomeres in the 
process of overall ageing would definitely help us to contribute to the fight against 
cancer. 
 
Taken together, as cancer continues to be a common and deadly disease in dogs and 
humans, there are growing requirements for novel anticancer drug targets, as well as 
molecular biomarkers for diagnosis in clinics. Thus understanding canine telomerase 
will not only benefit veterinary oncology, but will also provide a comparative model 





AHMED, A. U., ALEXIADES, N. G. & LESNIAK, M. S. (2010) The use of neural stem 
cells in cancer gene therapy: predicting the path to the clinic. Curr Opin Mol Ther, 
12, 546-52. 
AKHTAR, N., PADILLA, M. L., DICKERSON, E. B., STEINBERG, H., BREEN, M., 
AUERBACH, R. & HELFAND, S. C. (2004) Interleukin-12 inhibits tumor growth 
in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia, 6, 
106-16. 
ARGYLE, D. & KHANNA, C. (2006) The Biology of Cancer, Elsevier. 
ARGYLE, D. J. & NASIR, L. (2003) Telomerase: a potential diagnostic and therapeutic tool 
in canine oncology. Vet Pathol, 40, 1-7. 
ATTARDI, L. D. (2005) The role of p53-mediated apoptosis as a crucial anti-tumor response 
to genomic instability: lessons from mouse models. Mutat Res, 569, 145-57. 
AUTEXIER, C. & LUE, N. F. (2006) The structure and function of telomerase reverse 
transcriptase. Annu Rev Biochem, 75, 493-517. 
AZZAM, T. & DOMB, A. J. (2004) Current developments in gene transfection agents. Curr 
Drug Deliv, 1, 165-93. 
BARANOWSKI, E., RUIZ-JARABO, C. M. & DOMINGO, E. (2001) Evolution of cell 
recognition by viruses. Science, 292, 1102-5. 
BARAR, J., H., H., S.A., M. T., S.E., H.-A. & Y, O. (2009) Genomic signature and 
toxicogenomics comparison of polycationic gene delivery nanosystems in human 
alveolar epithelial A549 cells. DARU Journal of Pharmaceutical Sciences, 17, 139-
147. 
BARMA, D. K., ELAYADI, A., FALCK, J. R. & COREY, D. R. (2003) Inhibition of 
telomerase by BIBR 1532 and related analogues. Bioorg Med Chem Lett, 13, 1333-6. 
BAUMER, Y., FUNK, D. & SCHLOSSHAUER, B. (2010) Does telomerase reverse 
transcriptase induce functional de-differentiation of human endothelial cells? 
Cellular and Molecular Life Sciences, 67, 2451-2465. 
BEAUSEJOUR, C. M., KRTOLICA, A., GALIMI, F., NARITA, M., LOWE, S. W., 
YASWEN, P. & CAMPISI, J. (2003) Reversal of human cellular senescence: roles of 
the p53 and p16 pathways. Embo J, 22, 4212-22. 
BEN-PORATH, I. & WEINBERG, R. A. (2005) The signals and pathways activating cellular 
senescence. Int J Biochem Cell Biol, 37, 961-76. 
BENETOS, A., OKUDA, K., LAJEMI, M., KIMURA, M., THOMAS, F., SKURNICK, J., 
LABAT, C., BEAN, K. & AVIV, A. (2001) Telomere length as an indicator of 
biological aging: The gender effect and relation with pulse pressure and pulse wave 
velocity. Hypertension, 37, 381-5. 
BENNETT, C. F. & SWAYZE, E. E. (2010) RNA targeting therapeutics: molecular 
mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev 
Pharmacol Toxicol, 50, 259-93. 
BERNSTEIN, E., CAUDY, A. A., HAMMOND, S. M. & HANNON, G. J. (2001) Role for a 
bidentate ribonuclease in the initiation step of RNA interference. Nature, 409, 363-6. 
BHATIA, P., TAYLOR, W. R., GREENBERG, A. H. & WRIGHT, J. A. (1994) Comparison 
of glyceraldehyde-3-phosphate dehydrogenase and 28S-ribosomal RNA gene 
expression as RNA loading controls for northern blot analysis of cell lines of varying 
malignant potential. Anal Biochem, 216, 223-6. 
BHOWMICK, N. A., NEILSON, E. G. & MOSES, H. L. (2004) Stromal fibroblasts in 
cancer initiation and progression. Nature, 432, 332-7. 
Bibliography 
 134 
BIGGIOGERA, M., BOTTONE, M. G. & PELLICCIARI, C. (1998) Nuclear RNA is 
extruded from apoptotic cells. J Histochem Cytochem, 46, 999-1005. 
BINZ, N., SHALABY, T., RIVERA, P., SHIN-YA, K. & GROTZER, M. A. (2005) 
Telomerase inhibition, telomere shortening, cell growth suppression and induction of 
apoptosis by telomestatin in childhood neuroblastoma cells. Eur J Cancer, 41, 2873-
81. 
BLACKBURN, E. H. (2001) Switching and signaling at the telomere. Cell, 106, 661-73. 
BLASCO, M. A. (2005) Telomeres and human disease: ageing, cancer and beyond. Nat Rev 
Genet, 6, 611-22. 
BODNAR, A. G., OUELLETTE, M., FROLKIS, M., HOLT, S. E., CHIU, C. P., MORIN, G. 
B., HARLEY, C. B., SHAY, J. W., LICHTSTEINER, S. & WRIGHT, W. E. (1998) 
Extension of life-span by introduction of telomerase into normal human cells. 
Science, 279, 349-52. 
BRENNAN, S. K., WANG, Q., TRESSLER, R., HARLEY, C., GO, N., BASSETT, E., HUFF, 
C. A., JONES, R. J. & MATSUI, W. (2010) Telomerase inhibition targets clonogenic 
multiple myeloma cells through telomere length-dependent and independent 
mechanisms. PLoS One, 5. 
BROWN, M. D., SCHATZLEIN, A. G. & UCHEGBU, I. F. (2001) Gene delivery with 
synthetic (non viral) carriers. Int J Pharm, 229, 1-21. 
BRUMMELKAMP, T. R., BERNARDS, R. & AGAMI, R. (2002a) Stable suppression of 
tumorigenicity by virus-mediated RNA interference. Cancer Cell, 2, 243-7. 
BRUMMELKAMP, T. R., BERNARDS, R. & AGAMI, R. (2002b) A system for stable 
expression of short interfering RNAs in mammalian cells. Science, 296, 550-3. 
BRYCE, L. A., MORRISON, N., HOARE, S. F., MUIR, S. & KEITH, W. N. (2000) 
Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to 
chromosome 5p15.33 by fluorescence in situ hybridization. Neoplasia, 2, 197-201. 
BURGER, A. M., DAI, F., SCHULTES, C. M., RESZKA, A. P., MOORE, M. J., DOUBLE, 
J. A. & NEIDLE, S. (2005) The G-quadruplex-interactive molecule BRACO-19 
inhibits tumor growth, consistent with telomere targeting and interference with 
telomerase function. Cancer Res, 65, 1489-96. 
CERKOVNIK, P., PERHAVEC, A., ZGAJNAR, J. & NOVAKOVIC, S. (2007) Optimization 
of an RNA isolation procedure from plasma samples. Int J Mol Med, 20, 293-300. 
CERONE, M. A., LONDONO-VALLEJO, J. A. & AUTEXIER, C. (2006a) Mutated 
telomeres sensitize tumor cells to anticancer drugs independently of telomere 
shortening and mechanisms of telomere maintenance. Oncogene, 25, 7411-20. 
CERONE, M. A., LONDONO-VALLEJO, J. A. & AUTEXIER, C. (2006b) Telomerase 
inhibition enhances the response to anticancer drug treatment in human breast cancer 
cells. Mol Cancer Ther, 5, 1669-75. 
CERRUTI MAINARDI, P. (2006) Cri du Chat syndrome. Orphanet J Rare Dis, 1, 33. 
CESARE, A. J. & REDDEL, R. R. (2010) Alternative lengthening of telomeres: models, 
mechanisms and implications. Nat Rev Genet, 11, 319-30. 
CHAN, J., O'DONOGHUE, K., DE LA FUENTE, J., ROBERTS, I. A., KUMAR, S., 
MORGAN, J. E. & FISK, N. M. (2005) Human fetal mesenchymal stem cells as 
vehicles for gene delivery. Stem Cells, 23, 93-102. 
CHANG, M., ARNERIC, M. & LINGNER, J. (2007) Telomerase repeat addition 
processivity is increased at critically short telomeres in a Tel1-dependent manner in 
Saccharomyces cerevisiae. Genes Dev, 21, 2485-94. 
CHEN, X., LIN, X., ZHAO, J., SHI, W., ZHANG, H., WANG, Y., KAN, B., DU, L., WANG, 
B., WEI, Y., LIU, Y. & ZHAO, X. (2008) A tumor-selective biotherapy with 
prolonged impact on established metastases based on cytokine gene-engineered 
MSCs. Mol Ther, 16, 749-56. 
CHEN, X. Q., BONNEFOI, H., PELTE, M. F., LYAUTEY, J., LEDERREY, C., 
MOVAREKHI, S., SCHAEFFER, P., MULCAHY, H. E., MEYER, P., STROUN, M. 
Bibliography 
 135 
& ANKER, P. (2000) Telomerase RNA as a detection marker in the serum of breast 
cancer patients. Clin Cancer Res, 6, 3823-6. 
CHISHOLM, E. J., VASSAUX, G., MARTIN-DUQUE, P., CHEVRE, R., LAMBERT, O., 
PITARD, B., MERRON, A., WEEKS, M., BURNET, J., PEERLINCK, I., DAI, M. 
S., ALUSI, G., MATHER, S. J., BOLTON, K., UCHEGBU, I. F., SCHATZLEIN, A. 
G. & BARIL, P. (2009) Cancer-specific transgene expression mediated by systemic 
injection of nanoparticles. Cancer Res, 69, 2655-62. 
CIMINO-REALE, G., PASCALE, E., BATTILORO, E., STARACE, G., VERNA, R. & 
D'AMBROSIO, E. (2001) The length of telomeric G-rich strand 3'-overhang 
measured by oligonucleotide ligation assay. Nucleic Acids Res, 29, E35. 
COHEN, S. B., GRAHAM, M. E., LOVRECZ, G. O., BACHE, N., ROBINSON, P. J. & 
REDDEL, R. R. (2007) Protein composition of catalytically active human 
telomerase from immortal cells. Science, 315, 1850-3. 
COLITZ, C. M. (2008) Telomerase inhibition: the way ahead for cancer therapy in humans 
and dogs? Vet J, 177, 153-4. 
COLLADO, M., BLASCO, M. A. & SERRANO, M. (2007) Cellular senescence in cancer 
and aging. Cell, 130, 223-33. 
COLLINS, K. (2006) The biogenesis and regulation of telomerase holoenzymes. Nat Rev 
Mol Cell Biol, 7, 484-94. 
COLOMBO, M. G., CITTI, L., BASTA, G., DE CATERINA, R., BIAGINI, A. & 
RAINALDI, G. (2001) Differential ability of human endothelial cells to internalize 
and express exogenous DNA. Cardiovasc Drugs Ther, 15, 25-9. 
CONG, Y. S., WRIGHT, W. E. & SHAY, J. W. (2002) Human telomerase and its regulation. 
Microbiol Mol Biol Rev, 66, 407-25, table of contents. 
COOPER, G. M. (2000) The Cell: A Molecular Approach. 2nd edition. , Sunderland. 
COUNTER, C. M., AVILION, A. A., LEFEUVRE, C. E., STEWART, N. G., GREIDER, C. 
W., HARLEY, C. B. & BACCHETTI, S. (1992) Telomere shortening associated with 
chromosome instability is arrested in immortal cells which express telomerase 
activity. Embo J, 11, 1921-9. 
CUKUSIC, A., SKROBOT VIDACEK, N., SOPTA, M. & RUBELJ, I. (2008) Telomerase 
regulation at the crossroads of cell fate. Cytogenet Genome Res, 122, 263-72. 
D'ADDA DI FAGAGNA, F., REAPER, P. M., CLAY-FARRACE, L., FIEGLER, H., CARR, 
P., VON ZGLINICKI, T., SARETZKI, G., CARTER, N. P. & JACKSON, S. P. (2003) 
A DNA damage checkpoint response in telomere-initiated senescence. Nature, 426, 
194-8. 
DAI, C. Y. & ENDERS, G. H. (2000) p16 INK4a can initiate an autonomous senescence 
program. Oncogene, 19, 1613-22. 
DALBA, C., BELLIER, B., KASAHARA, N. & KLATZMANN, D. (2007) Replication-
competent vectors and empty virus-like particles: new retroviral vector designs for 
cancer gene therapy or vaccines. Mol Ther, 15, 457-66. 
DALBY, B., CATES, S., HARRIS, A., OHKI, E. C., TILKINS, M. L., PRICE, P. J. & 
CICCARONE, V. C. (2004) Advanced transfection with Lipofectamine 2000 reagent: 
primary neurons, siRNA, and high-throughput applications. Methods, 33, 95-103. 
DASI, F., LLEDO, S., GARCIA-GRANERO, E., RIPOLL, R., MARUGAN, M., TORMO, 
M., GARCIA-CONDE, J. & ALINO, S. F. (2001) Real-time quantification in plasma 
of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to 
monitor disease in cancer patients. Lab Invest, 81, 767-9. 
DASI, F., MARTINEZ-RODES, P., MARCH, J. A., SANTAMARIA, J., MARTINEZ-
JAVALOYAS, J. M., GIL, M. & ALINO, S. F. (2006) Real-time quantification of 
human telomerase reverse transcriptase mRNA in the plasma of patients with 
prostate cancer. Ann N Y Acad Sci, 1075, 204-10. 
DE BRABANDER-VAN DEN BERG, E. M. M. & MEIJER, E. W. (1993) Poly(propylene 
imine) Dendrimers: Large-Scale Synthesis by Hetereogeneously Catalyzed 
Bibliography 
 136 
Hydrogenations. Angewandte Chemie International Edition in English, 32, 1308-
1311. 
DE JESUS, B. B., SCHNEEBERGER, K., VERA, E., TEJERA, A., HARLEY, C. B. & 
BLASCO, M. A. (2011) The telomerase activator TA-65 elongates short telomeres 
and increases health span of adult/old mice without increasing cancer incidence. 
Aging Cell. 
DE LEEUW, W. J., SLAGBOOM, P. E. & VIJG, J. (1989) Quantitative comparison of 
mRNA levels in mammalian tissues: 28S ribosomal RNA level as an accurate 
internal control. Nucleic Acids Res, 17, 10137-8. 
DELHOMMEAU, F., THIERRY, A., FENEUX, D., LAURET, E., LECLERCQ, E., 
COURTIER, M. H., SAINTENY, F., VAINCHENKER, W. & BENNACEUR-
GRISCELLI, A. (2002) Telomere dysfunction and telomerase reactivation in human 
leukemia cell lines after telomerase inhibition by the expression of a dominant-
negative hTERT mutant. Oncogene, 21, 8262-71. 
DELONG, R., STEPHENSON, K., LOFTUS, T., FISHER, M., ALAHARI, S., NOLTING, A. 
& JULIANO, R. L. (1997) Characterization of complexes of oligonucleotides with 
polyamidoamine starburst dendrimers and effects on intracellular delivery. J Pharm 
Sci, 86, 762-4. 
DENG, Y., CHAN, S. S. & CHANG, S. (2008) Telomere dysfunction and tumour 
suppression: the senescence connection. Nat Rev Cancer, 8, 450-8. 
DIMRI, G. P., LEE, X., BASILE, G., ACOSTA, M., SCOTT, G., ROSKELLEY, C., 
MEDRANO, E. E., LINSKENS, M., RUBELJ, I., PEREIRA-SMITH, O. & ET AL. 
(1995) A biomarker that identifies senescent human cells in culture and in aging skin 
in vivo. Proc Natl Acad Sci U S A, 92, 9363-7. 
DJOJOSUBROTO, M. W., CHIN, A. C., GO, N., SCHAETZLEIN, S., MANNS, M. P., 
GRYAZNOV, S., HARLEY, C. B. & RUDOLPH, K. L. (2005) Telomerase 
antagonists GRN163 and GRN163L inhibit tumor growth and increase 
chemosensitivity of human hepatoma. Hepatology, 42, 1127-36. 
DOBSON, J. M., SAMUEL, S., MILSTEIN, H., ROGERS, K. & WOOD, J. L. (2002) 
Canine neoplasia in the UK: estimates of incidence rates from a population of 
insured dogs. J Small Anim Pract, 43, 240-6. 
DOME, B., HENDRIX, M. J., PAKU, S., TOVARI, J. & TIMAR, J. (2007) Alternative 
vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J 
Pathol, 170, 1-15. 
DONATE, L. E. & BLASCO, M. A. (2011) Telomeres in cancer and ageing. Philos Trans R 
Soc Lond B Biol Sci, 366, 76-84. 
DOUGLAS, K. L. (2008) Toward development of artificial viruses for gene therapy: a 
comparative evaluation of viral and non-viral transfection. Biotechnol Prog, 24, 871-
83. 
DU, Q. Y., WANG, X. B., CHEN, X. J., ZHENG, W. & WANG, S. Q. (2003) Antitumor 
mechanism of antisense cantide targeting human telomerase reverse transcriptase. 
World J Gastroenterol, 9, 2030-5. 
DUDA, D. G., COHEN, K. S., KOZIN, S. V., PERENTES, J. Y., FUKUMURA, D., 
SCADDEN, D. T. & JAIN, R. K. (2006) Evidence for incorporation of bone 
marrow-derived endothelial cells into perfused blood vessels in tumors. Blood, 107, 
2774-6. 
DUDEK, A. Z., BODEMPUDI, V., WELSH, B. W., JASINSKI, P., GRIFFIN, R. J., 
MILBAUER, L. & HEBBEL, R. P. (2007) Systemic inhibition of tumour 
angiogenesis by endothelial cell-based gene therapy. Br J Cancer, 97, 513-22. 
DUFES, C., UCHEGBU, I. F. & SCHATZLEIN, A. G. (2005) Dendrimers in gene delivery. 
Adv Drug Deliv Rev, 57, 2177-202. 
DWYER, R. M., POTTER-BEIRNE, S. M., HARRINGTON, K. A., LOWERY, A. J., 
HENNESSY, E., MURPHY, J. M., BARRY, F. P., O'BRIEN, T. & KERIN, M. J. 
Bibliography 
 137 
(2007) Monocyte chemotactic protein-1 secreted by primary breast tumors 
stimulates migration of mesenchymal stem cells. Clin Cancer Res, 13, 5020-7. 
EL-DALY, H., KULL, M., ZIMMERMANN, S., PANTIC, M., WALLER, C. F. & 
MARTENS, U. M. (2005) Selective cytotoxicity and telomere damage in leukemia 
cells using the telomerase inhibitor BIBR1532. Blood, 105, 1742-9. 
EL-HEFNAWY, T., RAJA, S., KELLY, L., BIGBEE, W. L., KIRKWOOD, J. M., 
LUKETICH, J. D. & GODFREY, T. E. (2004) Characterization of amplifiable, 
circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin 
Chem, 50, 564-73. 
EL DALY, H. & MARTENS, U. M. (2007) Telomerase inhibition and telomere targeting in 
hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds 
(BIBR1532). Methods Mol Biol, 405, 47-60. 
ELBASHIR, S. M., HARBORTH, J., LENDECKEL, W., YALCIN, A., WEBER, K. & 
TUSCHL, T. (2001a) Duplexes of 21-nucleotide RNAs mediate RNA interference in 
cultured mammalian cells. Nature, 411, 494-8. 
ELBASHIR, S. M., LENDECKEL, W. & TUSCHL, T. (2001b) RNA interference is 
mediated by 21- and 22-nucleotide RNAs. Genes Dev, 15, 188-200. 
ESPEJEL, S., FRANCO, S., RODRIGUEZ-PERALES, S., BOUFFLER, S. D., CIGUDOSA, 
J. C. & BLASCO, M. A. (2002) Mammalian Ku86 mediates chromosomal fusions 
and apoptosis caused by critically short telomeres. Embo J, 21, 2207-19. 
FAJKUS, J. (2006) Detection of telomerase activity by the TRAP assay and its variants and 
alternatives. Clin Chim Acta, 371, 25-31. 
FAUCE, S. R., JAMIESON, B. D., CHIN, A. C., MITSUYASU, R. T., PARISH, S. T., NG, H. 
L., KITCHEN, C. M., YANG, O. O., HARLEY, C. B. & EFFROS, R. B. (2008) 
Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ 
T lymphocytes. J Immunol, 181, 7400-6. 
FENG, J., FUNK, W. D., WANG, S. S., WEINRICH, S. L., AVILION, A. A., CHIU, C. P., 
ADAMS, R. R., CHANG, E., ALLSOPP, R. C., YU, J. & ET AL. (1995) The RNA 
component of human telomerase. Science, 269, 1236-41. 
FERRARI, N., GLOD, J., LEE, J., KOBILER, D. & FINE, H. A. (2003) Bone marrow-
derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting 
vectors. Gene Ther, 10, 647-56. 
FIFE, K., BOWER, M., COOPER, R. G., STEWART, L., ETHERIDGE, C. J., COOMBES, 
R. C., BULUWELA, L. & MILLER, A. D. (1998) Endothelial cell transfection with 
cationic liposomes and herpes simplex-thymidine kinase mediated killing. Gene Ther, 
5, 614-20. 
FINKEL, T., SERRANO, M. & BLASCO, M. A. (2007) The common biology of cancer and 
ageing. Nature, 448, 767-74. 
FIRE, A., ALBERTSON, D., HARRISON, S. W. & MOERMAN, D. G. (1991) Production of 
antisense RNA leads to effective and specific inhibition of gene expression in C. 
elegans muscle. Development, 113, 503-14. 
FIRE, A., XU, S., MONTGOMERY, M. K., KOSTAS, S. A., DRIVER, S. E. & MELLO, C. 
C. (1998) Potent and specific genetic interference by double-stranded RNA in 
Caenorhabditis elegans. Nature, 391, 806-11. 
FISCHER, D., LI, Y., AHLEMEYER, B., KRIEGLSTEIN, J. & KISSEL, T. (2003) In vitro 
cytotoxicity testing of polycations: influence of polymer structure on cell viability 
and hemolysis. Biomaterials, 24, 1121-31. 
FLEISCHHACKER, M. & SCHMIDT, B. (2007) Circulating nucleic acids (CNAs) and 
cancer--a survey. Biochim Biophys Acta, 1775, 181-232. 
FLORES, I. & BLASCO, M. A. (2010) The role of telomeres and telomerase in stem cell 
aging. FEBS Lett, 584, 3826-30. 
FOLKMAN, J. & SHING, Y. (1992) Angiogenesis. J Biol Chem, 267, 10931-4. 




FORBES, N. S., MUNN, L. L., FUKUMURA, D. & JAIN, R. K. (2003) Sparse initial 
entrapment of systemically injected Salmonella typhimurium leads to heterogeneous 
accumulation within tumors. Cancer Res, 63, 5188-93. 
FOURNIE, G. J., MARTRES, F., POURRAT, J. P., ALARY, C. & RUMEAU, M. (1993) 
Plasma DNA as cell death marker in elderly patients. Gerontology, 39, 215-21. 
FRIEDENSTEIN, A. J., CHAILAKHYAN, R. K. & GERASIMOV, U. V. (1987) Bone 
marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion 
chambers. Cell Tissue Kinet, 20, 263-72. 
FU, D. & COLLINS, K. (2007) Purification of human telomerase complexes identifies 
factors involved in telomerase biogenesis and telomere length regulation. Mol Cell, 
28, 773-85. 
FU, Y. T., KEPPLER, B. R., SOARES, J. & JARSTFER, M. B. (2009) BRACO19 analog 
dimers with improved inhibition of telomerase and hPot 1. Bioorg Med Chem, 17, 
2030-7. 
FUKAZAWA, T., MATSUOKA, J., YAMATSUJI, T., MAEDA, Y., DURBIN, M. L. & 
NAOMOTO, Y. (2010) Adenovirus-mediated cancer gene therapy and virotherapy 
(Review). Int J Mol Med, 25, 3-10. 
GANDELLINI, P., FOLINI, M., BANDIERA, R., DE CESARE, M., BINDA, M., 
VERONESE, S., DAIDONE, M. G., ZUNINO, F. & ZAFFARONI, N. (2007) 
Down-regulation of human telomerase reverse transcriptase through specific 
activation of RNAi pathway quickly results in cancer cell growth impairment. 
Biochem Pharmacol, 73, 1703-14. 
GARCIA, C. K., WRIGHT, W. E. & SHAY, J. W. (2007) Human diseases of telomerase 
dysfunction: insights into tissue aging. Nucleic Acids Res, 35, 7406-16. 
GARCIA, J. M., GARCIA, V., PENA, C., DOMINGUEZ, G., SILVA, J., DIAZ, R., 
ESPINOSA, P., CITORES, M. J., COLLADO, M. & BONILLA, F. (2008) 
Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like 
structure and is mRNA-enriched. Rna, 14, 1424-32. 
GARDLIK, R. & FRUEHAUF, J. H. (2010) Bacterial vectors and delivery systems in cancer 
therapy. IDrugs, 13, 701-6. 
GARRIDO-RAMOS, M. A., DE LA HERRAN, R., REJON, C. R. & REJON, M. R. (1998) 
A satellite DNA of the Sparidae family (pisces, perciformes) associated with 
telomeric sequences. Cytogenet Cell Genet, 83, 3-9. 
GEBHART, C. L. & KABANOV, A. V. (2001) Evaluation of polyplexes as gene transfer 
agents. J Control Release, 73, 401-16. 
GELLERT, G. C., DIKMEN, Z. G., WRIGHT, W. E., GRYAZNOV, S. & SHAY, J. W. (2006) 
Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast 
Cancer Res Treat, 96, 73-81. 
GIRE, V. (2004) Dysfunctional telomeres at senescence signal cell cycle arrest via Chk2. 
Cell Cycle, 3, 1217-20. 
GLASGOW, J. N., BAUERSCHMITZ, G. J., CURIEL, D. T. & HEMMINKI, A. (2004) 
Transductional and transcriptional targeting of adenovirus for clinical applications. 
Curr Gene Ther, 4, 1-14. 
GOLDBLATT, E. M., ERICKSON, P. A., GENTRY, E. R., GRYAZNOV, S. M. & 
HERBERT, B. S. (2009a) Lipid-conjugated telomerase template antagonists 
sensitize resistant HER2-positive breast cancer cells to trastuzumab. Breast Cancer 
Res Treat, 118, 21-32. 
GOLDBLATT, E. M., GENTRY, E. R., FOX, M. J., GRYAZNOV, S. M., SHEN, C. & 
HERBERT, B. S. (2009b) The telomerase template antagonist GRN163L alters 
MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the 
effects of paclitaxel. Mol Cancer Ther, 8, 2027-35. 
GOLDKORN, A. & BLACKBURN, E. H. (2006) Assembly of mutant-template telomerase 
Bibliography 
 139 
RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres 
is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res, 66, 
5763-71. 
GONZALEZ-SUAREZ, E., GESERICK, C., FLORES, J. M. & BLASCO, M. A. (2005) 
Antagonistic effects of telomerase on cancer and aging in K5-mTert transgenic mice. 
Oncogene, 24, 2256-70. 
GRECO, O., SCOTT, S. D., MARPLES, B. & DACHS, G. U. (2002) Cancer gene therapy: 
'delivery, delivery, delivery'. Front Biosci, 7, d1516-24. 
GREIDER, C. W. (1999) Telomeres do D-loop-T-loop. Cell, 97, 419-22. 
GREIDER, C. W. & BLACKBURN, E. H. (1985) Identification of a specific telomere 
terminal transferase activity in Tetrahymena extracts. Cell, 43, 405-13. 
GRIFFITH, J. D., COMEAU, L., ROSENFIELD, S., STANSEL, R. M., BIANCHI, A., 
MOSS, H. & DE LANGE, T. (1999) Mammalian telomeres end in a large duplex 
loop. Cell, 97, 503-14. 
GRILLOT-COURVALIN, C., GOUSSARD, S. & COURVALIN, P. (2002) Wild-type 
intracellular bacteria deliver DNA into mammalian cells. Cell Microbiol, 4, 177-86. 
GUNARATNAM, M., GREEN, C., MOREIRA, J. B., MOORHOUSE, A. D., KELLAND, L. 
R., MOSES, J. E. & NEIDLE, S. (2009) G-quadruplex compounds and cis-platin act 
synergistically to inhibit cancer cell growth in vitro and in vivo. Biochem Pharmacol, 
78, 115-22. 
GUO, C., ARMBRUSTER, B. N., PRICE, D. T. & COUNTER, C. M. (2003) In vivo 
regulation of hTERT expression and telomerase activity by androgen. J Urol, 170, 
615-8. 
GUO, X., DENG, Y., LIN, Y., COSME-BLANCO, W., CHAN, S., HE, H., YUAN, G., 
BROWN, E. J. & CHANG, S. (2007) Dysfunctional telomeres activate an ATM-
ATR-dependent DNA damage response to suppress tumorigenesis. Embo J, 26, 
4709-19. 
HACEIN-BEY-ABINA, S., VON KALLE, C., SCHMIDT, M., LE DEIST, F., WULFFRAAT, 
N., MCINTYRE, E., RADFORD, I., VILLEVAL, J. L., FRASER, C. C., 
CAVAZZANA-CALVO, M. & FISCHER, A. (2003) A serious adverse event after 
successful gene therapy for X-linked severe combined immunodeficiency. N Engl J 
Med, 348, 255-6. 
HAHN, W. C., STEWART, S. A., BROOKS, M. W., YORK, S. G., EATON, E., KURACHI, 
A., BEIJERSBERGEN, R. L., KNOLL, J. H., MEYERSON, M. & WEINBERG, R. 
A. (1999) Inhibition of telomerase limits the growth of human cancer cells. Nat Med, 
5, 1164-70. 
HALAMA, A., KULINSKI, M., LIBROWSKI, T. & LOCHYNSKI, S. (2009) Polymer-
based non-viral gene delivery as a concept for the treatment of cancer. Pharmacol 
Rep, 61, 993-9. 
HAMMOND, S. M., BERNSTEIN, E., BEACH, D. & HANNON, G. J. (2000) An RNA-
directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. 
Nature, 404, 293-6. 
HAN, M., CHEN, J. L., HU, Y., HE, C. L., SHUAI, W. P., YU, J. H., CHEN, H. L., LIANG, 
W. Q., MAYUMI, T., SHINSAKU, N. & GAO, J. Q. (2008) In vitro and in vivo 
tumor suppressive activity induced by human telomerase transcriptase-targeting 
antisense oligonucleotides mediated by cationic liposomes. J Biosci Bioeng, 106, 
243-7. 
HANAHAN, D. & WEINBERG, R. A. (2000) The hallmarks of cancer. Cell, 100, 57-70. 
HANNON, G. J. (2002) RNA interference. Nature, 418, 244-51. 
HAO, Z. M., LUO, J. Y., CHENG, J., LI, L., HE, D., WANG, Q. Y. & YANG, G. X. (2005) 
Intensive inhibition of hTERT expression by a ribozyme induces rapid apoptosis of 




HARLEY, C. B. (2008) Telomerase and cancer therapeutics. Nat Rev Cancer, 8, 167-79. 
HARLEY, C. B., FUTCHER, A. B. & GREIDER, C. W. (1990) Telomeres shorten during 
ageing of human fibroblasts. Nature, 345, 458-60. 
HARLEY, C. B., LIU, W., BLASCO, M., VERA, E., ANDREWS, W. H., BRIGGS, L. A. & 
RAFFAELE, J. M. (2010) A natural product telomerase activator as part of a health 
maintenance program. Rejuvenation Res, 14, 45-56. 
HARLEY, C. B., LIU, W., BLASCO, M., VERA, E., ANDREWS, W. H., BRIGGS, L. A. & 
RAFFAELE, J. M. (2011) A natural product telomerase activator as part of a health 
maintenance program. Rejuvenation Res, 14, 45-56. 
HASSELMANN, D. O., RAPPL, G., TILGEN, W. & REINHOLD, U. (2001) Extracellular 
tyrosinase mRNA within apoptotic bodies is protected from degradation in human 
serum. Clin Chem, 47, 1488-9. 
HAYASHIDANI, Y., HIYAMA, E., MURAKAMI, Y. & SUEDA, T. (2005) Attenuation of 
telomerase activity by hammerhead ribozymes targeting human telomerase RNA and 
telomerase reverse transcriptase in pancreatic carcinoma cells. Hiroshima J Med Sci, 
54, 21-7. 
HAYFLICK, L. & MOORHEAD, P. S. (1961) The serial cultivation of human diploid cell 
strains. Exp Cell Res, 25, 585-621. 
HENRY, C. J. (2010) Biomarkers in veterinary cancer screening: Applications, limitations 
and expectations. Vet J, 185, 10-4. 
HERBERT, B. S., GELLERT, G. C., HOCHREITER, A., PONGRACZ, K., WRIGHT, W. E., 
ZIELINSKA, D., CHIN, A. C., HARLEY, C. B., SHAY, J. W. & GRYAZNOV, S. M. 
(2005) Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate 
oligonucleotide, enhances the potency of telomerase inhibition. Oncogene, 24, 5262-
8. 
HERBIG, U., JOBLING, W. A., CHEN, B. P., CHEN, D. J. & SEDIVY, J. M. (2004) 
Telomere shortening triggers senescence of human cells through a pathway 
involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell, 14, 501-13. 
HESS, J. L. & HIGHSMITH, W. E., JR. (2002) Telomerase detection in body fluids. Clin 
Chem, 48, 18-24. 
HIYAMA, E., GOLLAHON, L., KATAOKA, T., KUROI, K., YOKOYAMA, T., GAZDAR, 
A. F., HIYAMA, K., PIATYSZEK, M. A. & SHAY, J. W. (1996) Telomerase activity 
in human breast tumors. J Natl Cancer Inst, 88, 116-22. 
HIYAMA, E. & HIYAMA, K. (2002) Clinical utility of telomerase in cancer. Oncogene, 21, 
643-9. 
HIYAMA, E. & HIYAMA, K. (2003) Telomerase as tumor marker. Cancer Lett, 194, 221-33. 
HIYAMA, E. & HIYAMA, K. (2007) Telomere and telomerase in stem cells. Br J Cancer, 96, 
1020-4. 
HIYAMA, E., YOKOYAMA, T., TATSUMOTO, N., HIYAMA, K., IMAMURA, Y., 
MURAKAMI, Y., KODAMA, T., PIATYSZEK, M. A., SHAY, J. W. & 
MATSUURA, Y. (1995a) Telomerase activity in gastric cancer. Cancer Res, 55, 
3258-62. 
HIYAMA, K., HIRAI, Y., KYOIZUMI, S., AKIYAMA, M., HIYAMA, E., PIATYSZEK, M. 
A., SHAY, J. W., ISHIOKA, S. & YAMAKIDO, M. (1995b) Activation of 
telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol, 
155, 3711-5. 
HOCHREITER, A. E., XIAO, H., GOLDBLATT, E. M., GRYAZNOV, S. M., MILLER, K. 
D., BADVE, S., SLEDGE, G. W. & HERBERT, B. S. (2006) Telomerase template 
antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis 
of breast cancer. Clin Cancer Res, 12, 3184-92. 
HOLEN, T., AMARZGUIOUI, M., WIIGER, M. T., BABAIE, E. & PRYDZ, H. (2002) 
Positional effects of short interfering RNAs targeting the human coagulation trigger 
Tissue Factor. Nucleic Acids Res, 30, 1757-66. 
Bibliography 
 141 
HOLLINS, A. J., BENBOUBETRA, M., OMIDI, Y., ZINSELMEYER, B. H., 
SCHATZLEIN, A. G., UCHEGBU, I. F. & AKHTAR, S. (2004) Evaluation of 
generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular 
delivery of antisense oligonucleotides targeting the epidermal growth factor receptor. 
Pharm Res, 21, 458-66. 
HONG, S. H., JEONG, J. S., LEE, Y. J., JUNG, H. I., CHO, K. S., KIM, C. M., KWON, B. S., 
SULLENGER, B. A., LEE, S. W. & KIM, I. H. (2008) In vivo reprogramming of 
hTERT by trans-splicing ribozyme to target tumor cells. Mol Ther, 16, 74-80. 
HU, Y. L., FU, Y. H., TABATA, Y. & GAO, J. Q. (2010) Mesenchymal stem cells: a 
promising targeted-delivery vehicle in cancer gene therapy. J Control Release, 147, 
154-62. 
HUANG, Y., HONG, J., ZHENG, S., DING, Y., GUO, S., ZHANG, H., ZHANG, X., DU, Q. 
& LIANG, Z. (2011) Elimination Pathways of Systemically Delivered siRNA. Mol 
Ther, 19, 381-5. 
HUDA, N., TANAKA, H., HERBERT, B. S., REED, T. & GILLEY, D. (2007) Shared 
environmental factors associated with telomere length maintenance in elderly male 
twins. Aging Cell, 6, 709-13. 
HUNT, M. A., CURRIE, M. J., ROBINSON, B. A. & DACHS, G. U. (2010) Optimizing 
transfection of primary human umbilical vein endothelial cells using commercially 
available chemical transfection reagents. J Biomol Tech, 21, 66-72. 
HUTVAGNER, G. & ZAMORE, P. D. (2002) A microRNA in a multiple-turnover RNAi 
enzyme complex. Science, 297, 2056-60. 
INCLES, C. M., SCHULTES, C. M., KELLAND, L. R. & NEIDLE, S. (2003) Acquired 
cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-
regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of 
resistant cells to combination treatment with a telomerase inhibitor. Mol Pharmacol, 
64, 1101-8. 
IVERSEN, P. (1991) In vivo studies with phosphorothioate oligonucleotides: 
pharmacokinetics prologue. Anticancer Drug Des, 6, 531-8. 
JACKSON, A. L. & LINSLEY, P. S. (2010) Recognizing and avoiding siRNA off-target 
effects for target identification and therapeutic application. Nat Rev Drug Discov, 9, 
57-67. 
JACOBS, J. J. & DE LANGE, T. (2004) Significant role for p16INK4a in p53-independent 
telomere-directed senescence. Curr Biol, 14, 2302-8. 
JAHR, S., HENTZE, H., ENGLISCH, S., HARDT, D., FACKELMAYER, F. O., HESCH, R. 
D. & KNIPPERS, R. (2001) DNA fragments in the blood plasma of cancer patients: 
quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer 
Res, 61, 1659-65. 
JIA, L. J. & HUA, Z. C. (2009) Development of bacterial vectors for tumor-targeted gene 
therapy. Methods Mol Biol, 542, 131-54. 
JIANG, S. N., PHAN, T. X., NAM, T. K., NGUYEN, V. H., KIM, H. S., BOM, H. S., CHOY, 
H. E., HONG, Y. & MIN, J. J. (2010) Inhibition of tumor growth and metastasis by a 
combination of Escherichia coli-mediated cytolytic therapy and radiotherapy. Mol 
Ther, 18, 635-42. 
JIANG, Y. A., LUO, H. S., ZHANG, Y. Y., FAN, L. F., JIANG, C. Q. & CHEN, W. J. (2003) 
Telomerase activity and cell apoptosis in colon cancer cell by human telomerase 
reverse transcriptase gene antisense oligodeoxynucleotide. World J Gastroenterol, 9, 
1981-4. 
JONES, J. T., LEE, S. W. & SULLENGER, B. A. (1996) Tagging ribozyme reaction sites to 
follow trans-splicing in mammalian cells. Nat Med, 2, 643-8. 
JOSEPH, I., TRESSLER, R., BASSETT, E., HARLEY, C., BUSEMAN, C. M., 
PATTAMATTA, P., WRIGHT, W. E., SHAY, J. W. & GO, N. F. (2010) The 
telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic 
Bibliography 
 142 
cancer cell lines. Cancer Res, 70, 9494-504. 
KAISER, S. & TOBOREK, M. (2001) Liposome-mediated high-efficiency transfection of 
human endothelial cells. J Vasc Res, 38, 133-43. 
KAMM, R. C. & SMITH, A. G. (1972) Ribonuclease activity in human plasma. Clin 
Biochem, 5, 198-200. 
KANAYA, T., KYO, S., TAKAKURA, M., ITO, H., NAMIKI, M. & INOUE, M. (1998) 
hTERT is a critical determinant of telomerase activity in renal-cell carcinoma. Int J 
Cancer, 78, 539-43. 
KANEDA, Y. (2010) Update on non-viral delivery methods for cancer therapy: possibilities 
of a drug delivery system with anticancer activities beyond delivery as a new 
therapeutic tool. Expert Opin Drug Deliv, 7, 1079-93. 
KARLSEDER, J., BROCCOLI, D., DAI, Y., HARDY, S. & DE LANGE, T. (1999) p53- and 
ATM-dependent apoptosis induced by telomeres lacking TRF2. Science, 283, 1321-5. 
KASINSKAS, R. W. & FORBES, N. S. (2006) Salmonella typhimurium specifically 
chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol Bioeng, 
94, 710-21. 
KASINSKAS, R. W. & FORBES, N. S. (2007) Salmonella typhimurium lacking ribose 
chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res, 67, 
3201-9. 
KAWABATA, K., TAKAKURA, Y. & HASHIDA, M. (1995) The fate of plasmid DNA after 
intravenous injection in mice: involvement of scavenger receptors in its hepatic 
uptake. Pharm Res, 12, 825-30. 
KAWAKAMI, S., HIGUCHI, Y. & HASHIDA, M. (2008) Nonviral approaches for targeted 
delivery of plasmid DNA and oligonucleotide. J Pharm Sci, 97, 726-45. 
KAY, M. A., GLORIOSO, J. C. & NALDINI, L. (2001) Viral vectors for gene therapy: the 
art of turning infectious agents into vehicles of therapeutics. Nat Med, 7, 33-40. 
KEALY, B., LIEW, A., MCMAHON, J. M., RITTER, T., O'DOHERTY, A., HOARE, M., 
GREISER, U., VAUGHAN, E. E., MAENZ, M., O'SHEA, C., BARRY, F. & 
O'BRIEN, T. (2009) Comparison of viral and nonviral vectors for gene transfer to 
human endothelial progenitor cells. Tissue Eng Part C Methods, 15, 223-31. 
KERBEL, R. S., BENEZRA, R., LYDEN, D. C., HATTORI, K., HEISSIG, B., NOLAN, D. 
J., MITTAL, V., SHAKED, Y., DIAS, S., BERTOLINI, F. & RAFII, S. (2008) 
Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain 
aggressive adenocarcinomas and metastatic transition but not adenomas. Proc Natl 
Acad Sci U S A, 105, E54; author reply E55. 
KHANNA, K. K. & JACKSON, S. P. (2001) DNA double-strand breaks: signaling, repair 
and the cancer connection. Nat Genet, 27, 247-54. 
KICHLER, A. (2004) Gene transfer with modified polyethylenimines. J Gene Med, 6 Suppl 
1, S3-10. 
KICHLER, A., LEBORGNE, C., COEYTAUX, E. & DANOS, O. (2001) Polyethylenimine-
mediated gene delivery: a mechanistic study. J Gene Med, 3, 135-44. 
KIDD, S., SPAETH, E., DEMBINSKI, J. L., DIETRICH, M., WATSON, K., KLOPP, A., 
BATTULA, V. L., WEIL, M., ANDREEFF, M. & MARINI, F. C. (2009) Direct 
evidence of mesenchymal stem cell tropism for tumor and wounding 
microenvironments using in vivo bioluminescent imaging. Stem Cells, 27, 2614-23. 
KILIAN, A., BOWTELL, D. D., ABUD, H. E., HIME, G. R., VENTER, D. J., KEESE, P. K., 
DUNCAN, E. L., REDDEL, R. R. & JEFFERSON, R. A. (1997) Isolation of a 
candidate human telomerase catalytic subunit gene, which reveals complex splicing 
patterns in different cell types. Hum Mol Genet, 6, 2011-9. 
KIM, M. M., RIVERA, M. A., BOTCHKINA, I. L., SHALABY, R., THOR, A. D. & 
BLACKBURN, E. H. (2001) A low threshold level of expression of mutant-template 




KIM, N. W., PIATYSZEK, M. A., PROWSE, K. R., HARLEY, C. B., WEST, M. D., HO, P. 
L., COVIELLO, G. M., WRIGHT, W. E., WEINRICH, S. L. & SHAY, J. W. (1994) 
Specific association of human telomerase activity with immortal cells and cancer. 
Science, 266, 2011-5. 
KIM, T. H., COOK, S. E., AROTE, R. B., CHO, M. H., NAH, J. W., CHOI, Y. J. & CHO, C. 
S. (2007) A degradable hyperbranched poly(ester amine) based on poloxamer 
diacrylate and polyethylenimine as a gene carrier. Macromol Biosci, 7, 611-9. 
KIMURA, N. T., TANIGUCHI, S., AOKI, K. & BABA, T. (1980) Selective localization and 
growth of Bifidobacterium bifidum in mouse tumors following intravenous 
administration. Cancer Res, 40, 2061-8. 
KIRKWOOD, T. B. (2005) Understanding the odd science of aging. Cell, 120, 437-47. 
KLOPP, A. H., SPAETH, E. L., DEMBINSKI, J. L., WOODWARD, W. A., MUNSHI, A., 
MEYN, R. E., COX, J. D., ANDREEFF, M. & MARINI, F. C. (2007) Tumor 
irradiation increases the recruitment of circulating mesenchymal stem cells into the 
tumor microenvironment. Cancer Res, 67, 11687-95. 
KNIGHT, S. W., VULLIAMY, T. J., MORGAN, B., DEVRIENDT, K., MASON, P. J. & 
DOKAL, I. (2001) Identification of novel DKC1 mutations in patients with 
dyskeratosis congenita: implications for pathophysiology and diagnosis. Hum Genet, 
108, 299-303. 
KOK, K. H., NG, M. H., CHING, Y. P. & JIN, D. Y. (2007) Human TRBP and PACT directly 
interact with each other and associate with dicer to facilitate the production of small 
interfering RNA. J Biol Chem, 282, 17649-57. 
KOPRESKI, M. S., BENKO, F. A. & GOCKE, C. D. (2001) Circulating RNA as a tumor 
marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Ann N Y 
Acad Sci, 945, 172-8. 
KOPRESKI, M. S., BENKO, F. A., KWAK, L. W. & GOCKE, C. D. (1999) Detection of 
tumor messenger RNA in the serum of patients with malignant melanoma. Clin 
Cancer Res, 5, 1961-5. 
KOSCIOLEK, B. A., KALANTIDIS, K., TABLER, M. & ROWLEY, P. T. (2003) Inhibition 
of telomerase activity in human cancer cells by RNA interference. Mol Cancer Ther, 
2, 209-16. 
KRAEMER, K., FUESSEL, S., KOTZSCH, M., NING, S., SCHMIDT, U., WIRTH, M. P. & 
MEYE, A. (2004) Chemosensitization of bladder cancer cell lines by human 
telomerase reverse transcriptase antisense treatment. J Urol, 172, 2023-8. 
KRAEMER, K., FUESSEL, S., SCHMIDT, U., KOTZSCH, M., SCHWENZER, B., WIRTH, 
M. P. & MEYE, A. (2003) Antisense-mediated hTERT inhibition specifically 
reduces the growth of human bladder cancer cells. Clin Cancer Res, 9, 3794-800. 
KREPPEL, F. & KOCHANEK, S. (2008) Modification of adenovirus gene transfer vectors 
with synthetic polymers: a scientific review and technical guide. Mol Ther, 16, 16-29. 
KRISKY, D. M., MARCONI, P. C., OLIGINO, T. J., ROUSE, R. J., FINK, D. J., COHEN, J. 
B., WATKINS, S. C. & GLORIOSO, J. C. (1998) Development of herpes simplex 
virus replication-defective multigene vectors for combination gene therapy 
applications. Gene Ther, 5, 1517-30. 
KUCEROVA, L., ALTANEROVA, V., MATUSKOVA, M., TYCIAKOVA, S. & ALTANER, 
C. (2007) Adipose tissue-derived human mesenchymal stem cells mediated prodrug 
cancer gene therapy. Cancer Res, 67, 6304-13. 
KUWABARA, T., WARASHINA, M. & TAIRA, K. (2000) Allosterically controllable 
maxizymes cleave mRNA with high efficiency and specificity. Trends Biotechnol, 18, 
462-8. 
KYO, S., TAKAKURA, M., KANAYA, T., ZHUO, W., FUJIMOTO, K., NISHIO, Y., 
ORIMO, A. & INOUE, M. (1999) Estrogen activates telomerase. Cancer Res, 59, 
5917-21. 
LAFFERTY-WHYTE, K., CAIRNEY, C. J., WILL, M. B., SERAKINCI, N., DAIDONE, M. 
Bibliography 
 144 
G., ZAFFARONI, N., BILSLAND, A. & KEITH, W. N. (2009) A gene expression 
signature classifying telomerase and ALT immortalization reveals an hTERT 
regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene, 
28, 3765-74. 
LATIF, C., DEN ELZEN, N. R. & O'CONNELL, M. J. (2004) DNA damage checkpoint 
maintenance through sustained Chk1 activity. J Cell Sci, 117, 3489-98. 
LEE, Y., AHN, C., HAN, J., CHOI, H., KIM, J., YIM, J., LEE, J., PROVOST, P., 
RADMARK, O., KIM, S. & KIM, V. N. (2003) The nuclear RNase III Drosha 
initiates microRNA processing. Nature, 425, 415-9. 
LEON, S. A., REVACH, M., EHRLICH, G. E., ADLER, R., PETERSEN, V. & SHAPIRO, B. 
(1981) DNA in synovial fluid and the circulation of patients with arthritis. Arthritis 
Rheum, 24, 1142-50. 
LEON, S. A., SHAPIRO, B., SKLAROFF, D. M. & YAROS, M. J. (1977) Free DNA in the 
serum of cancer patients and the effect of therapy. Cancer Res, 37, 646-50. 
LEWIS, B. P., BURGE, C. B. & BARTEL, D. P. (2005) Conserved seed pairing, often 
flanked by adenosines, indicates that thousands of human genes are microRNA 
targets. Cell, 120, 15-20. 
LI, A. Q., SI, J. M., SHANG, Y., GAN, L. H., GUO, L. & ZHOU, T. H. (2010) [Construction 
of COL1A1 short hairpin RNA vector and its effect on cell proliferation and 
migration of gastric cancer cells]. Zhejiang Da Xue Xue Bao Yi Xue Ban, 39, 257-63. 
LI, H., FAN, X., KOVI, R. C., JO, Y., MOQUIN, B., KONZ, R., STOICOV, C., KURT-
JONES, E., GROSSMAN, S. R., LYLE, S., ROGERS, A. B., MONTROSE, M. & 
HOUGHTON, J. (2007a) Spontaneous expression of embryonic factors and p53 
point mutations in aged mesenchymal stem cells: a model of age-related 
tumorigenesis in mice. Cancer Res, 67, 10889-98. 
LI, H., GERALD, W. L. & BENEZRA, R. (2004a) Utilization of bone marrow-derived 
endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. 
Cancer Res, 64, 6137-43. 
LI, S., ROSENBERG, J. E., DONJACOUR, A. A., BOTCHKINA, I. L., HOM, Y. K., 
CUNHA, G. R. & BLACKBURN, E. H. (2004b) Rapid inhibition of cancer cell 
growth induced by lentiviral delivery and expression of mutant-template telomerase 
RNA and anti-telomerase short-interfering RNA. Cancer Res, 64, 4833-40. 
LI, Y., ELASHOFF, D., OH, M., SINHA, U., ST JOHN, M. A., ZHOU, X., ABEMAYOR, E. 
& WONG, D. T. (2006) Serum circulating human mRNA profiling and its utility for 
oral cancer detection. J Clin Oncol, 24, 1754-60. 
LI, Y., LI, H., YAO, G., LI, W., WANG, F., JIANG, Z. & LI, M. (2007b) Inhibition of 
telomerase RNA (hTR) in cervical cancer by adenovirus-delivered siRNA. Cancer 
Gene Ther, 14, 748-55. 
LI, Y., LI, M., YAO, G., GENG, N., XIE, Y., FENG, Y., ZHANG, P., KONG, X., XUE, J., 
CHENG, S., ZHOU, J. & XIAO, L. (2011) Telomerase inhibition strategies by 
siRNAs against either hTR or hTERT in oral squamous cell carcinoma. Cancer Gene 
Ther. 
LIN, R. X., TUO, C. W., LU, Q. J., ZHANG, W. & WANG, S. Q. (2005) Inhibition of tumor 
growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in 
an in situ human hepatocellular carcinoma model. Acta Pharmacol Sin, 26, 762-8. 
LIN, S. Y. & ELLEDGE, S. J. (2003) Multiple tumor suppressor pathways negatively 
regulate telomerase. Cell, 113, 881-9. 
LIU, J., CARMELL, M. A., RIVAS, F. V., MARSDEN, C. G., THOMSON, J. M., SONG, J. 
J., HAMMOND, S. M., JOSHUA-TOR, L. & HANNON, G. J. (2004a) Argonaute2 
is the catalytic engine of mammalian RNAi. Science, 305, 1437-41. 
LIU, Q., RAND, T. A., KALIDAS, S., DU, F., KIM, H. E., SMITH, D. P. & WANG, X. 
(2003) R2D2, a bridge between the initiation and effector steps of the Drosophila 
RNAi pathway. Science, 301, 1921-5. 
Bibliography 
 145 
LIU, S. X., SUN, W. S., CAO, Y. L., MA, C. H., HAN, L. H., ZHANG, L. N., WANG, Z. G. 
& ZHU, F. L. (2004b) Antisense oligonucleotide targeting at the initiator of hTERT 
arrests growth of hepatoma cells. World J Gastroenterol, 10, 366-70. 
LLEDO, S. M., GARCIA-GRANERO, E., DASI, F., RIPOLI, R., GARCIA, S. A., 
CERVANTES, A. & ALINO, S. F. (2004) Real time quantification in plasma of 
human telomerase reverse transcriptase (hTERT) mRNA in patients with colorectal 
cancer. Colorectal Dis, 6, 236-42. 
LO, K. W., LO, Y. M., LEUNG, S. F., TSANG, Y. S., CHAN, L. Y., JOHNSON, P. J., 
HJELM, N. M., LEE, J. C. & HUANG, D. P. (1999) Analysis of cell-free Epstein-
Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. 
Clin Chem, 45, 1292-4. 
LOEBINGER, M. R., EDDAOUDI, A., DAVIES, D. & JANES, S. M. (2009) Mesenchymal 
stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res, 69, 4134-
42. 
LUDWIG, A., SARETZKI, G., HOLM, P. S., TIEMANN, F., LORENZ, M., EMRICH, T., 
HARLEY, C. B. & VON ZGLINICKI, T. (2001) Ribozyme cleavage of telomerase 
mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res, 
61, 3053-61. 
LUND, J. R., PAOLONI, M., KURZMAN, I., PADILLA, M. & ARGYLE, D. J. (2008) 
Inhibition of canine telomerase in vitro and in vivo using RNAi: further 
development of a natural canine model for telomerase-based cancer therapies. Vet J, 
177, 192-7. 
MA, J. B., YUAN, Y. R., MEISTER, G., PEI, Y., TUSCHL, T. & PATEL, D. J. (2005) 
Structural basis for 5'-end-specific recognition of guide RNA by the A. fulgidus Piwi 
protein. Nature, 434, 666-70. 
MADLAMBAYAN, G. J., BUTLER, J. M., HOSAKA, K., JORGENSEN, M., FU, D., 
GUTHRIE, S. M., SHENOY, A. K., BRANK, A., RUSSELL, K. J., OTERO, J., 
SIEMANN, D. W., SCOTT, E. W. & COGLE, C. R. (2009) Bone marrow stem and 
progenitor cell contribution to neovasculogenesis is dependent on model system with 
SDF-1 as a permissive trigger. Blood, 114, 4310-9. 
MAEHARA, K., YAMAKOSHI, K., OHTANI, N., KUBO, Y., TAKAHASHI, A., ARASE, 
S., JONES, N. & HARA, E. (2005) Reduction of total E2F/DP activity induces 
senescence-like cell cycle arrest in cancer cells lacking functional pRB and p53. J 
Cell Biol, 168, 553-60. 
MAIDA, Y., KYO, S., KANAYA, T., WANG, Z., YATABE, N., TANAKA, M., 
NAKAMURA, M., OHMICHI, M., GOTOH, N., MURAKAMI, S. & INOUE, M. 
(2002) Direct activation of telomerase by EGF through Ets-mediated transactivation 
of TERT via MAP kinase signaling pathway. Oncogene, 21, 4071-9. 
MALMGREN, R. A. & FLANIGAN, C. C. (1955) Localization of the vegetative form of 
Clostridium tetani in mouse tumors following intravenous spore administration. 
Cancer Res, 15, 473-8. 
MANDEL P, M. P. (1948) Les acides nucleiques du plasma sanguin chez l'homme. C R Acad 
Sci, 1, 241-243. 
MANILLA, P., REBELLO, T., AFABLE, C., LU, X., SLEPUSHKIN, V., HUMEAU, L. M., 
SCHONELY, K., NI, Y., BINDER, G. K., LEVINE, B. L., MACGREGOR, R. R., 
JUNE, C. H. & DROPULIC, B. (2005) Regulatory considerations for novel gene 
therapy products: a review of the process leading to the first clinical lentiviral vector. 
Hum Gene Ther, 16, 17-25. 
MANSUR, N. R., MEYER-SIEGLER, K., WURZER, J. C. & SIROVER, M. A. (1993) Cell 
cycle regulation of the glyceraldehyde-3-phosphate dehydrogenase/uracil DNA 
glycosylase gene in normal human cells. Nucleic Acids Res, 21, 993-8. 
MARCONI, P., ARGNANI, R., BERTO, E., EPSTEIN, A. L. & MANSERVIGI, R. (2008) 
HSV as a vector in vaccine development and gene therapy. Hum Vaccin, 4, 91-105. 
Bibliography 
 146 
MARIAN, C. O., CHO, S. K., MCELLIN, B. M., MAHER, E. A., HATANPAA, K. J., 
MADDEN, C. J., MICKEY, B. E., WRIGHT, W. E., SHAY, J. W. & BACHOO, R. 
M. (2010) The telomerase antagonist, imetelstat, efficiently targets glioblastoma 
tumor-initiating cells leading to decreased proliferation and tumor growth. Clin 
Cancer Res, 16, 154-63. 
MARIE-EGYPTIENNE, D. T., BRAULT, M. E., ZHU, S. & AUTEXIER, C. (2008) 
Telomerase inhibition in a mouse cell line with long telomeres leads to rapid 
telomerase reactivation. Exp Cell Res, 314, 668-75. 
MARRA, A. & ISBERG, R. R. (1996) Common entry mechanisms. Bacterial pathogenesis. 
Curr Biol, 6, 1084-6. 
MARSHALL, E. (1999) Gene therapy death prompts review of adenovirus vector. Science, 
286, 2244-5. 
MARTIN-RIVERA, L., HERRERA, E., ALBAR, J. P. & BLASCO, M. A. (1998) 
Expression of mouse telomerase catalytic subunit in embryos and adult tissues. Proc 
Natl Acad Sci U S A, 95, 10471-6. 
MARTIN, S. G. & MURRAY, J. C. (2000) Gene-transfer systems for human endothelial cells. 
stewart.martin@nottingham.ac.uk. Adv Drug Deliv Rev, 41, 223-33. 
MARTINEZ, J., PATKANIOWSKA, A., URLAUB, H., LUHRMANN, R. & TUSCHL, T. 
(2002) Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell, 
110, 563-74. 
MARTINEZ, J. & TUSCHL, T. (2004) RISC is a 5' phosphomonoester-producing RNA 
endonuclease. Genes Dev, 18, 975-80. 
MARTINEZ, P. & BLASCO, M. A. (2011) Telomeric and extra-telomeric roles for 
telomerase and the telomere-binding proteins. Nat Rev Cancer, 11, 161-76. 
MASIERO, M., NARDO, G., INDRACCOLO, S. & FAVARO, E. (2007) RNA interference: 
implications for cancer treatment. Mol Aspects Med, 28, 143-66. 
MATHER, K. A., JORM, A. F., PARSLOW, R. A. & CHRISTENSEN, H. (2011) Is telomere 
length a biomarker of aging? A review. J Gerontol A Biol Sci Med Sci, 66, 202-13. 
MATRANGA, C., TOMARI, Y., SHIN, C., BARTEL, D. P. & ZAMORE, P. D. (2005) 
Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi 
enzyme complexes. Cell, 123, 607-20. 
MATTHEWS, P., JONES, C. J., SKINNER, J., HAUGHTON, M., DE MICCO, C. & 
WYNFORD-THOMAS, D. (2001) Telomerase activity and telomere length in 
thyroid neoplasia: biological and clinical implications. J Pathol, 194, 183-93. 
MCCAW, D. L., CHAN, A. S., STEGNER, A. L., MOONEY, B., BRYAN, J. N., 
TURNQUIST, S. E., HENRY, C. J., ALEXANDER, H. & ALEXANDER, S. (2007) 
Proteomics of canine lymphoma identifies potential cancer-specific protein markers. 
Clin Cancer Res, 13, 2496-503. 
MERRICK, A. F., SHEWRING, L. D., SAWYER, G. J., GUSTAFSSON, K. T. & FABRE, J. 
W. (1996) Comparison of adenovirus gene transfer to vascular endothelial cells in 
cell culture, organ culture, and in vivo. Transplantation, 62, 1085-9. 
MEYNE, J., RATLIFF, R. L. & MOYZIS, R. K. (1989) Conservation of the human telomere 
sequence (TTAGGG)n among vertebrates. Proc Natl Acad Sci U S A, 86, 7049-53. 
MISITI, S., NANNI, S., FONTEMAGGI, G., CONG, Y. S., WEN, J., HIRTE, H. W., 
PIAGGIO, G., SACCHI, A., PONTECORVI, A., BACCHETTI, S. & FARSETTI, A. 
(2000) Induction of hTERT expression and telomerase activity by estrogens in 
human ovary epithelium cells. Mol Cell Biol, 20, 3764-71. 
MIURA, N., SHIOTA, G., NAKAGAWA, T., MAEDA, Y., SANO, A., MARUMOTO, A., 
KISHIMOTO, Y., MURAWAKI, Y. & HASEGAWA, J. (2003) Sensitive detection of 
human telomerase reverse transcriptase mRNA in the serum of patients with 
hepatocellular carcinoma. Oncology, 64, 430-4. 
MODARAI, B., BURNAND, K. G., SAWYER, B. & SMITH, A. (2005) Endothelial 




MOREIRA, J. N., GASPAR, R. & ALLEN, T. M. (2001) Targeting Stealth liposomes in a 
murine model of human small cell lung cancer. Biochim Biophys Acta, 1515, 167-76. 
MORENO, M., KRAMER, M. G., YIM, L. & CHABALGOITY, J. A. (2010) Salmonella as 
live trojan horse for vaccine development and cancer gene therapy. Curr Gene Ther, 
10, 56-76. 
MORILLE, M., PASSIRANI, C., VONARBOURG, A., CLAVREUL, A. & BENOIT, J. P. 
(2008) Progress in developing cationic vectors for non-viral systemic gene therapy 
against cancer. Biomaterials, 29, 3477-96. 
MUELLER, S., HARTMANN, U., MAYER, F., BALABANOV, S., HARTMANN, J. T., 
BRUMMENDORF, T. H. & BOKEMEYER, C. (2007) Targeting telomerase activity 
by BIBR1532 as a therapeutic approach in germ cell tumors. Invest New Drugs, 25, 
519-24. 
NAKAGAWA, M., KOYANAGI, M., TANABE, K., TAKAHASHI, K., ICHISAKA, T., AOI, 
T., OKITA, K., MOCHIDUKI, Y., TAKIZAWA, N. & YAMANAKA, S. (2008) 
Generation of induced pluripotent stem cells without Myc from mouse and human 
fibroblasts. Nat Biotechnol, 26, 101-6. 
NAKAMIZO, A., MARINI, F., AMANO, T., KHAN, A., STUDENY, M., GUMIN, J., 
CHEN, J., HENTSCHEL, S., VECIL, G., DEMBINSKI, J., ANDREEFF, M. & 
LANG, F. F. (2005) Human bone marrow-derived mesenchymal stem cells in the 
treatment of gliomas. Cancer Res, 65, 3307-18. 
NAKAMURA, T. M., MORIN, G. B., CHAPMAN, K. B., WEINRICH, S. L., ANDREWS, 
W. H., LINGNER, J., HARLEY, C. B. & CECH, T. R. (1997) Telomerase catalytic 
subunit homologs from fission yeast and human. Science, 277, 955-9. 
NASIR, L. (2008) Telomeres and telomerase: Biological and clinical importance in dogs. Vet 
J, 175, 155-63. 
NASIR, L., DEVLIN, P., MCKEVITT, T., RUTTEMAN, G. & ARGYLE, D. J. (2001) 
Telomere lengths and telomerase activity in dog tissues: a potential model system to 
study human telomere and telomerase biology. Neoplasia, 3, 351-9. 
NEIDLE, S. (2010) Human telomeric G-quadruplex: the current status of telomeric G-
quadruplexes as therapeutic targets in human cancer. Febs J, 277, 1118-25. 
NGUYEN, B. N., ELMORE, L. W. & HOLT, S. E. (2009) Mechanism of dominant-negative 
telomerase function. Cell Cycle, 8, 3227-33. 
NOVAKOVIC, S., HOCEVAR, M., ZGAJNAR, J., BESIC, N. & STEGEL, V. (2004) 
Detection of telomerase RNA in the plasma of patients with breast cancer, malignant 
melanoma or thyroid cancer. Oncol Rep, 11, 245-52. 
O'SULLIVAN, R. J. & KARLSEDER, J. (2010) Telomeres: protecting chromosomes against 
genome instability. Nat Rev Mol Cell Biol, 11, 171-81. 
OH, S., SONG, Y. H., YIM, J. & KIM, T. K. (2000) Identification of Mad as a repressor of 
the human telomerase (hTERT) gene. Oncogene, 19, 1485-90. 
OJEIFO, J. O., LEE, H. R., REZZA, P., SU, N. & ZWIEBEL, J. A. (2001) Endothelial cell-
based systemic gene therapy of metastatic melanoma. Cancer Gene Ther, 8, 636-48. 
OLOVNIKOV, A. M. (1996) Telomeres, telomerase, and aging: origin of the theory. Exp 
Gerontol, 31, 443-8. 
OMIDI, Y. & BARAR, J. (2009) Induction of human alveolar epithelial cell growth factor 
receptors by dendrimeric nanostructures. Int J Toxicol, 28, 113-22. 
OMIDI, Y., HOLLINS, A. J., DRAYTON, R. M. & AKHTAR, S. (2005) Polypropylenimine 
dendrimer-induced gene expression changes: the effect of complexation with DNA, 
dendrimer generation and cell type. J Drug Target, 13, 431-43. 
PADDISON, P. J., CAUDY, A. A., BERNSTEIN, E., HANNON, G. J. & CONKLIN, D. S. 
(2002) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in 
mammalian cells. Genes Dev, 16, 948-58. 
PALLINI, R., SORRENTINO, A., PIERCONTI, F., MAGGIANO, N., FAGGI, R., 
Bibliography 
 148 
MONTANO, N., MAIRA, G., LAROCCA, L. M., LEVI, A. & FALCHETTI, M. L. 
(2006) Telomerase inhibition by stable RNA interference impairs tumor growth and 
angiogenesis in glioblastoma xenografts. Int J Cancer, 118, 2158-67. 
PANG, L. Y. & ARGYLE, D. (2010) Cancer stem cells and telomerase as potential 
biomarkers in veterinary oncology. Vet J, 185, 15-22. 
PAPADOPOULOU, E., DAVILAS, E., SOTIRIOU, V., KOLIOPANOS, A., AGGELAKIS, 
F., DARDOUFAS, K., AGNANTI, N. J., KARYDAS, I. & NASIOULAS, G. (2004) 
Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer. 
Oncol Res, 14, 439-45. 
PARK, I. K., VON RECUM, H. A., JIANG, S. & PUN, S. H. (2006) Supramolecular 
assembly of cyclodextrin-based nanoparticles on solid surfaces for gene delivery. 
Langmuir, 22, 8478-84. 
PARSCH, D., BRASSAT, U., BRUMMENDORF, T. H. & FELLENBERG, J. (2008) 
Consequences of telomerase inhibition by BIBR1532 on proliferation and 
chemosensitivity of chondrosarcoma cell lines. Cancer Invest, 26, 590-6. 
PASCOLO, E., WENZ, C., LINGNER, J., HAUEL, N., PRIEPKE, H., KAUFFMANN, I., 
GARIN-CHESA, P., RETTIG, W. J., DAMM, K. & SCHNAPP, A. (2002) 
Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-
nucleosidic drug candidate. J Biol Chem, 277, 15566-72. 
PETRELLI, N. J., WINER, E. P., BRAHMER, J., DUBEY, S., SMITH, S., THOMAS, C., 
VAHDAT, L. T., OBEL, J., VOGELZANG, N., MARKMAN, M., SWEETENHAM, 
J. W., PFISTER, D., KRIS, M. G., SCHUCHTER, L. M., SAWAYA, R., 
RAGHAVAN, D., GANZ, P. A. & KRAMER, B. (2009) Clinical Cancer Advances 
2009: major research advances in cancer treatment, prevention, and screening--a 
report from the American Society of Clinical Oncology. J Clin Oncol, 27, 6052-69. 
PICHON, C., BILLIET, L. & MIDOUX, P. (2010) Chemical vectors for gene delivery: 
uptake and intracellular trafficking. Curr Opin Biotechnol, 21, 640-5. 
PIOTROWSKA, K., KLEIDEITER, E., MURDTER, T. E., TAETZ, S., BALDES, C., 
SCHAEFER, U., LEHR, C. M. & KLOTZ, U. (2005) Optimization of the TRAP 
assay to evaluate specificity of telomerase inhibitors. Lab Invest, 85, 1565-9. 
POST, D. E., FULCI, G., CHIOCCA, E. A. & VAN MEIR, E. G. (2004) Replicative 
oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther, 4, 
41-51. 
POTAPOVA, I. A., BRINK, P. R., COHEN, I. S. & DORONIN, S. V. (2008) Culturing of 
human mesenchymal stem cells as three-dimensional aggregates induces functional 
expression of CXCR4 that regulates adhesion to endothelial cells. J Biol Chem, 283, 
13100-7. 
POYNTER, K. R., SACHS, P. C., BRIGHT, A. T., BREED, M. S., NGUYEN, B. N., 
ELMORE, L. W. & HOLT, S. E. (2009) Genetic inhibition of telomerase results in 
sensitization and recovery of breast tumor cells. Mol Cancer Ther. 
RAFII, S. & LYDEN, D. (2003) Therapeutic stem and progenitor cell transplantation for 
organ vascularization and regeneration. Nat Med, 9, 702-12. 
RAINER, T. H., LAM, N. Y., TSUI, N. B., NG, E. K., CHIU, R. W., JOYNT, G. M. & LO, Y. 
M. (2004) Effects of filtration on glyceraldehyde-3-phosphate dehydrogenase 
mRNA in the plasma of trauma patients and healthy individuals. Clin Chem, 50, 
206-8. 
RAINOV, N. G. & REN, H. (2003) Clinical trials with retrovirus mediated gene therapy--
what have we learned? J Neurooncol, 65, 227-36. 
RAND, T. A., PETERSEN, S., DU, F. & WANG, X. (2005) Argonaute2 cleaves the anti-
guide strand of siRNA during RISC activation. Cell, 123, 621-9. 
RATY, J. K., LESCH, H. P., WIRTH, T. & YLA-HERTTUALA, S. (2008) Improving safety 
of gene therapy. Curr Drug Saf, 3, 46-53. 
REDDI, K. K. & HOLLAND, J. F. (1976) Elevated serum ribonuclease in patients with 
Bibliography 
 149 
pancreatic cancer. Proc Natl Acad Sci U S A, 73, 2308-10. 
REN, C., KUMAR, S., CHANDA, D., KALLMAN, L., CHEN, J., MOUNTZ, J. D. & 
PONNAZHAGAN, S. (2008) Cancer gene therapy using mesenchymal stem cells 
expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene 
Ther, 15, 1446-53. 
RIES, C., EGEA, V., KAROW, M., KOLB, H., JOCHUM, M. & NETH, P. (2007) MMP-2, 
MT1-MMP, and TIMP-2 are essential for the invasive capacity of human 
mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood, 
109, 4055-63. 
ROSI, A., GUIDONI, L., LUCIANI, A. M., MARIUTTI, G. & VITI, V. (1988) RNA-lipid 
complexes released from the plasma membrane of human colon carcinoma cells. 
Cancer Lett, 39, 153-60. 
ROSSI, D. J., BRYDER, D., SEITA, J., NUSSENZWEIG, A., HOEIJMAKERS, J. & 
WEISSMAN, I. L. (2007) Deficiencies in DNA damage repair limit the function of 
haematopoietic stem cells with age. Nature, 447, 725-9. 
ROSSI, D. J., JAMIESON, C. H. & WEISSMAN, I. L. (2008) Stems cells and the pathways 
to aging and cancer. Cell, 132, 681-96. 
ROTH, A., HARLEY, C. B. & BAERLOCHER, G. M. (2010) Imetelstat (GRN163L)--
telomerase-based cancer therapy. Recent Results Cancer Res, 184, 221-34. 
ROTH, J. C., CURIEL, D. T. & PEREBOEVA, L. (2008) Cell vehicle targeting strategies. 
Gene Ther, 15, 716-29. 
RUAS, M. & PETERS, G. (1998) The p16INK4a/CDKN2A tumor suppressor and its 
relatives. Biochim Biophys Acta, 1378, F115-77. 
RUBINSON, D. A., DILLON, C. P., KWIATKOWSKI, A. V., SIEVERS, C., YANG, L., 
KOPINJA, J., ROONEY, D. L., ZHANG, M., IHRIG, M. M., MCMANUS, M. T., 
GERTLER, F. B., SCOTT, M. L. & VAN PARIJS, L. (2003) A lentivirus-based 
system to functionally silence genes in primary mammalian cells, stem cells and 
transgenic mice by RNA interference. Nat Genet, 33, 401-6. 
RUSSELL, J. & ZOMERDIJK, J. C. (2005) RNA-polymerase-I-directed rDNA transcription, 
life and works. Trends Biochem Sci, 30, 87-96. 
RUZINOVA, M. B., SCHOER, R. A., GERALD, W., EGAN, J. E., PANDOLFI, P. P., RAFII, 
S., MANOVA, K., MITTAL, V. & BENEZRA, R. (2003) Effect of angiogenesis 
inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells 
in spontaneous murine tumors. Cancer Cell, 4, 277-89. 
RYKOVA, E. Y., WUNSCHE, W., BRIZGUNOVA, O. E., SKVORTSOVA, T. E., 
TAMKOVICH, S. N., SENIN, I. S., LAKTIONOV, P. P., SCZAKIEL, G. & 
VLASSOV, V. V. (2006) Concentrations of circulating RNA from healthy donors and 
cancer patients estimated by different methods. Ann N Y Acad Sci, 1075, 328-33. 
SACHSINGER, J., GONZALEZ-SUAREZ, E., SAMPER, E., HEICAPPELL, R., MULLER, 
M. & BLASCO, M. A. (2001) Telomerase inhibition in RenCa, a murine tumor cell 
line with short telomeres, by overexpression of a dominant negative mTERT mutant, 
reveals fundamental differences in telomerase regulation between human and murine 
cells. Cancer Res, 61, 5580-6. 
SAHIN, E. & DEPINHO, R. A. (2010) Linking functional decline of telomeres, 
mitochondria and stem cells during ageing. Nature, 464, 520-8. 
SAITO, T., KUANG, J. Q., BITTIRA, B., AL-KHALDI, A. & CHIU, R. C. (2002) 
Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac 
Surg, 74, 19-24; discussion 24. 
SAKHUJA, K., REDDY, P. S., GANESH, S., CANTANIAG, F., PATTISON, S., LIMBACH, 
P., KAYDA, D. B., KADAN, M. J., KALEKO, M. & CONNELLY, S. (2003) 
Optimization of the generation and propagation of gutless adenoviral vectors. Hum 
Gene Ther, 14, 243-54. 
SALTZMAN, D. A., KATSANIS, E., HEISE, C. P., HASZ, D. E., VIGDOROVICH, V., 
Bibliography 
 150 
KELLY, S. M., CURTISS, R., 3RD, LEONARD, A. S. & ANDERSON, P. M. (1997) 
Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene 
for human interleukin-2: a novel antitumor agent? J Pediatr Surg, 32, 301-6. 
SANTHAKUMARAN, L. M., THOMAS, T. & THOMAS, T. J. (2004) Enhanced cellular 
uptake of a triplex-forming oligonucleotide by nanoparticle formation in the 
presence of polypropylenimine dendrimers. Nucleic Acids Res, 32, 2102-12. 
SARETZKI, G., LUDWIG, A., VON ZGLINICKI, T. & RUNNEBAUM, I. B. (2001) 
Ribozyme-mediated telomerase inhibition induces immediate cell loss but not 
telomere shortening in ovarian cancer cells. Cancer Gene Ther, 8, 827-34. 
SAYDAM, O., GLAUSER, D. L., HEID, I., TURKERI, G., HILBE, M., JACOBS, A. H., 
ACKERMANN, M. & FRAEFEL, C. (2005) Herpes simplex virus 1 amplicon 
vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of 
human glioma cells in vivo. Mol Ther, 12, 803-12. 
SCHICHOR, C., BIRNBAUM, T., ETMINAN, N., SCHNELL, O., GRAU, S., MIEBACH, 
S., ABOODY, K., PADOVAN, C., STRAUBE, A., TONN, J. C. & 
GOLDBRUNNER, R. (2006) Vascular endothelial growth factor A contributes to 
glioma-induced migration of human marrow stromal cells (hMSC). Exp Neurol, 199, 
301-10. 
SCHWARZ, D. S., HUTVAGNER, G., DU, T., XU, Z., ARONIN, N. & ZAMORE, P. D. 
(2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell, 115, 199-
208. 
SCHWARZENBACH, H., HOON, D. S. & PANTEL, K. (2011) Cell-free nucleic acids as 
biomarkers in cancer patients. Nat Rev Cancer, 11, 426-37. 
SENA-ESTEVES, M., SAEKI, Y., FRAEFEL, C. & BREAKEFIELD, X. O. (2000) HSV-1 
amplicon vectors--simplicity and versatility. Mol Ther, 2, 9-15. 
SHAMMAS, M. A., KOLEY, H., BERTHEAU, R. C., NERI, P., FULCINITI, M., 
TASSONE, P., BLOTTA, S., PROTOPOPOV, A., MITSIADES, C., BATCHU, R. B., 
ANDERSON, K. C., CHIN, A., GRYAZNOV, S. & MUNSHI, N. C. (2008) 
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. 
Leukemia, 22, 1410-8. 
SHAN, Z., LIN, Q., DENG, C., LI, X., HUANG, W., TAN, H., FU, Y., YANG, M. & YU, X. 
Y. (2009) An efficient method to enhance gene silencing by using precursor 
microRNA designed small hairpin RNAs. Mol Biol Rep, 36, 1483-9. 
SHAW, R. J. (2006) Glucose metabolism and cancer. Curr Opin Cell Biol, 18, 598-608. 
SHAY, J. W. & BACCHETTI, S. (1997) A survey of telomerase activity in human cancer. 
Eur J Cancer, 33, 787-91. 
SHI, Q., RAFII, S., WU, M. H., WIJELATH, E. S., YU, C., ISHIDA, A., FUJITA, Y., 
KOTHARI, S., MOHLE, R., SAUVAGE, L. R., MOORE, M. A., STORB, R. F. & 
HAMMOND, W. P. (1998) Evidence for circulating bone marrow-derived 
endothelial cells. Blood, 92, 362-7. 
SHIN, K. S., SULLENGER, B. A. & LEE, S. W. (2004) Ribozyme-mediated induction of 
apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Mol Ther, 10, 
365-72. 
SHIRAKAWA, T. (2008) The current status of adenovirus-based cancer gene therapy. Mol 
Cells, 25, 462-6. 
SILVA, J. M., DOMINGUEZ, G., SILVA, J., GARCIA, J. M., SANCHEZ, A., RODRIGUEZ, 
O., PROVENCIO, M., ESPANA, P. & BONILLA, F. (2001) Detection of epithelial 
messenger RNA in the plasma of breast cancer patients is associated with poor 
prognosis tumor characteristics. Clin Cancer Res, 7, 2821-5. 
SILVA, J. M., RODRIGUEZ, R., GARCIA, J. M., MUNOZ, C., SILVA, J., DOMINGUEZ, 
G., PROVENCIO, M., ESPANA, P. & BONILLA, F. (2002) Detection of epithelial 
tumour RNA in the plasma of colon cancer patients is associated with advanced 
stages and circulating tumour cells. Gut, 50, 530-4. 
Bibliography 
 151 
SIPEHIA, R. & MARTUCCI, G. (1995) High-efficiency transformation of human 
endothelial cells by Apo E-mediated transfection with plasmid DNA. Biochem 
Biophys Res Commun, 214, 206-11. 
SISCO, K. L. (2001) Is RNA in serum bound to nucleoprotein complexes? Clin Chem, 47, 
1744-5. 
SIZEMORE, D. R., BRANSTROM, A. A. & SADOFF, J. C. (1995) Attenuated Shigella as a 
DNA delivery vehicle for DNA-mediated immunization. Science, 270, 299-302. 
SMOGORZEWSKA, A. & DE LANGE, T. (2002) Different telomere damage signaling 
pathways in human and mouse cells. Embo J, 21, 4338-48. 
SONG, M. S., JEONG, J. S., BAN, G., LEE, J. H., WON, Y. S., CHO, K. S., KIM, I. H. & 
LEE, S. W. (2009) Validation of tissue-specific promoter-driven tumor-targeting 
trans-splicing ribozyme system as a multifunctional cancer gene therapy device in 
vivo. Cancer Gene Ther, 16, 113-25. 
SONG, M. S., JEONG, J. S., CHO, K. S. & LEE, S. W. (2007) Gene expression responses in 
vivo by human telomerase reverse transcriptase (hTERT)-targeting trans-splicing 
ribozyme. Exp Mol Med, 39, 722-32. 
SPANAKIS, E. (1993) Problems related to the interpretation of autoradiographic data on 
gene expression using common constitutive transcripts as controls. Nucleic Acids 
Res, 21, 3809-19. 
SPRING, H., SCHULER, T., ARNOLD, B., HAMMERLING, G. J. & GANSS, R. (2005) 
Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad 
Sci U S A, 102, 18111-6. 
STEIN, G. H. & DULIC, V. (1995) Origins of G1 arrest in senescent human fibroblasts. 
Bioessays, 17, 537-43. 
STEWART, S. A., DYKXHOORN, D. M., PALLISER, D., MIZUNO, H., YU, E. Y., AN, D. 
S., SABATINI, D. M., CHEN, I. S., HAHN, W. C., SHARP, P. A., WEINBERG, R. 
A. & NOVINA, C. D. (2003) Lentivirus-delivered stable gene silencing by RNAi in 
primary cells. Rna, 9, 493-501. 
STOLL, B. R., MIGLIORINI, C., KADAMBI, A., MUNN, L. L. & JAIN, R. K. (2003) A 
mathematical model of the contribution of endothelial progenitor cells to 
angiogenesis in tumors: implications for antiangiogenic therapy. Blood, 102, 2555-
61. 
STROUN, M., ANKER, P., BELJANSKI, M., HENRI, J., LEDERREY, C., OJHA, M. & 
MAURICE, P. A. (1978) Presence of RNA in the nucleoprotein complex 
spontaneously released by human lymphocytes and frog auricles in culture. Cancer 
Res, 38, 3546-54. 
STUDENY, M., MARINI, F. C., CHAMPLIN, R. E., ZOMPETTA, C., FIDLER, I. J. & 
ANDREEFF, M. (2002) Bone marrow-derived mesenchymal stem cells as vehicles 
for interferon-beta delivery into tumors. Cancer Res, 62, 3603-8. 
STUDENY, M., MARINI, F. C., DEMBINSKI, J. L., ZOMPETTA, C., CABREIRA-
HANSEN, M., BEKELE, B. N., CHAMPLIN, R. E. & ANDREEFF, M. (2004) 
Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery 
vehicles for anticancer agents. J Natl Cancer Inst, 96, 1593-603. 
SU, Y., ZHENG, L., WANG, Q., LI, W., CAI, Z., XIONG, S. & BAO, J. (2010) Quantity and 
clinical relevance of circulating endothelial progenitor cells in human ovarian cancer. 
J Exp Clin Cancer Res, 29, 27. 
SUGITA, M., TANAKA, N., DAVIDSON, S., SEKIYA, S., VARELLA-GARCIA, M., 
WEST, J., DRABKIN, H. A. & GEMMILL, R. M. (2000) Molecular definition of a 
small amplification domain within 3q26 in tumors of cervix, ovary, and lung. Cancer 
Genet Cytogenet, 117, 9-18. 
SUMI, M., TAUCHI, T., SASHIDA, G., NAKAJIMA, A., GOTOH, A., SHIN-YA, K., 
OHYASHIKI, J. H. & OHYASHIKI, K. (2004) A G-quadruplex-interactive agent, 
telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances 
Bibliography 
 152 
chemosensitivity in acute myeloid leukemia. Int J Oncol, 24, 1481-7. 
SUMIMOTO, H. & KAWAKAMI, Y. (2007) Lentiviral vector-mediated RNAi and its use 
for cancer research. Future Oncol, 3, 655-64. 
SURIANO, R., CHAUDHURI, D., JOHNSON, R. S., LAMBERS, E., ASHOK, B. T., 
KISHORE, R. & TIWARI, R. K. (2008) 17Beta-estradiol mobilizes bone marrow-
derived endothelial progenitor cells to tumors. Cancer Res, 68, 6038-42. 
SWARUP, V. & RAJESWARI, M. R. (2007) Circulating (cell-free) nucleic acids--a 
promising, non-invasive tool for early detection of several human diseases. FEBS 
Lett, 581, 795-9. 
TAHARA, H., KUNIYASU, H., YOKOZAKI, H., YASUI, W., SHAY, J. W., IDE, T. & 
TAHARA, E. (1995) Telomerase activity in preneoplastic and neoplastic gastric and 
colorectal lesions. Clin Cancer Res, 1, 1245-51. 
TAMAKAWA, R. A., FLEISIG, H. B. & WONG, J. M. (2010) Telomerase inhibition 
potentiates the effects of genotoxic agents in breast and colorectal cancer cells in a 
cell cycle-specific manner. Cancer Res, 70, 8684-94. 
TAO, Z., CHEN, S., WU, Z., XIAO, B., LIU, J. & HOU, W. (2005) Targeted therapy of 
human laryngeal squamous cell carcinoma in vitro by antisense oligonucleotides 
directed against telomerase reverse transcriptase mRNA. J Laryngol Otol, 119, 92-6. 
TARAHOVSKY, Y. S. (2009) Cell transfection by DNA-lipid complexes - lipoplexes. 
Biochemistry (Mosc), 74, 1293-304. 
TATSUMOTO, N., HIYAMA, E., MURAKAMI, Y., IMAMURA, Y., SHAY, J. W., 
MATSUURA, Y. & YOKOYAMA, T. (2000) High telomerase activity is an 
independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer 
Res, 6, 2696-701. 
TAUCHI, T., SHIN-YA, K., SASHIDA, G., SUMI, M., OKABE, S., OHYASHIKI, J. H. & 
OHYASHIKI, K. (2006) Telomerase inhibition with a novel G-quadruplex-
interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. 
Oncogene, 25, 5719-25. 
TAYLOR, D. D., HOMESLEY, H. D. & DOELLGAST, G. J. (1980) Binding of specific 
peroxidase-labeled antibody to placental-type phosphatase on tumor-derived 
membrane fragments. Cancer Res, 40, 4064-9. 
TEIFEL, M., HEINE, L. T., MILBREDT, S. & FRIEDL, P. (1997) Optimization of 
transfection of human endothelial cells. Endothelium, 5, 21-35. 
TEKADE, R. K., KUMAR, P. V. & JAIN, N. K. (2009) Dendrimers in oncology: an 
expanding horizon. Chem Rev, 109, 49-87. 
TENG, L., SPECHT, M. C., BARDEN, C. B. & FAHEY, T. J., 3RD (2003) Antisense hTERT 
inhibits thyroid cancer cell growth. J Clin Endocrinol Metab, 88, 1362-6. 
TENTORI, L., PORTARENA, I., BARBARINO, M., BALDUZZI, A., LEVATI, L., 
VERGATI, M., BIROCCIO, A., GOLD, B., LOMBARDI, M. L. & GRAZIANI, G. 
(2003) Inhibition of telomerase increases resistance of melanoma cells to 
temozolomide, but not to temozolomide combined with poly (adp-ribose) 
polymerase inhibitor. Mol Pharmacol, 63, 192-202. 
THEIMER, C. A. & FEIGON, J. (2006) Structure and function of telomerase RNA. Curr 
Opin Struct Biol, 16, 307-18. 
THOMAS, P., NJ, O. C. & FENECH, M. (2008) Telomere length in white blood cells, buccal 
cells and brain tissue and its variation with ageing and Alzheimer's disease. Mech 
Ageing Dev, 129, 183-90. 
THOMLINSON, R. H. & GRAY, L. H. (1955) The histological structure of some human 
lung cancers and the possible implications for radiotherapy. Br J Cancer, 9, 539-49. 
TOMALIA, D. A., BAKER, H., DEWALD, J., HALL, M., KALLOS, G., MARTIN, S., 
ROECK, J., RYDER, J. & SMITH, P. (1985) A New Class of Polymers: Starburst-
Dendritic Macromolecules. Polymer Journal, 17, 117-132. 
TOMANIN, R. & SCARPA, M. (2004) Why do we need new gene therapy viral vectors? 
Bibliography 
 153 
Characteristics, limitations and future perspectives of viral vector transduction. Curr 
Gene Ther, 4, 357-72. 
TOMARI, Y., MATRANGA, C., HALEY, B., MARTINEZ, N. & ZAMORE, P. D. (2004) A 
protein sensor for siRNA asymmetry. Science, 306, 1377-80. 
TONG, A. W., JAY, C. M., SENZER, N., MAPLES, P. B. & NEMUNAITIS, J. (2009) 
Systemic therapeutic gene delivery for cancer: crafting Paris' arrow. Curr Gene Ther, 
9, 45-60. 
TOUSIGNANT, J. D., GATES, A. L., INGRAM, L. A., JOHNSON, C. L., NIETUPSKI, J. 
B., CHENG, S. H., EASTMAN, S. J. & SCHEULE, R. K. (2000) Comprehensive 
analysis of the acute toxicities induced by systemic administration of cationic 
lipid:plasmid DNA complexes in mice. Hum Gene Ther, 11, 2493-513. 
TSUI, N. B., NG, E. K. & LO, Y. M. (2002) Stability of endogenous and added RNA in 
blood specimens, serum, and plasma. Clin Chem, 48, 1647-53. 
TUSCHL, T., ZAMORE, P. D., LEHMANN, R., BARTEL, D. P. & SHARP, P. A. (1999) 
Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev, 13, 3191-
7. 
TUSELL, L., SOLER, D., AGOSTINI, M., PAMPALONA, J. & GENESCA, A. (2008) The 
number of dysfunctional telomeres in a cell: one amplifies; more than one 
translocate. Cytogenet Genome Res, 122, 315-25. 
ULANER, G. A., HU, J. F., VU, T. H., GIUDICE, L. C. & HOFFMAN, A. R. (1998) 
Telomerase activity in human development is regulated by human telomerase reverse 
transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. 
Cancer Res, 58, 4168-72. 
UZIEL, O., BEERY, E., DRONICHEV, V., SAMOCHA, K., GRYAZNOV, S., WEISS, L., 
SLAVIN, S., KUSHNIR, M., NORDENBERG, Y., RABINOWITZ, C., 
RINKEVICH, B., ZEHAVI, T. & LAHAV, M. (2010) Telomere shortening sensitizes 
cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative 
mechanisms. PLoS One, 5, e9132. 
VASSAUX, G., NITCHEU, J., JEZZARD, S. & LEMOINE, N. R. (2006) Bacterial gene 
therapy strategies. J Pathol, 208, 290-8. 
VENTEICHER, A. S. & ARTANDI, S. E. (2009) TCAB1: driving telomerase to Cajal bodies. 
Cell Cycle, 8, 1329-31. 
VENTEICHER, A. S., MENG, Z., MASON, P. J., VEENSTRA, T. D. & ARTANDI, S. E. 
(2008) Identification of ATPases pontin and reptin as telomerase components 
essential for holoenzyme assembly. Cell, 132, 945-57. 
VILLEMEJANE, J. & MIR, L. M. (2009) Physical methods of nucleic acid transfer: general 
concepts and applications. Br J Pharmacol, 157, 207-19. 
WACHECK, V. & ZANGEMEISTER-WITTKE, U. (2006) Antisense molecules for targeted 
cancer therapy. Crit Rev Oncol Hematol, 59, 65-73. 
WANG, W. J., TAI, C. K., KASAHARA, N. & CHEN, T. C. (2003) Highly efficient and 
tumor-restricted gene transfer to malignant gliomas by replication-competent 
retroviral vectors. Hum Gene Ther, 14, 117-27. 
WANG, Y. F., GUO, K. J., HUANG, B. T., LIU, Y., TANG, X. Y., ZHANG, J. J. & XIA, Q. 
(2006) Inhibitory effects of antisense phosphorothioate oligodeoxynucleotides on 
pancreatic cancer cell Bxpc-3 telomerase activity and cell growth in vitro. World J 
Gastroenterol, 12, 4004-8. 
WARD, R. J. & AUTEXIER, C. (2005) Pharmacological telomerase inhibition can sensitize 
drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol 
Pharmacol, 68, 779-86. 
WATSON, J. D. (1972) Origin of concatemeric T7 DNA. Nat New Biol, 239, 197-201. 
WEI, J., BLUM, S., UNGER, M., JARMY, G., LAMPARTER, M., GEISHAUSER, A., 
VLASTOS, G. A., CHAN, G., FISCHER, K. D., RATTAT, D., DEBATIN, K. M., 
HATZOPOULOS, A. K. & BELTINGER, C. (2004) Embryonic endothelial 
Bibliography 
 154 
progenitor cells armed with a suicide gene target hypoxic lung metastases after 
intravenous delivery. Cancer Cell, 5, 477-88. 
WEI, M. Q., ELLEM, K. A., DUNN, P., WEST, M. J., BAI, C. X. & VOGELSTEIN, B. 
(2007) Facultative or obligate anaerobic bacteria have the potential for 
multimodality therapy of solid tumours. Eur J Cancer, 43, 490-6. 
WEI, M. Q., MENGESHA, A., GOOD, D. & ANNE, J. (2008) Bacterial targeted tumour 
therapy-dawn of a new era. Cancer Lett, 259, 16-27. 
WEINRICH, S. L., PRUZAN, R., MA, L., OUELLETTE, M., TESMER, V. M., HOLT, S. E., 
BODNAR, A. G., LICHTSTEINER, S., KIM, N. W., TRAGER, J. B., TAYLOR, R. 
D., CARLOS, R., ANDREWS, W. H., WRIGHT, W. E., SHAY, J. W., HARLEY, C. 
B. & MORIN, G. B. (1997) Reconstitution of human telomerase with the template 
RNA component hTR and the catalytic protein subunit hTRT. Nat Genet, 17, 498-
502. 
WIANNY, F. & ZERNICKA-GOETZ, M. (2000) Specific interference with gene function by 
double-stranded RNA in early mouse development. Nat Cell Biol, 2, 70-5. 
WILLEIT, P., WILLEIT, J., BRANDSTATTER, A., EHRLENBACH, S., MAYR, A., 
GASPERI, A., WEGER, S., OBERHOLLENZER, F., REINDL, M., 
KRONENBERG, F. & KIECHL, S. (2010) Cellular aging reflected by leukocyte 
telomere length predicts advanced atherosclerosis and cardiovascular disease risk. 
Arterioscler Thromb Vasc Biol, 30, 1649-56. 
WONG, B. C., CHAN, K. C., CHAN, A. T., LEUNG, S. F., CHAN, L. Y., CHOW, K. C. & 
LO, Y. M. (2006) Reduced plasma RNA integrity in nasopharyngeal carcinoma 
patients. Clin Cancer Res, 12, 2512-6. 
WONG, L. S., OESEBURG, H., DE BOER, R. A., VAN GILST, W. H., VAN VELDHUISEN, 
D. J. & VAN DER HARST, P. (2009) Telomere biology in cardiovascular disease: 
the TERC-/- mouse as a model for heart failure and ageing. Cardiovasc Res, 81, 244-
52. 
WONG, S. C., LO, S. F., CHEUNG, M. T., NG, K. O., TSE, C. W., LAI, B. S., LEE, K. C. & 
LO, Y. M. (2004) Quantification of plasma beta-catenin mRNA in colorectal cancer 
and adenoma patients. Clin Cancer Res, 10, 1613-7. 
WORK, L. M., RITCHIE, N., NICKLIN, S. A., REYNOLDS, P. N. & BAKER, A. H. (2004) 
Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 
fibers and cell-selective transcriptional control. Gene Ther, 11, 1296-300. 
WRIGHT, W. E., SHAY, J. W. & PIATYSZEK, M. A. (1995) Modifications of a telomeric 
repeat amplification protocol (TRAP) result in increased reliability, linearity and 
sensitivity. Nucleic Acids Res, 23, 3794-5. 
WRIGHTON, C. J., HOFER-WARBINEK, R., MOLL, T., EYTNER, R., BACH, F. H. & DE 
MARTIN, R. (1996) Inhibition of endothelial cell activation by adenovirus-mediated 
expression of I kappa B alpha, an inhibitor of the transcription factor NF-kappa B. J 
Exp Med, 183, 1013-22. 
WU, A., ICHIHASHI, M. & UEDA, M. (1999a) Correlation of the expression of human 
telomerase subunits with telomerase activity in normal skin and skin tumors. Cancer, 
86, 2038-44. 
WU, G. Y. & WU, C. H. (1987) Receptor-mediated in vitro gene transformation by a soluble 
DNA carrier system. J Biol Chem, 262, 4429-32. 
WU, K. J., GRANDORI, C., AMACKER, M., SIMON-VERMOT, N., POLACK, A., 
LINGNER, J. & DALLA-FAVERA, R. (1999b) Direct activation of TERT 
transcription by c-MYC. Nat Genet, 21, 220-4. 
WU, S. Y. & MCMILLAN, N. A. (2009) Lipidic systems for in vivo siRNA delivery. Aaps J, 
11, 639-52. 
WU, Y. & BROSH, R. M., JR. (2010) G-quadruplex nucleic acids and human disease. Febs J, 
277, 3470-88. 
WYATT, H. D., WEST, S. C. & BEATTIE, T. L. (2010) InTERTpreting telomerase structure 
Bibliography 
 155 
and function. Nucleic Acids Res, 38, 5609-22. 
WYNFORD-THOMAS, D. (1999) Cellular senescence and cancer. J Pathol, 187, 100-11. 
XIA, L., WANG, X. X., HU, X. S., GUO, X. G., SHANG, Y. P., CHEN, H. J., ZENG, C. L., 
ZHANG, F. R. & CHEN, J. Z. (2008) Resveratrol reduces endothelial progenitor 
cells senescence through augmentation of telomerase activity by Akt-dependent 
mechanisms. Br J Pharmacol, 155, 387-94. 
XIANG, J., TANG, J., SONG, C., YANG, Z., HIRST, D. G., ZHENG, Q. J. & LI, G. (2009) 
Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. 
Cytotherapy, 11, 516-26. 
XIN, H., KANEHIRA, M., MIZUGUCHI, H., HAYAKAWA, T., KIKUCHI, T., NUKIWA, T. 
& SAIJO, Y. (2007) Targeted delivery of CX3CL1 to multiple lung tumors by 
mesenchymal stem cells. Stem Cells, 25, 1618-26. 
XU, D., LI, H. & LIU, J. P. (2007) Inhibition of telomerase by targeting MAP kinase 
signaling. Methods Mol Biol, 405, 147-65. 
XU, F. & ZHU, J. H. (2007) Stem cells tropism for malignant gliomas. Neurosci Bull, 23, 
363-9. 
XU, L., PIROLLO, K. F., TANG, W. H., RAIT, A. & CHANG, E. H. (1999) Transferrin-
liposome-mediated systemic p53 gene therapy in combination with radiation results 
in regression of human head and neck cancer xenografts. Hum Gene Ther, 10, 2941-
52. 
XU, T., XU, Y., LIAO, C. P., LAU, R. & GOLDKORN, A. (2010) Reprogramming murine 
telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo. 
Mol Cancer Ther, 9, 438-49. 
YAMAGUCHI, H. (2007) Mutations of telomerase complex genes linked to bone marrow 
failures. J Nippon Med Sch, 74, 202-9. 
YAMAGUCHI, H., BAERLOCHER, G. M., LANSDORP, P. M., CHANOCK, S. J., NUNEZ, 
O., SLOAND, E. & YOUNG, N. S. (2003) Mutations of the human telomerase RNA 
gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood, 102, 916-8. 
YAMAGUCHI, H., CALADO, R. T., LY, H., KAJIGAYA, S., BAERLOCHER, G. M., 
CHANOCK, S. J., LANSDORP, P. M. & YOUNG, N. S. (2005) Mutations in TERT, 
the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med, 352, 
1413-24. 
YI, R., QIN, Y., MACARA, I. G. & CULLEN, B. R. (2003) Exportin-5 mediates the nuclear 
export of pre-microRNAs and short hairpin RNAs. Genes Dev, 17, 3011-6. 
YI, X., TESMER, V. M., SAVRE-TRAIN, I., SHAY, J. W. & WRIGHT, W. E. (1999) Both 
transcriptional and posttranscriptional mechanisms regulate human telomerase 
template RNA levels. Mol Cell Biol, 19, 3989-97. 
YOKOYAMA, Y., TAKAHASHI, Y., SHINOHARA, A., WAN, X., TAKAHASHI, S., 
NIWA, K. & TAMAYA, T. (2000) The 5'-end of hTERT mRNA is a good target for 
hammerhead ribozyme to suppress telomerase activity. Biochem Biophys Res 
Commun, 273, 316-21. 
YOKOYAMA, Y., WAN, X., SHINOHARA, A., TAKAHASHI, Y. & TAMAYA, T. (2001) 
Hammerhead ribozymes to modulate telomerase activity of endometrial carcinoma 
cells. Hum Cell, 14, 223-31. 
YUAN, B. & MI, R. (2002) [Antisense oligodeoxynucleotides of human telomerse catalytic 
sub-unit inhibits telomerase activity and proliferation in SKOV3 and COC1]. 
Zhonghua Fu Chan Ke Za Zhi, 37, 198-201. 
ZAHLER, A. M., WILLIAMSON, J. R., CECH, T. R. & PRESCOTT, D. M. (1991) 
Inhibition of telomerase by G-quartet DNA structures. Nature, 350, 718-20. 
ZAMORE, P. D. (2002) Ancient pathways programmed by small RNAs. Science, 296, 1265-
9. 
ZAMORE, P. D., TUSCHL, T., SHARP, P. A. & BARTEL, D. P. (2000) RNAi: double-
stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide 
Bibliography 
 156 
intervals. Cell, 101, 25-33. 
ZEIGER, E., GOLLAPUDI, B. & SPENCER, P. (2005) Genetic toxicity and carcinogenicity 
studies of glutaraldehyde--a review. Mutat Res, 589, 136-51. 
ZENG, G., NYSTROM, F. H., RAVICHANDRAN, L. V., CONG, L. N., KIRBY, M., 
MOSTOWSKI, H. & QUON, M. J. (2000) Roles for insulin receptor, PI3-kinase, 
and Akt in insulin-signaling pathways related to production of nitric oxide in human 
vascular endothelial cells. Circulation, 101, 1539-45. 
ZENG, Y., YI, R. & CULLEN, B. R. (2003) MicroRNAs and small interfering RNAs can 
inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A, 100, 
9779-84. 
ZHANG, A., ZHENG, C., HOU, M., LINDVALL, C., LI, K. J., ERLANDSSON, F., 
BJORKHOLM, M., GRUBER, A., BLENNOW, E. & XU, D. (2003) Deletion of the 
telomerase reverse transcriptase gene and haploinsufficiency of telomere 
maintenance in Cri du chat syndrome. Am J Hum Genet, 72, 940-8. 
ZHANG, H. R., CHEN, F. L., XU, C. P., PING, Y. F., WANG, Q. L., LIANG, Z. Q., WANG, J. 
M. & BIAN, X. W. (2009) Incorporation of endothelial progenitor cells into the 
neovasculature of malignant glioma xenograft. J Neurooncol, 93, 165-74. 
ZHANG, J. S., LIU, F. & HUANG, L. (2005) Implications of pharmacokinetic behavior of 
lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev, 57, 689-98. 
ZHANG, J. X., KANG, C. S., SHI, L., ZHAO, P., LIU, N. & YOU, Y. P. (2010) Use of 
thymidine kinase gene-modified endothelial progenitor cells as a vector targeting 
angiogenesis in glioma gene therapy. Oncology, 78, 94-102. 
ZHANG, R. G., FANG, D. C., LUO, Y. H. & GUO, L. P. (2006) [Effects of hTERT RNAi on 
apoptosis of hepatocellular carcinoma cells induced by TRAIL]. Zhonghua Gan 
Zang Bing Za Zhi, 14, 435-40. 
ZHANG, X., MAR, V., ZHOU, W., HARRINGTON, L. & ROBINSON, M. O. (1999) 
Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. 
Genes Dev, 13, 2388-99. 
ZHENG, J. N., SUN, Y. F., PEI, D. S., LIU, J. J., CHEN, J. C., LI, W., SUN, X. Q., SHI, Q. 
D., HAN, R. F. & MA, T. X. (2006) Inhibition of proliferation and induction of 
apoptosis in human renal carcinoma cells by anti-telomerase small interfering RNAs. 
Acta Biochim Biophys Sin (Shanghai), 38, 500-6. 
ZHENG, P. P., HOP, W. C., LUIDER, T. M., SILLEVIS SMITT, P. A. & KROS, J. M. (2007) 
Increased levels of circulating endothelial progenitor cells and circulating 
endothelial nitric oxide synthase in patients with gliomas. Ann Neurol, 62, 40-8. 
ZINSELMEYER, B. H., MACKAY, S. P., SCHATZLEIN, A. G. & UCHEGBU, I. F. (2002) 
The lower-generation polypropylenimine dendrimers are effective gene-transfer 
agents. Pharm Res, 19, 960-7. 
 
 
